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Abstract
Binding of gonadotropin releasing hormone (GnRH) to its receptor on the surface of
gonadotroph cells within the anterior pituitary triggers the pulsatile release of the
gonadotropin hormones, luteinising hormone and follicle stimulating (LH and FSH)
into the blood stream. These hormones then act on their target organs, the gonads, to
stimulate and regulate spermatogenesis in males and folliculogenesis in females. LH
and FSH are heterodimeric glycoproteins comprised of a common a subunit (aGSU)
and a unique beta subunit (LH(3 or FSH(3), each encoded by a single gene. The
processes by which GnRH regulates gonadotropin gene transcription are not fully
characterised but variation in GnRH pulsatility, differential activation of GnRH
receptor and coupling to second messenger signalling pathways, all contribute to
give distinct, subunit-specific effects on gene transcription. The identification of
transcripts and proteins regulated by GnRH could further characterise the bio-
molecular processes by which GnRH controls LH and FSH production.
Previous work performed within the laboratory, using the technique of differential
display RT-PCR (DD-RT-PCR), identified that a DNA damage repair gene, Fanconi
Anaemia complementation group a (Fanca), is differentially expressed in response to
hormone. FANCA is mutated in > 60% of cases of Fanconi anaemia (FA), a
genetically heterogeneous autosomal recessive disorder characterised by bone
marrow failure, endocrine tissue cancer susceptibility and infertility.
Detailed analysis of Fanca mRNA expression using northern blotting, semi¬
quantitative RT-PCR and quantitative RT-PCR analysis reveals that GnRH induces a
rapid and transient increase in Fanca mRNA within L|3T2 gonadotroph cells.
Indirect immunofluorescence and western blotting analysis show that Fanca protein
is expressed in the cytoplasm and nucleus of L|3T2 cells and GnRH induces a
transient 2-fold increase in Fanca protein levels within both cellular compartments.
Furthermore, treatment with inhibitors of nuclear import and export demonstrated
that Fanca protein actively shuttles between the nucleus and cytoplasm of
iii
Abstract
gonadotroph cells, via a CRM-1 (yeast chromosome region maintenance protein 1)
dependent mechanism.
Transient transfection assays using wildtype and dominant negative, point mutated
forms of FANCA reveal that wildtype FANCA protein is required for GnRH induced
activity of the aGSU promoter, but not LH|3 or FSH[3 promoter activity. The
construction of adenoviral vectors expressing wildtype and mutant FANCA proteins
and the characterisation of siRNAs to knockdown expression of Fanca in L|3T2 cells
will allow the confirmation of a novel role for Fanca in gonadotropin gene
transcription.
The discovery that GnRH regulates Fanca expression, which in turn regulates GnRH
induced aGsu transcription, provides the first molecular evidence of a role for Fanca
in the control of fertility.
iv
Publication and presentations relating to this thesis
Publications in peer reviewed journals
Larder, R., Chang, L., Clinton, M. and Brown, P. (2004) Gonadotropin-releasing
hormone regulates expression of the DNA damage repair gene, Fanconi anemia A, in
pituitary gonadotroph cells. Biol Reprod. 71(3):828-36.
Oral presentations
Larder, R., Chang, L. and Brown, P. (2002) Gonadotropin releasing hormone
regulates expression and cellular distribution of Fanconi Anaemia A. 193rd meeting
of the Society for Endocrinology, London, UK.
Poster presentations
Larder, R., Chang, L., Clinton, M. and Brown, P. (2004) Expression of Fanconi
Anaemia a (Fanca), a gene implicated in DNA damage repair, is regulated by
gonadotropin releasing hormone (GnRH) in L|3T2 gonadotroph cells. 37th Annual
meeting of the Society for the Study ofReproduction (SSR), Vancouver, Canada.
Larder, R., Karali, D. and Brown, P. (2004) Activation of gonadotropin gene
transcription by gonadotropin-releasing hormone requires nuclear localisation of
Fanconi Anaemia a (Fanca): evidence that Fanca acts as a signalling molecule. 12th







Publications and presentations relating to this thesis v
Table ofContents vi
List ofFigures xii
List of Tables xv
Abbreviations xvi
Chapter One : Literature Review
1.1 The neuroendocrinology of reproduction 2
1.1.1 The hypothalamic-pituitary-gonadal axis 2
1.1.2 The gonadotropins 3
1.1.3 The female reproductive cycle 3
1.1.4 Regulation of male fertility 7
1.2 Mouse models and human gonadotropin signalling phenotypes 8
1.2.1 GnRH signalling mutations 8
1.2.2 GnRH receptor mutations 8
1.2.3 Common a-subunit mutations 9
1.2.4 Specific |3-subunit mutations 9
1.2.4.1 FSH (3-subunit ligand mutations 9
1.2.4.2 FSH receptor mutations 10
1.2.4.3 LH (3-subunit mutations 10
1.2.4.4 LH receptor mutations 11
1.3 Development of the pituitary-gonadal axis 12
1.3.1 The pituitary 12
1.3.2 Pituitary gland development 14
1.3.3 Transcription factors crucial for pituitary development and patterning 14
1.3.3.1 Hesxl/Rpxl 14
1.3.3.2 LIM homeodomain transcription factors 15
1.3.3.3 Pitx transcription factors 15
1.3.3.4 Pitl 16
1.3.3.5 Prophet of Pitl 16
1.3.4 Factors required for gonadotroph specific gene expression 17
1.3.4.1 Steroidogenic factor 1 18
1.3.4.2 Early growth response factor 1 18
1.4 Gonadotropin releasing hormone 21
1.4.1 GnRH decapeptide 21
1.4.2 GnRH type I receptor 22
1.4.3 GnRH pulse frequency 23
1.4.4 GnRH signalling pathways 25
1.4.4.1 Initiation of gonadotropin gene transcription via calcium signalling.... 27
1.4.4.2 Initiation of gonadotropin gene transcription via MAPK signalling 27
1.5 GnRH and cancer 31
vi
Table of Contents
1.6 Regulation of gene expression by GnRH 32
1.7 Fanconi Anaemia 33
1.7.1 Clinical phenotypes ofFanconi Anaemia 33
1.7.2 Cellular phenotypes ofFanconi Anaemia 34
1.7.3 Genetics of Fanconi Anaemia 35
1.7.4 Fanconi Anaemia complementation group A (FANCA) 35
1.7.4.1 Targeted disruption of the Fanca gene in mice 36
1.7.5 Fanconi Anaemia complementation group C (FANCC) 37
1.7.6 Fanconi Anaemia complementation group G (FANCG) 38
1.7.7 Fanconi Anaemia complementation group E (FANCE) 38
1.7.8 Fanconi Anaemia complementation group F (FANCF) 39
1.7.9 Fanconi Anaemia complementation group D 39
1.7.9.1 FANCD2 40
1.7.9.2 FANCD1 40
1.7.10 Fanconi Anaemia complementation group L (FANCL) 41
1.7.11 FA protein complex formation 41
1.8 Fanconi Anaemia and the HPG axis 44
1.9 Aims of this thesis 45
Chapter Two : Materials and Methods
2.1 Nucleic acid manipulation 47
2.1.1 Solutions 47
2.1.2 Primer design and oligonucleotide synthesis 48
2.1.3 Reverse transcription-PCR 49
2.1.3.1 cDNA synthesis 49
2.1.3.2 PCR conditions 49
2.1.4 Agarose gel electrophoresis 51
2.1.5 Cloning ofRT-PCR products 51
2.2 Microbiology 52
2.2.1 Bacterial solutions 52
2.2.2 Transformation of competent cells 53
2.3 Nucleic acid analysis 54
2.3.1 Solutions 54
2.3.2 Small scale DNA preparation 55
2.3.3 Preparation ofDNA over a caesium chloride gradient 55
2.3.4 Spectrophotometrical analysis of nucleic acids 57
2.3.5 Restriction digest analysis of plasmid DNA 57
2.3.6 Sequencing analysis 58
2.3.7 Restriction enzyme digest of plasmid DNA for cloning 58
2.3.8 Extraction of DNA from agarose gel fragments 59
2.3.9 Ligation ofDNA inserts into other vectors 59
2.3.10 Southern blotting of RT-PCR products 59
2.3.10.1 Probe design to verily Fanca PCR products 60
2.3.10.2 Radiolabelling of probes 60
2.3.10.3 Hybridisation and washing conditions 61
2.3.11 Site-directed mutagenesis of human FANCA 61
Table of Contents
2.4 Tissue Culture 65
2.4.1 Cell lines 65
2.4.2 Cell growth conditions 65
2.4.3 Solutions 65
2.4.4 Resuscitation of cell lines from liquid nitrogen store 66
2.4.5 Passaging of cell lines 66
2.4.6 Matrigel coating of tissue-culture flasks 67
2.4.7 GnRH treatment of cells 67
2.4.8 Treatment of L(3T2 cells with inhibitor chemicals 67
2.5 Transient transfection ofDNA into in vitro cultured cells 68
2.5.1 Transient transfection ofGFP expressing plasmids into cultured cells 68
2.5.1.1 Preparation of EGFP transfected cells prior to image analysis 68
2.5.1.2 Image analysis of EGFP tagged proteins in mammalian cell culture 69
2.5.2 Transient transfection of constructs for reporter gene assays 69
2.5.2.1 Transient transfection of L|3T2 cells using Fugene 70
2.5.2.2 Transient transfection of FSH(3 promoter constructs 70
2.5.2.3 Transient transfection of aT3-l cells using Geneporter 71
2.5.3 Luciferase/p-galactosidase chemiluminescent reporter gene assay 71
2.6 RNA expression analysis 72
2.6.1 Solutions 72
2.6.2 RNA extraction 72
2.6.3 Northern blot analysis 72
2.6.3.1 Preparation of northern blot 73
2.6.3.2 Probe design for detecting Fanca and Zfp276 transcripts by northern
blotting 73
2.6.3.3 Hybridisation and washing conditions 74
2.6.4 Quantitative RT-PCR 74
2.7 Protein expression analysis 77
2.7.1 Solutions 77
2.7.2 Protein extraction from cells grown in culture 79
2.7.2.1 Whole cell extracts 79
2.7.2.2 Nuclear and cytoplasmic cell extracts 79
2.7.3 Bradford assay ofprotein extracts 80
2.7.4 Preparation of SDS-polyacrylamide gels 80
2.7.4.1 SDS-polyacrylamide gel electrophoresis 80
2.7.5 Western analysis of protein extracts 81
2.7.6 Transfer of proteins to PVDF membrane 81
2.7.7 Immuno-blotting 82
2.7.8 Quantification of protein expression 83
2.7.9 Crude purification ofFanca antisera 83
2.7.10 Immunohistochemistry ofmammalian cells cultured in vitro 84
2.8 'Knockdown'of Fanca gene expression using siRNAs 86
2.8.1 siRNA design and production 86
2.8.2 Transfection of siRNAs into L(3T2 cells using Fugene 87
2.8.3 Analysis of Fanca mRNA levels after siRNA treatment 88
2.8.4 Analysis of Fanca protein levels after siRNA treatment 88
2.9 Construction of recombinant adenoviral vectors expressing FANCA 89
2.9.1 Materials and solutions 90
2.9.2 Cloning of FANCA into'donor'vector 90
viii
Table of Contents
2.9.3 Cloning ofFANCA into adenoviral 'acceptor' vector 91
2.9.4 Small scale preparation of recombinant adenoviral vectors 91
2.9.5 Confirmation ofpositive clones by PCR 92
2.9.6 Large scale preparation of recombinant adenoviral vectors 92
2.9.7 Producing recombinant adenovirus 93
2.9.7.1 PacI digestion of recombinant plasmid 93
2.9.7.2 Transfecting HEK293 cells with recombinant adenoviral DNA 93
2.9.7.3 Amplification and preparation of viral stock 94
2.9.8 Plaque assay to determine adenoviral titer 94
Chapter Three : Regulation ofFanca expression by GnRH
3.1 Introduction 97
3.1.1 Background 97
3.1.2 Aims of this chapter 100
3.2 Results 101
3.2.1 Fanca mRNA is expressed in LPT2 cells 101
3.2.2 Fanca mRNA is expressed in adult mouse pituitary 101
3.2.3 Fanca mRNA is not expressed in immature pituitary gonadotrophs 106
3.2.4 Zfp276 mRNA is not regulated by GnRH 109
3.2.5 An alternative Zfp276 transcript is expressed in L(3T2 cells 109
3.2.6 Fanca mRNA levels are regulated by GnRH 112
3.2.7 Fanca mRNA levels increase 2-fold in response to GnRH 114
3.2.8 Fanca protein levels increase 2-fold in response to GnRH 116
3.3 Discussion 119
3.3.1 Fanca mRNA is expressed in mature gonadotroph 119
3.3.2 An alternative Zfp276 transcript is expressed within L|3T2 cells 122
3.3.3 Fanca mRNA is regulated by GnRH 126
3.3.4 Fanca protein is regulated by GnRH 128
3.3.5 Possible role of Fanca in gonadotrophs 129
3.3.6 Fanca, GnRH and cancer 129
3.3.7 Conclusions 130
Chapter Four : Localization ofFanca protein in L/3T2 cells
4.1 Introduction 132
4.1.1 Background 132
4.1.2 Aims of this chapter 134
4.2 Results 135
4.2.1 Sub-cellular localization of Fanca protein in L|3T2 cells 135
4.2.2 Western blotting analysis of Fanca sub-cellular localization in LPT2
cells 137
4.2.3 Nuclear-cytoplasmic shuttling of Fanca protein in LPT2 cells 137
4.2.4 Generation ofGFP-tagged mutant FANCA clones 142




4.2.6 Expression analysis ofGFP-tagged mutant FANCA constructs 143
4.3 Discussion 148
4.3.1 Fanca protein is expressed in both the cytoplasm and nucleus of LPT2
cells 148
4.3.2 Fanca protein shuttles between the nucleus and cytoplasm of LPT2
cells 149
4.3.3 Specific mutations affect FANCA sub-cellular localization 152
4.3.4 Conclusions 155
Chapter Five : Fanca and gonadotropin gene expression
5.1 Introduction 157
5.1.1 Background 157
5.1.2 Aims of this chapter 161
5.2 Results 162
5.2.1 Mutating FANCA has no effect on LFip promoter activity 162
5.2.2 Mutating FANCA increases FSFip basal promoter activity 162
5.2.3 Mutating FANCA obliterates GnRH induced aGSU promoter activity.... 163
5.2.4 Design of siRNAs against Fanca 167
5.2.5 RT-PCR analysis of Fanca mRNA expression in LPT2 cells treated with
siRNAs 167
5.2.6 Indirect immunofluorescence of Fanca protein expression in LPT2 cells
treated with siRNAs 170
5.2.7 Western blotting analysis of Fanca protein expression in LPT2 cells
After treatment with siRNAs 172
5.2.8 Generation of adenoviral vectors expressing wildtype and mutant
FANCA 174
5.2.9 Expression analysis ofFanconi Anaemia complex members 176
5.2.10 Expression of Fanca and Fancc in aT3-l cells augments the GnRH
induced response of the aGSU promoter 178
5.3 Discussion 180
5.3.1 FANCA is required for GnRH induced aGSU transcription 180
5.3.2 Role of the other FA complex members in activation of aGsu promoter
transcription 183
5.3.3 Analysis of gonadotropin levels in FA patients 185
5.3.4 Fanca expression can be knocked down in LPT2 cells using siRNAs 186
5.3.5 Further studies using FANCA expressing adenoviral vectors 189
5.3.6 Conclusions 190
Chapter Six : General Discussion and Conclusions
6.1 Introduction 192
6.1.1 Regulation of Fanca expression by GnRH 192
6.1.2 Effects of knocking out Fanca expression in mice 193
6.1.3 Fanca, GnRH and cancer 194
x
Table of Contents
6.1.4 Fanca protein expression in gonadotroph cells 197
6.1.4.1 Does Fanca act as a molecular scaffold? 198
6.1.4.2 Is Fanca involved in GnRH receptor desensitization? 200
6.1.5 Fanca and gonadotropin subunit transcription 202
6.1.6 Role of the FA complex in transcriptional regulation via ubiquitination... 206
6.1.7 FA phenotypes and genotypes 209




I Vector maps 249
II Academic Sources and commercial suppliers 255
III Publications 259
xi
List of Figures and Tables
List of Figures
Chapter One : Literature Review
Figure 1.1 Modulation of hormones regulating the reproductive cycle in females 5
Figure 1.2 Flormonal regulation of the reproductive cycle in females 6
Figure 1.3 Flormonal regulation of testicular function 7
Figure 1.4 Cell types within the mammalian anterior pituitary gland 13
Figure 1.5 Gradient of transcription factors required for patterning of anterior
pituitary cell types 17
Figure 1.6 Transcription factors controlling cell type specification during pituitary
organogenesis 20
Figure 1.7 Amino acid composition ofmammalian GnRH 22
Figure 1.8 Organisation of the seven transmembrane domains of the human GnRH
receptor 23
Figure 1.9 Frequency ofGnRH pulses during the reproductive cycle in females 24
Figure 1.10 Factors involved in signalling through the GnRH receptor to initiate
gonadotropin gene transcription 26
Figure 1.11 MAPK cascades initiated in L(3T2 cells in response to GnRH 29
Figure 1.12 Proposed functions ofGnRH in tumour progression 31
Figure 1.13 FANCA genomic structure 36
Figure 1.14 A model of the Fanconi Anaemia pathway 43
Chapter Two : Materials and methods
Figure 2.1 Overview of the QuikChange site-directed mutagenesis method 63
Figure 2.2 Method of detection of Fanca protein by ECL Plus detection kit 82
Figure 2.3 Detection of Fanca protein expression by indirect immunofluorescence.... 84
Figure 2.4 Construction of recombinant adenovirus with BD Creator Technology.... 89
Chapter Three : Regulation ofFanca expression by GnRH
Figure 3.1 Alignment of the 74 bp clone DD-RT-PCR product and mouse Fanca
cDNA nucleotide sequence 99
Figure 3.2 Schematic representation of the Fanca locus showing overlap between
Fanca and Zfp276 102
Figure 3.3 Expression of full-length Fanca and Zfp276 mRNA transcripts in L(3T2
cells 103
Figure 3.4 Location of northern probes and PCR primers relative to Fanca genomic
structure 104
Figure 3.5 Fanca in vivo expression analysis 105
Figure 3.6 Fanca in vitro expression analysis 107
Figure 3.7 Southern blotting analysis of Fanca expression in aT3-l cells 108
Figure 3.8 Semi-quantitative RT-PCR analysis ofZfp276 mRNA expression in
LPT2 cells 110
xii
List of Figures and Tables
Figure 3.9 Alignment of Zfp276 PCR Clone A and Zfp276 PCR Clone B and
predicted amino acid sequence Ill
Figure 3.10 Semi-quantitative RT-PCR analysis of Fanca expression in LPT2 cells... 113
Figure 3.11 Quantitative RT-PCR analysis of Fanca mRNA levels after treatment
with GnRH 115
Figure 3.12 Western blotting analysis of Fanca protein levels after treatment with
GnRH 117
Figure 3.13 Fanca mRNA and protein levels increase after treatment with GnRH 118
Figure 3.14 Schematic representation of the Fanca locus showing the location of the
isolated differential display RT-PCR clone 120
Figure 3.15 Addition of 70 bp of genomic sequence disrupts the protein domain
structure of Zfp276 125
Chapter Four : Localization ofFanca protein in L/3T2 cells
Figure 4.1 Detection of sub-cellular localization ofFanca protein in LPT2 cells
using indirect immunofluorescence 136
Figure 4.2 Detection of sub-cellular localization of Fanca protein in LPT2 cells
using western blotting analysis 139
Figure 4.3 Western blotting analysis of cytoplasmic Fanca protein levels after
treatment with inhibitors and GnRH 140
Figure 4.4 Western blotting analysis of nuclear Fanca protein levels after treatment
with inhibitors and GnRH 141
Figure 4.5 Confirmation of site-directed mutagenesis ofGFP-FANCA 142
Figure 4.6 Western blotting analysis of GFP-FANCA expression constructs in
LPT2 cells 145
Figure 4.7 Expression analysis ofwildtype and mutant FANCA protein in HeLa
cells 146
Figure 4.8 Expression analysis ofwildtype and mutant FANCA protein in LPT2
cells 147
Chapter Five : Fanca and gonadotropin gene expression
Figure 5.1 Transcription factors involved in basal and GnRH activated
gonadotropin subunit gene expression 159
Figure 5.2 Effects of mutating FANCA on GnRH induced LHP promoter activity
in LPT2 cells 164
Figure 5.3 Effects of mutating FANCA on GnRH induced FSHp promoter activity
in LPT2 cells 165
Figure 5.4 Effects of mutating FANCA on GnRH induced aGsu promoter activity
in LPT2 cells 166
Figure 5.5 Schematic representation of the Fanca locus showing the location of
siRNAs designed from Fanca sequence 168
Figure 5.6 Semi-quantitative RT-PCR analysis of Fanca expression in LPT2 cells
after transfection with siRNAs 169
Figure 5.7 siRNA knockdown of Fanca protein expression in LPT2 cells 171
xiii
List of Figures and Tables
Figure 5.8 Western blotting analysis of siRNA knockdown ofFanca protein
expression in LPT2 cells 173
Figure 5.9 Vector maps ofEGFP-FANCA adenoviral constructs 175
Figure 5.10 In vitro expression analysis ofFA complex members 177
Figure 5.11 Effects of Fanca and Fancc on GnRH induced aGsu promoter activity in
aT3-l cells 179
Figure 5.12 RNAi-mediated gene silencing 187
Chapter Six : General Discussion and Conclusions
Figure 6.1 Elypothetical role ofGnRH and FANCA in the control of tumour
development 196
Figure 6.2 Hypothetical role ofGnRH in the shuttling of Fanca protein 199
Figure 6.3 Hypothetical role ofFANCA and SNX5 in recycling ofGnRHR 202
Figure 6.4 Hypothetical role of FANCA in GnRH induced aGsu promoter activity... 204
Figure 6.5 Hypothetical role ofFANCA in basal FSHp promoter transcription 205
Figure 6.6 Hypothetical role of the FA complex in control of gonadotropin gene
transcription 208
Figure 6.7 Hypothetical consequences ofmono-allelic loss of FANCA 210
Appendix I
Figure Al.l Vector map ofpCRII-TOPO plasmid 250
Figure Al.2 Vector map ofpBluescript plasmid 251
Figure A1.3 Vector map of pBluescript-FANCA-EcoRV 252
Figure A1.4 Vector map of pCEP4-Fanca 253
Figure Al .5 Vector map ofpEGFP-FANCA(Hl 110P/Q1128E) 254
xiv
List of Figures and Tables
List of Tables
Chapter One : Literature Review
Table 1.1 Frequency of abnormalities seen in Fanconi Anaemia patients 34
Table 1.2 Interactions between FA proteins 42
Chapter Two : Materials and methods
Table 2.1 DNA sequence ofprimers used for RT-PCR expression analysis 50
Table 2.2 Chemically competent cells 53
Table 2.3 DNA sequence of primers used for site-directed mutagenesis of
FANCA 62
Table 2.4 DNA sequence ofFANCA sequencing primers 64
Table 2.5 Expression constructs used during the course of this thesis 69
Table 2.6 DNA sequence ofprimers used to generate probes for northern blotting
analysis 74
Table 2.7 DNA sequence ofprimers used for LightCycler quantitative RT-PCR 75
Table 2.8 Components required to make 100 ml SDS-PAGE acrylamide gel 81
Table 2.9 Antisera and conditions used for western blotting analysis of cell
extracts 83
Table 2.10 DNA sequence of Fanca and scrambled siRNAs 87
Chapter Five : Fanca and gonadotropin gene expression
Table 5.1 Transcription factors shown to be involved in basal and/or GnRH
transcription 158






aGSU alpha gonadotropin subunit
aMSH alpha melanin-stimulating hormone
AMD actinomycin D
ANOVA analysis of variance





BLAST basic local alignment search tool
BMK BiMC related kinase
BMP bone morphogenetic protein
bp base pairs
BRCA1/2 breast cancer susceptibility gene 1/2












CNS central nervous system
CRH corticotrophin releasing hormone
CRHR corticotrophin releasing hormone receptor
CPE cytopathic effect
ccpm cherenkov counts per minute
CPHD combined pituitary hormone deficiency
CRM1 yeast chromosome region maintenance protein 1
CsCl caesium chloride
DAG diacylglycerol








DMEM Dulbeccos modified eagles media
dpm disintergrations per minute
dsRNA double stranded RNA
E embryonic day
EDTA ethylene diaminetetra-acetic acid
EGFP enhanced green fluorescent protein
Egrl early growth response factor protein 1
EGTA ethylene glycolbis (aminoethyl-ether)-tetra-acetic acid
ERK extracellular signal related kinase
EST expressed sequence tag
EtOH ethanol
FA Fanconi Anaemia
Fanca Fanconi anaemia complementation group a
Fancc Fanconi anaemia complementation group c
Fancdl Fanconi anaemia complementation group dl
Fancd2 Fanconi anaemia complementation group d2
Fance Fanconi anaemia complementation group e
Fancf Fanconi anaemia complementation group f
Fancg Fanconi anaemia complementation group g
Fancl Fanconi anaemia complementation group 1
FCS fetal calf serum
FSF1 follicle stimulating hormone
FSH(3 follicle stimulating hormone beta-subunit
FSFIR follicle stimulating hormone receptor
g grams
G guanosine
GAP GnRH associated protein
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GATA2 gata binding protein 2
GH growth hormone
GHRH growth hormone releasing hormone
GE1RHR growth hormone releasing hormone receptor




GPCR G-protein coupled receptor
GnRH gonadotropin releasing hormone
GnRHR gonadotropin releasing hormone receptor




hcG human chorionic gonadotropin
HC1 hydrochloric acid
HEPES N-[2-hydroxyethyl]-piperazine-N'-ethane sulphonic acid]
Hesxl Homeobox gene expressed in ES cells
His histidine







ITR inverted tandem repeats










LH|3 luteinising hormone beta-subunit
LHR luteinising hormone receptor




MAPK mitogen activated protein kinase











NaH2P04 sodium phosphate, monobasic
Na2HP04 sodium phosphate, dibasic
NaOH sodium hydroxide
NES nuclear export signal





OHSS ovarian hyperstimulation syndrome
ORE open reading frame
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCOS polycystic ovarian syndrome
PCR polymerase chain reaction
pfu plaque forming units
PGBE pituitary glycoprotein hormone basal element
PHF9 PHD finger protein 9
Pitl pituitary specific transcription factor 1
Pitxl/2 paired like homeodomain transcription factor 1/2
PKC protein kinase C
PLC phospholipase C
Pro proline
Propl prophet of Pitl
PRL prolactin
PRH prolactin releasing hormone





rpm revolutions per minute
Rpx Rathke's pouch homeobox gene
RT-PCR reverse transcriptase PCR
SAP shrimp alkaline phosphatase
SDS sodium dodecyl sulphate
Ser serine
Sfl steroidogenic factor 1
SH2/3 Src-homology module 2/3
siRNA short interfering RNA
Abbreviations
SNX5 sorting nexin 5
Sox9 sry-box containing gene 9
T thymidine
TAE tris acetate EDTA





TSH thyroid stimulating hormone
TSH|3 thyroid stimulating hormone beta subunit
TRH thyrotropin releasing hormone











Zfp276 zinc finger protein 276
A note on nomenclature
To distinguish between different species approved gene names and abbreviations
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Discovery consists of seeing what everyone else has seen and thinking what no-one
else has thought - Albert Szent Gyorgyi.
Chapter One Literature Review
1 Literature Review
This chapter is split into two sections. Firstly, the current knowledge concerning the
regulation of gonadotropin hormone biosynthesis by gonadotropin releasing hormone
(GnRH) is discussed. Attention is focused on the development of the hypothalamic-
pituitary-gonadal (HPG) axis and the differential biosynthesis of the gonadotropin
subunits, within gonadotroph cells of the anterior pituitary. The review then focuses
on Fanconi Anaemia, an autosomal recessive disease classified as a DNA damage
repair disorder. The major gene mutated in Fanconi Anaemia, Fanconi Anaemia
Complementation group a (Fanca), accounts for >60% of cases and was previously
identified as a GnRFl regulated gene in this laboratory (Chang, 2002). This thesis
presents further evidence to show that GnRH regulates Fanca expression in
gonadotroph cells (Larder et al., 2004) and the possible impact of this regulation on
gonadotropin gene transcription.
1.1 The neuroendocrinology of reproduction
1.1.1 The hypothalamic-pituitary-gonadal axis
Together, the hypothalamus, pituitary gland and gonads regulate the development
and continuation of reproductive function in mammals. A finely tuned system has
evolved in which higher central nervous system (CNS) centres, influenced by both
internal and external stimuli, affect in a positive and negative way the secretion of
GnRH from the hypothalamus into the pituitary portal circulation. This releasing
hormone stimulates the anterior pituitary gland to secrete follicle stimulating
hormone (FSH) and luteinising hormone (LH), which, in turn, act on the ovary and
testis to promote follicular development and ovulation in females and
spermatogenesis in males. FSH and LH also stimulate the gonads to secrete various
steroidal and non-steroidal hormones. These target gland hormones then act at the
levels of the CNS and/or anterior pituitary to further regulate the system. In this
2
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section, a review of the current knowledge and understanding of the regulation of
gonadotropin biosynthesis and secretion is discussed.
1.1.2 The gonadotropins
The pituitary gonadotropins are fundamental to endocrine communication along the
HPG axis. FSH and LH are heterodimeric glycoproteins comprised of a common a-
subunit and a unique (Tsubunit (Bonsfield, 1994). The a-subunit is also common to
the glycoproteins, human chorionic gonadotropin (hCG) and thyroid-stimulating
hormone (TSH). Functional heterodimers of LH and FSH are synthesized and
secreted into the blood stream in response to hypothalamic GnRH. FSH and LH
elicit intracellular signalling pathways by binding to their respective G-protein
coupled transmembrane receptors, FSH receptor (FSHR) and LH receptor (LHR)
(Minegishi et al., 1990; Minegishi et al., 1991).
1.1.3 The female reproductive cycle
LH and FSH control the ovarian cycle in females, which lasts approximately 28 days
in humans, and is defined as the interval between successive ovulations. The cycle is
split into two phases: prior to ovulation the ovary is in the follicular phase, after
ovulation the ovary is in the luteal phase (Figure 1.1). The trophic actions of LH and
FSH are dependent on other factors such as inhibins (Mason et al., 1986b; Robertson
et al., 1996), activins (Vale et al., 1986; Risbridger and Cancilla, 2000), progesterone
and oestrogen (Diczfalusy, 1998). At the beginning of each cycle, an increase in
FSH levels leads to increased stimulation of the FSHR on the surface of granulosa
cells resulting in the recruitment of multiple follicles to begin pre-ovulatory
development. By the mid follicular phase, a rise in oestrogen and inhibin levels
precedes a fall in FSH levels and a slow increase in LH levels. Usually, at around
day 10 of the cycle, a 'dominant' follicle is selected and a further rise in oestrogen
levels is seen (Figure 1.1). This surge in oestrogen levels feeds back positively
triggering an increase in the frequency of hypothalamic GnRH pulses (Clarke et al.,
1987). This in turn causes the rapid release of LH from a bank of LH containing
granules within gonadotroph cells. This LH surge is crucial for reproduction as it
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triggers ovulation i.e. the release of the ovum from the mature follicle (Figure 1.1),
allowing the cycle to enter the luteal phase. An increase in FSF1 levels is also seen at
the time of ovulation as the increase in LH suppresses synthesis of inhibin
(McNeilly, 1988). The ruptured follicle then forms the corpus luteum (CL), and
begins to secrete progesterone (Filicori et al., 1984) (See Figure 1.1 and 1.2).
Progesterone depresses gonadotropin levels thus preventing the development of any
more antral follicles. If, at the end of the luteal phase fertilization of the ovum has
not occurred then luteolysis of the CL takes place resulting in the decline of
progesterone, oestrogen and inhibin levels. This allows FSH levels to increase again
and signals the rescue ofpre-antral follicles and repetition of the cycle (Figure 1.1).
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Figure 1.1 Modulation of hormones regulating the reproductive cycle in
females.
Relative gonadotropin and gonadal hormone plasma levels are indicated on the
graphs. Ovum development throughout the cycle is indicated below the graphs as
are the two phases separated by ovulation (arrow). Picture adapted from diagram
available at http://www.colorado.edu/. LH, luteinising hormone; FSH, follicle
stimulating hormone.
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Figure 1.2 Hormonal regulation of the reproductive cycle in females.
Diagram showing hormones involved in the early follicular and luteal phases of the
female reproductive cycle. Positive effects and sites of action of hormones
produced during the female cycle are shown in green. Negative feedback pathways
in operation are shown by red arrows. GnRH, gonadotropin releasing hormone, LH,
luteinising hormone, FSH, follicle stimulating hormone.
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1.1.4 Regulation ofmale fertility
The neuroendocrine mechanisms governing testicular function are fundamentally
similar to those regulating ovarian function. The main difference being, after
puberty, control of gonadal function is continuous rather than cyclical. In males, LH
controls testosterone secretion from Leydig cells (Matsumoto et al., 1984) whilst
FSH acts on seminiferous tubules to control spermatogenesis (Means et al., 1980).
Negative feedback by testosterone and inhibin ensures tight control of LH and FSH
production from the pituitary. Testosterone inhibits the pulse frequency of GnRH
from the hypothalamus (Matsumoto and Bremner, 1984) as well as acting on the
pituitary to decrease GnRH receptor (GnRHR) sensitivity to its ligand. FSH levels
are regulated by inhibin secreted from Sertoli cells (Carroll et al., 1989). See Figure
1.3 below.
Figure 1.3 Hormonal regulation of testicular function.
Diagram showing hormones involved in male reproduction. Positive effects and
sites of action of hormones produced during the control of male reproduction are
shown in green. Negative feedback pathways in operation are shown by red
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1.2 Mouse models and human gonadotropin signalling
phenotypes
Mutations of genes concerned with HPG function are rare, however, they offer the
opportunity to understand the mechanisms of reproduction much more clearly.
These naturally occurring mutations have been corroborated by genetic manipulation
of animal models to allow additional study of the particular phenotypes arising from
disruption of the HPG axis.
1.2.1 GnRH signalling mutations
To date, no loss-of-function mutations of the GnRH gene have been described in
humans (Weiss et al., 1991). However, in mice, there is a naturally occurring
deletion in the Gnrh gene resulting in a model of hereditary hypogonadism (hpg)
(Cattanach et al., 1977; Mason et al., 1986a). Mutant hpg mice completely lack
GnRH, resulting in severely reduced levels of LH and FSH within the pituitary and
consequently infertility and immature gonads. The phenotype can be rescued by
administration of GnRH directly, rather than by stimulation of the hypothalamus,
indicating that gonadotroph cells in these mice are still responsive to GnRH
(Charlton et al., 1983; Lewis et al., 1986). Patients presenting with a similar
phenotype to the hpg mouse will predictably have mutations in either; genes
involved in GnRH releasing neuron migration [Kallmans Syndrome] (Franco et al.,
1991; Dode et al., 2003); genes involved in GnRH processing (Seminara et al., 2000)
genes hypothesised to be involved in the hypothalamic regulation ofGnRH secretion
by gonadal steroids (Seminara et al., 2003; Gottsch et al., 2004) or the gene encoding
the GnRHR (de Roux and Milgrom, 2001).
1.2.2 GnRH receptormutations
Several patients with idiopathic hypogonadtropic hypogonadism (IHH) have been
shown to carry bi-allelic mutations of the GnRHR gene (de Roux et al., 1997;
Layman et al., 1998; de Roux et al., 1999; Pralong et al., 1999; Kottler et al., 2000).
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These patients have a broad spectrum of phenotypes varying from partial
hypogonadotrophic deficiency with moderately altered levels of gonadotropins and
gonadal steroids to complete hypogonadism with the absence of pubertal
development (Kottler et al, 1999; Beranova et al., 2001).
1.2.3 Common a-subunit mutations
As hCG is possibly required for embryo implantation in humans, no mutations of a-
subunit have been described in man, since they would probably result in embryonic
lethality (Licht et al., 2001). However, transgenic mice carrying mutations in a-
subunit, and therefore lacking bioactive LH and FSH, have been engineered.
Heterozygote mice have normal growth and fertility but homozygote mice are
severely growth retarded and infertile. Analysis of these mice shows that whilst
neonatal gonads appear normal, adult gonads are pre-pubertal in appearance
suggesting that gonadotropins are not necessary for initial programming of the
gonads but are required for their continued maturation and adequate function
(Kendall et al., 1995).
1.2.4 Specific (3-subunit mutations
Unlike a-subunit, naturally occurring mutations in LH(3 and FSH|3 subunit ligands
and receptors have been described in man.
1.2.4.1 FSH /3-subunit ligand mutations
To date, only a few inactivating mutations in the FSH(3 ligand have been reported
(Matthews et al., 1993; Layman et al., 1997; Phillip et al., 1998). In each case the
mutation blocks the dimerization of FSH(3 and aGSU. In women, this results in
delayed puberty, primary amenorrhea and no breast development, consistent with the
functions of FSH in stimulating follicular development and oocyte maturation.
Males with mutations in FSH/3 have small testicles and are azoospermia suggesting
a role for FSH in pubertal development and spermatogenesis. Targeted disruption of
the Fsh/3 gene in mice affects female mice more severely than males (Kumar et al.,
9
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1997). Histological examination of females revealed small ovaries that showed a
complete failure of follicular development beyond the preantral stage. In male mice
much milder phenotypic effects are seen, they have smaller testes with a 75%
reduction in epididymal sperm numbers, but they can still reproduce. Studies of
mice over-expressing human FSH reveal that males have elevated levels of
testosterone and are infertile whilst females develop ovarian cysts (Kumar et al.,
1999), a phenotype observed in women with ovarian hyperstimulation syndrome
(OHSS). Similarly, mice that can synthesise and secrete FSH, but not LH, are also
infertile as males have disrupted spermatogenesis and females do not develop corpus
lutea (Allan et al., 2001).
1.2.4.2 FSH receptor mutations
Missense, inactivating mutations of the FSH receptor (FSHR) result in premature
ovarian failure and impaired spermatogenesis whilst, activating mutations have been
associated with OHSS (Aittomaki et al., 1995; Tapanainen et al., 1997; Smits et al.,
2003; Vasseur et al., 2003; Montanelli et al., 2004). Fshr gene knockout mice have a
similar phenotype to Fsh/3 gene disrupted mice (Abel et al., 2000), thus, FSH activity
is required for sexual development and spermatogenesis and is crucial for female
reproduction.
1.2.4.3 LH /3-subunit mutations
LH (3-subunit mutations are extremely rare and to date, no homozygous LH/3
mutations have been described in human females. However, there are two reports of
male patients that are homozygous for a single base mutation in the LH(3 gene
resulting in a non-functional LH protein. In the first reported case, the proband
presented with delayed puberty, low testosterone, arrested spermatogenesis and
elevated levels of both FSH and LH (Weiss et al., 1992). In a recently reported
second case, a patient presented with similar clinical symptoms to the first case, but
whilst FSH levels were elevated, LH levels were undetectable (Valdes-Socin, 2003).
The undetectable LH levels in the second patient are due to the single base change
disrupting the dimerization of LH(3 with aGSU. An Lh/3 knockout mouse has yet to
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be generated, there is however a mouse line engineered to over-express LH (Risma et
al., 1995). Females have enlarged ovaries due to the presence of multiple corpora
lutea, cysts and tumours. Further analysis reveals that these mice also have
precocious puberty and hyperandrogenemia (Risma et al., 1997), a clinical feature
seen in women with elevated levels of LH who have polycystic ovary syndrome
[PCOS] (McCartney et al., 2002).
1.2.4.4 LH receptor mutations
Two groups have demonstrated that cases of familial precocious puberty in males,
characterised by enlarged testicles by age 4 yr and increased testosterone levels, were
caused by single amino acid changes resulting in constitutive activation of the LH
receptor (LHR) (Kremer et al., 1993; Shenker et al., 1993). Activating receptor
mutations in the female appear to have no obvious phenotype but may impact on the
timing of the LH surge in cycling women (Rosenthal et al., 1996). Male patients
with inactivating mutations of the LH receptor present with pseudohermaphroditism,
female genitalia and un-descended testes which contain no Leydig cells, presumably
due to lack of testosterone secretion. (Berthezene et al., 1976; Brown et al., 1978; Eil
et al., 1984). In contrast, females present with primary amenorrhea and anovulation
(Toledo et al., 1996). Targeted deletion of the Lhr gene in mice generated a similar
phenotype to that described in humans (Zhang et al., 2001).
In summary, analysis of HPG axis mutations has identified several specific roles for
GnRH, LH and FSH. Firstly, GnRH is required for up-regulation of LH and FSH.
Secondly, FSH is crucial for the recruitment of follicles within the ovary and is
required for Sertoli cell function and consequently spermatogenesis in males.
Finally, LH controls the secretion of testosterone in males, a factor crucial for
spermatogenesis and is required for ovulation in females.
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1.3 Development of the pituitary-gonadal axis
In recent years it has been shown that a controlled cascade of temporally and
spatially regulated transcription factors are required for the development of specific
cell types within the anterior pituitary as well as the initiation and maintenance of
production of specialized hormones from these cells. This section will discuss some
of the transcription factors crucial for normal anterior pituitary development with
particular reference to those required for gonadotroph cell determination and basal
expression of gonadotropin genes.
1.3.1 The pituitary
The mature human pituitary gland is comprised of three lobes (anterior, intermediate
and posterior). The gland integrates complex feedback mechanisms from the brain,
via the hypothalamus, to signal to endocrine organs such as the thyroid, adrenals and
gonads, in order to regulate processes such as metabolism, growth and reproduction.
The five specialised cell types that comprise the anterior pituitary gland are defined
by the hormones they produce and secrete in response to levels of releasing and
inhibitory hormones secreted by the hypothalamus. Corticotrophs secrete
adrenocorticotrophin (ACTH) to regulate adrenal function; thyrotrophs secrete
thyroid-stimulating hormone (TSH) to control thyroid hormone production;
somatotrophs secrete growth hormone (GH); lactotrophs secrete prolactin (PRL) to
regulate milk production; melanotrophs secrete melanin-stimulating hormone
(aMSH) and gonadotrophs secrete luteinising hormone (LH) and follicle stimulating
hormone (FSH) to control gonadal function (Dasen and Rosenfeld, 2001). (Figure
1.4). Studies of hormone gene activation in rodents show that the cell types
differentiate in a defined temporal order (Simmons et al., 1990; Japon et al., 1994)
and arise in distinct regions of the developing gland (Dasen et al., 1999; Kioussi et
al., 1999). However this spatial organisation does not appear to be maintained in
adulthood as the different cells become dispersed throughout the pituitary (Mikimi,
1992).
12
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Figure 1.4 Cell types within the mammalian anterior pituitary gland.
Stimulation of specific receptors on the surface of anterior pituitary cells results in
the synthesis and secretion of cell specific hormones. The five anterior pituitary
hormone secreting cell types, the receptors that allow regulation of pituitary
hormone secretion, their hormone products, and the target organs of the hormones
are shown. Gonadotropin releasing hormone receptor (GnRHr), FSH (follicle
stimulating hormone), LH (luteinising hormone), thyrotropin releasing hormone
receptor (TRHr), thyroid stimulating hormone (TSH), growth hormone releasing
hormone receptor (GHRHr), growth hormone (GH), prolactin releasing hormone
receptor (PRHr), prolactin (PRL), corticotrophin releasing hormone receptor (CRHr),
adrenocorticotrophin hormone (ACTH)
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1.3.2 Pituitary gland development
The mature pituitary gland is derived from two distinct embryological sources. The
anterior gland develops as an invagination of the oral ectoderm forming Rathke's
pouch at embryonic stage 9.5 (E9.5) in mouse. At around the same time, the
posterior gland forms from an evagination of the neuroectoderm (infundibulum)
(Kauffman, 1992). Direct contact between these structures is required for the early
phases of pituitary development and it is known that pituitary cell determination
occurs in response to the formation of signalling gradients of various transcription
factors (Ericson et al., 1998; Takuma et al., 1998; Treier et al., 1998).
1.3.3 Transcription factors crucial for pituitary development and patterning
Several transcription factors have been identified as being crucial for early pituitary
development through identification of mutations in humans with pituitary disorders
and the engineering ofmouse models.
1.3.3.1 Hesx1/Rpx1
Homeobox gene expressed in ES cells (Hesxl) is a paired-class homeodomain
transcription factor expressed early in mouse embryogenesis in the developing neural
plate and later restricted to Rathke's pouch (Thomas et ah, 1995). Expression of
Hesxl is down regulated by E13.5, this coincides with the expression of
differentiation markers of the various anterior pituitary cell types such as pituitary
specific transcription factor 1 [Pitl] (Hermesz et ah, 1996) and Prophet ofPitl
[Propl] (Gage et ah, 1996a). Persistent mis-expression ofHesxl prevents pituitary
expansion suggesting that Hesxl down-regulation is required for pituitary cell type
specification (Gage et ah, 1996a). Targeted mutation of the Hesxl gene in mice
shows that it is essential for the development of the forebrain, eyes and pituitary,
which is corroborated by combined pituitary hormone deficiency (CPHD) in humans
with HESX1 mutations (Dattani et ah, 1998; Dattani et ah, 1999; Thomas et ah,
2001). Recently, Hesxl has been shown to repress aGsu and Lh/3 promoters
indicating a possible role for Hesxl in the inhibition of terminal differentiation
markers (Quirk and Brown, 2002).
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1.3.3.2 LIM homeodomain transcription factors
Several members of the LIM (Zinc finger binding domain present in Lin-1, Isl-1 and
Mec-3) homeodomain family, including Isll, Isl2, Lhx2, Lhx3 and Lhx4, are
expressed during pituitary development. Lhx3 expression is switched on in Rathke's
pouch and is maintained in the adult pituitary (Zhadanov et ah, 1995). Targeted
disruption of the Lhx3 gene in mice arrests pituitary gland formation at the Rathke's
pouch stage in Lhx3~f~ mice and only corticotrophs can be detected, suggesting that
Lhx3 expression is required for development of the other anterior pituitary cell types
(Sheng et al., 1996; Sheng et al., 1997). Human patients homozygous for a point
mutation in LHX3 (Y114C)have growth, reproductive and metabolic disorders
consistent with a role for the gene in the differentiation of somatotrophs,
gonadotrophs and thyrotrophs (Netchine et al., 2000). This mutation also affects the
functional properties of Lhx3, as the mutant protein does not activate aGsu or FSH/3
transcription, supporting a role for Lhx3 in gonadotropin regulation (Howard and
Maurer, 2001; West et al., 2004). Lhx4 is closely related to Lhx3, and is expressed
during pituitary development. Lhx4 knockout mice display a lack of pituitary
development beyond Rathke's pouch due to a failure to expand the pouch (Raetzman
et al., 2002).
1.3.3.3 Pitx transcription factors
Paired-like homeodomain transcription factor (PITX) proteins are important for
many developmental pathways including pituitary organogenesis (Gage et al.,
1999a). Pitxl expression precedes Rathke's pouch formation and continues
throughout anterior pituitary development in several cell lineages. It is required for
aGsu and Lhx3 expression (Tremblay et al., 1998) and can act synergistically with
Pitl in somatotrophs and Steroidogenicfactor 1 (Sfl) in gonadotrophs to regulate Prl
and Lh(3 promoters respectively. Pitxl null mice have defects in hind limb
morphogenesis and have a diminished population of gonadotroph and thyrotroph
cells (Szeto et al., 1996; Lanctot et al., 1999; Marcil et al., 2003). This relatively
mild pituitary phenotype may be explained by a possible functional redundancy
between Pitxl and a related paired-homeodomain transcription factor, Pitx2.
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Expression analysis shows that Pitxl and Pitx2 are co-expressed during mouse
pituitary development (Gage and Camper, 1997). In Pitx2 mutant mice, the gland
fails to progress beyond El0.5 resulting in a failure of immature cells to proliferate
ventrally and populate the pituitary gland (Gage et al., 1999b; Lin et al., 1999; Suh et
al., 2002). Pitx2 is also hypothesised to be involved in terminal differentiation of
pituitary cell types as it can directly increase transcription from the Fshf3 and Prl
gene promoters (Amendt et al., 1999; Suszko et al., 2003).
1.3.3.4 Pitl
Expression of Pitl, a POU-class homeodomain protein, is activated coincident with
the down regulation of Hesxl expression and is important for development of
thyrotrophs, somatotrophs and lactotrophs due to its role in activation of Tsh/3, Gh
and Prl promoters (Li et al., 1990; Tremblay et al., 2000). Pitl expression is
excluded from gonadotrophs, but not thyrotrophs, by a high level of Gata2
expression, which inhibits the expression of Pitl, but allows expression of
gonadotroph specific transcription factors (Dasen et al., 1999). In dorsal cells, Gata
binding protein 2 (Gata2) expression is low therefore Pitl expression persists in
somatotrophs and lactotrophs precursors. In presumptive thyrotrophs, levels of
Gata2 are insufficient to inhibit Pitl expression therefore allowing the emergence of
a cell type expressing both Gata2 and Pitl. This is controlled by a bone
morphogenetic protein 2 (.Bmp2) gradient, which induces the dorsal to ventral Gata2
expression pattern (See Figure 1.5). If Pitl and Gata2 are disrupted, then this
expression gradient is lost and specific cell types fail to arise (Dasen et al., 1999).
1.3.3.5 Prophet of Pitl
The role of Prophet of Pitl (Propl), a paired-like homeodomain factor, was
determined through genetic and phenotypic analysis of the Ames (df) mouse. The
anterior pituitaries of these mice showed a severe lack of thyrotrophs, somatotrophs
and lactotrophs (Gage et al., 1996b), due to an absence ofPitl expression, linking
Propl to the activation of Pitl expression (Sornson et al., 1996). Propl also acts to
repress Hesxl expression so that pituitary cell-type determination, rather than
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proliferation, occurs (Gage et al., 1996a). Propl may also be required for the
determination of gonadotroph cells or gonadotropin gene activation as patients with
PROP1 mutations have severe defects in gonadotropin synthesis (Wu et al., 1998).
This is probably due to the persistence ofHesxl expression within the developing
anterior pituitary resulting in the repression of gonadotropin gene expression.
Figure 1.5 Gradient of transcription factors required for patterning of
anterior pituitary cell types.
A high level of Gata2 expression determines the differentiation of gonadotrophs
cells (G) due to repression of Pit1 expression. Expression of Pit1 determines the
differentiation of somatotrophs (S), lactotrophs (L) and corticotrophs (C).
Expression of both Gata2 and Pit1 determines the differentiation of thyrotrophs (T).
1.3.4 Factors required for gonadotroph specific gene expression
As discussed above, gonadotroph cells arise ventrally within the anterior pituitary.
The expression of gonadotroph cell terminal differentiation markers, LHfJ and FSH/3,
is controlled by various transcription factors including Early growth response-1
(EGR1), SF1 and PITX1. Analysis of mice engineered with targeted mutations in
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1.3.4.1 Steroidogenic factor 1
Steroidogenic factor 1 (Sfl) is expressed in several endocrine tissues during
development and targeted disruption of the Sfl gene reveals it is crucial for
reproductive development since Sfl'A mice lack gonads and adrenal glands. Males
exhibit sex reversal due to a regression of the gonads prior to sexual differentiation
(Ingraham et al., 1994; Luo et al., 1995). The lack of adrenal glands causes death
soon after birth due to adrenocortical insufficiency but the mice can be rescued by
corticosteroid injection. In pituitaries lacking Sfl expression, Tsh, Gh and Acth are
expressed as normal but there is a marked decrease in the expression of gonadotroph
specific markers (Ingraham et al., 1994). This is consistent with a role for Sfl in
aGsu (Barnhart and Mellon, 1994; Ingraham et al., 1994), Lhfi (Halvorson et al.,
1996; Keri and Nilson, 1996; Brown and McNeilly, 1997; Halvorson et al., 1998;
Dorn et al., 1999), Fshf (Brown and McNeilly, 1997) and GnRHr (Duval et al.,
1997; Ngan et al., 1999) expression. Interestingly, in mice rescued by corticosteroid
injection, LH and FSH levels can be restored by treatment with GnRH as lack of Sfl
does not affect GnRH synthesis but does prevent its secretion (Ikeda et al., 1995).
The importance of Sfl expression within the developing pituitary was confirmed by
tissue-specific targeted deletion of the gene (Zhao et al., 2001). The aGsu-Cre/loxP
targeted mice lacked Sfl expression within the anterior pituitary, but had normal
expression in the adrenal cortex and developing gonads. These mice had
underdeveloped gonads and markedly reduced levels of LH and FSH demonstrating
that locally produced Sfl is essential for normal gonadotroph function and
gonadotropin gene expression.
1.3.4.2 Early growth response factor 1
Egrl, a zinc finger protein transcription factor, is crucial for gonadotroph and
somatotroph cell development. There are two separate reports of mice with a
targeted disruption of the Egrl gene (Lee et al., 1996; Topilko et al., 1998) and in
both cases the mice had an infertility phenotype due to lack of Lh/5 expression. The
first report showed that both sexes had lowered levels of Lh/3 expression but only
female mice were sterile (Lee et al., 1996). This suggests that either the presence of
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an additional regulatory mechanism compensates in males for low levels of LH, or
that the gene was only partially inactivated retaining some residual function. A
second Egrl mutant allele produced a more severe phenotype; in this case both sexes
were infertile (Topilko et al., 1998). Further studies of mutant female ovaries
identified a role for Egrl in ovarian development as well as anterior pituitary
development. These phenotypes are consistent with a role for Egrl in activation of
the Lh/3 promoter, which contains Egrl binding sites that bind Egrl and synergise
with Sfl to transactivate the promoter (Lee et al., 1996).
Figure 1.6 summarises the transcription factors known to determine anterior pituitary
cell differentiation with particular reference to gonadotroph cells.
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1.4 Gonadotropin releasing hormone
The hypothalamic decapeptide, GnRH, is the central regulator of the reproductive
system. Neurons within the hypothalamus release GnRH into the portal blood
system, which transports it to the anterior pituitary gland. Binding of GnRH to its
receptor (GnRHR) on the surface of gonadotroph cells stimulates the release of the
gonadotropins, LH and FSH, into the blood stream, which carries them to their target
organs, the gonads. Although each of the components of the hypothalamic-pituitary-
gonadal axis is critical for reproductive function, any abnormality in GnRH
synthesis, storage, release or action will result in partial or complete failure of
gonadal function as previously described in Section 1.2.1.
I.4.1 GnRH decapeptide
There are several GnRH structural variants in vertebrates (King and Millar, 1979),
and to date 16 novel GnRH peptides have been identified (Millar, 2002) with at least
two, and usually three, forms of GnRH present in most vertebrate species. All
GnRH-like peptides are formed from 10 amino acids and are structurally related
sharing at least 50% sequence identity, with differences usually existing at amino
acids 5-8. In humans two forms ofGnRH have been identified, named GnRH-I and
II, although in humans there is only one functional GnRH receptor (Morgan et al.,
2003). GnRH-I is the prime regulator of the HPG axis in vertebrates and all further
reference to GnRH in this thesis refers to GnRH-I unless stated otherwise. The
cDNA sequence corresponding to GnRH encodes a 92 amino acid pre-pro-hormone
consisting of a 23 amino acid signal peptide, the decapeptide and the 56 amino acid
GnRH-associated peptide [GAP] (Seeburg and Adelman, 1984). The amino acid
sequence of mammalian GnRH decapeptide is shown in Figure 1.7. GnRH is
synthesized in neurosecretory cells within the hypothalamus. From here it is
secreted, via GnRH neurons, into the hypophyseal portal vessels which transport it to
gonadotroph cells within the anterior pituitary (Fink, 1988). The pulsatile delivery of
GnRH, every 15-120 minutes, from the hypothalamus is crucial for the maintenance
of gonadotropin gene expression and secretion of LH and FSH. The frequency of
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GnRH pulses is highest during the LH surge, triggering ovulation, and lowest during
the luteal phase (Clarke and Cummins, 1982; Fink, 1988). GnRH pulse frequency is
discussed in more detail in Section 1.4.3.
pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly
Figure 1.7 Amino acid composition of mammalian GnRH.
The amino-terminal residues (blue) have a role in receptor activation. Amino acid
residues in the middle of the decapeptide (grey) are required for binding to the
GnRH receptor. The carboxy-terminal residues (pink) are required for specificity
and high affinity binding to GnRH receptor.
1.4.2 GnRH type I receptor
To regulate gonadotropin gene expression, GnRH binds to GnRH type I receptor
(GnRHR) located on the surface of gonadotroph cells. The gene for GnRHR has
been cloned in various species including mice (Tsutsumi et al., 1992) and humans
(Kakar et al., 1992). The 328 amino acid protein belongs to the G-protein coupled
receptor (GPCR) family, defined by seven transmembrane domains, however
mammalian GnRHR is different from other GPCRs since it lacks a carboxy-terminal
cytoplasmic tail. As desensitisation and internalization ofGPCRs usually occurs via
this C-terminal cytoplasmic tail GnRHRs are resistant to desensitisation and
internalise slowly (McArdle et al., 2002). Figure 1.8 shows the organisation of the
seven transmembrane domains of the human GnRH receptor.
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GnRH
-COOH
Figure 1.8 Organisation of the seven transmembrane domains of the
human GnRH receptor.
Taken from (Ulloa-Aguirre et al., 2004). Note the lack of a C-terminal receptor tail
commonly seen in GPCR's.
1.4.3 GnRH pulse frequency
The frequency and amplitude of GnRH pulses determines the secretion of FSH and
LH from the pituitary. Before puberty, in both males and females, GnRH is released
sporadically from the hypothalamus resulting in basal plasma levels of LH and FSH.
At puberty, in males, GnRH pulse frequency increases to one GnRH pulse per hour,
and is maintained at this level throughout adult life (Lincoln et al., 1985). In
contrast, when females reach puberty the GnRH pulse frequency varies depending on
the stage of the reproductive cycle (Knobil, 1980). After ovulation, the GnRH pulse
frequency is at one pulse every 45-60 minutes, this increases to approximately one
pulse every 15 minutes immediately prior to the LH surge then returns to one pulse
every 60 minutes (Clarke et al., 1987; Moenter et al., 1991). Each GnRH pulse
increases the responsiveness of the pituitary to subsequent GnRH pulses. However,
continuous exposure of gonadotrophs to GnRH results in maintained occupancy of
the receptors and is followed eventually by receptor down regulation and a reduction
in pituitary LH and FSH content and secretion (Belchetz et al., 1978). Figure 1.9
shows GnRH pulse frequency throughout the female reproductive cycle.
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Figure 1.9 Frequency of GnRH pulses during the reproductive cycle in
females.
Relative gonadotropin and gonadal hormone plasma levels are indicated on the
graphs. GnRH pulses are indicated with an arrow. Picture adapted from diagram
available at http://www.colorado.edu/. LH, luteinising hormone; FSH, follicle
stimulating hormone.
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The importance of GnRH pulse frequency and amplitude has been shown in various
model systems. In rats, administration of GnRH increases both aGsu and Lhfl
mRNA levels, however, a specific pulse frequency is required to up regulate Lh/3
whereas aGsu mRNA up-regulation occurs in response to either continuous or
pulsatile GnRH administration (Papavasiliou et al., 1986; Shupnik, 1990; Weiss et
al., 1990; Haisenleder et al., 1991). These studies also showed that, in contrast to
aGsu and Lhfi, Fsh/3 mRNA was not significantly up-regulated by either a
continuous or pulsatile administration of GnRH. Further research has now
determined that only a slow GnRH pulse frequency of one pulse every 120 minutes
increases Fshfi mRNA (Dalkin et al., 1989) and that activin is also required for this
up-regulation (Weiss et al., 1993; Graham et al., 1999). The in vivo mRNA
expression profile of Fshfi can be manipulated to resemble that of Lh/3 by driving
Fsh/5 transgene expression using the Lh/3 promoter underlining the differential
effects ofGnRH on the gonadotropin promoters (Brown et al., 2001).
1.4.4 GnRH signalling pathways
G-protein coupled receptors use a number of different intracellular signalling
pathways, including sequential activation of kinases, to initiate cellular processes
such as proliferation, differentiation and development. GPCRs transmit their signals
primarily via GTP-binding proteins (G-proteins) comprised of an a, (3 and y subunit.
Upon stimulation, Ga dissociates from the G(3y dimer to allow it to interact with
other molecules. G-proteins are classified according to their a-subunit into the
following four groups: Gs; Gi/o; Gq/11, and G12/13. Studies of aT3-l gonadotroph
cells show that binding of GnRH to its receptor leads to the stimulation of Gqa
and/or Gila protein (Shah and Milligan, 1994). Mice lacking Gqa or Gila
respond to GnRH stimulation suggesting that either these G proteins are not
absolutely necessary or are able to compensate for each other (Stanislaus et al.,
1998), studies of double knockout mice would clarify the redundancy of Gqa and
Gila in GnRH signalling. Stimulation of Gqa/Glla leads to activation of
phospholipase C (PLC) (Hsieh and Martin, 1992) which results in enhanced inositol
1,4,5-triphosphate (IP3) turnover and production of diacylglycerol (DAG). This, in
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turn, leads to the activation of protein kinase C (PKC) and Ca2+ mobilization.
Downstream signalling to PKC leads to activation of mitogen activated protein
kinase (MAPK) signalling cascades which are involved in the regulation of gene
expression in various systems, either by activating transcription factors directly or by
phosphorylating other protein kinases (Seger and Krebs, 1995). See Figure 1.10.
Figure 1.10 Factors involved in signalling through the GnRH receptor
to initiate gonadotropin gene transcription.
GnRH binds to and activates the GnRH receptor (GnRHr) releasing the a-subunit of
the G protein. This activates phospolipase C (PLC) which results in activation of
protein kinase C (PKC) via diacylglycerol (DAG) and inositol phosphate (IP3). PKC
then initiates Ca2+ mobilization and MAPK cascades to initiate transcription.
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1.4.4.1 Initiation of gonadotropin gene transcription via calcium signalling
Evidence has suggested that an influx in calcium can induce transcription of both
aGSU and LHfl as well as regulating the secretion of aGSU, LH and FSH (Ben-
Menahem andNaor, 1994; Stojilkovic and Catt, 1995; Holdstock et ah, 1996; Week
et ah, 1998). However, current thinking now suggests that the release of calcium
from intracellular stores, rather than an influx of extracellular calcium, contributes to
the regulation of gonadotropin gene transcription (Mulvaney and Roberson, 2000;
Yokoi et ah, 2000).
1.4.4.2 Initiation ofgonadotropin gene transcription via MAPK signalling
Mitogen activated protein kinase (MAPK) signalling cascades are involved in the
regulation of gene expression in various systems and consist of a series of up to five
protein kinases that activate each other by phosphorylation. The ability of activated
MAPKs to translocate to the nucleus and trigger transcription enables the formation
of a signalling pathway from the receptor to the nucleus. To date, four distinct
MAPK cascades have been identified (extracellular signal regulated kinase [ERK], c-
Jun NH2-terminal kinase [JNK], p38MAPK and BiMC related kinase [BMK]).
GnRH activates them in a hierarchical manner in gonadotroph cell lines (See Section
3.1.1 for a detailed description of these cell lines) with, ERK and JNK activated first
(Naor et ah, 2000; Liu et ah, 2002).
GnRH responsive elements have been mapped to the proximal promoter of aGSU in
humans (Kay and Jameson, 1992), cows (Hamernik et ah, 1992) and mice
(Schoderbek et ah, 1993). Elkl, a factor known to be phosphorylated by ERK, has
been shown to bind to the GnRH-responsive element at -406 to -399 bp of the a-
subunit promoter in aT3-l cells (Roberson et ah, 1995) whilst a recent report shows
that ERKs are also involved in basal promoter activity as well as the GnRH-
stimulated response (Harris et ah, 2003).
GnRH responsive elements have been mapped to the LH/5 promoter of sheep (Brown
et ah, 1993; McNeilly et ah, 1996), rat (Fallest et ah, 1995) and cow (Keri et ah,
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1994). Induction of LH(5 subunit transcription is also contentious with two different
papers reporting conflicting results on the importance of PKC, ERK, Ca2+ and JNK
in basal and GnRH-induced transcription (Saunders et al., 1998; Week et al., 1998).
More recently, research into the roles of ERK and JNK in LPT2 cells has further
elucidated the roles of MAPK cascades in the control of LH/3 transcription. One
report shows that ERK signalling is PKC and Ca2+ dependent in LPT2 cells, but does
not control LH/5 transcription, whereas JNK signalling is involved in LH/3
transcription but through c-jun rather than PKC and/or Ca2+ (Yokoi et al., 2000).
However, recent results indicate that both ERK and JNK are involved in LH/3
transcription in response to GnRH (Harris et al., 2002; Liu et al., 2002) (P.Brown,
personal communication).
GnRH regulation ofFSH/3 subunit transcription requires PKC, ERK and JNK (Bonfd
et al., 2004). JNK directly activates c-jun and c-fos, which dimerize to form
activator-protein-1 (AP-1), a factor that is critical for FSH/5 promoter activity (Strahl
et al., 1997; Strahl et al., 1998; Coss et al., 2004) supporting a role for MAPK
cascades in FSH/3 transcription.
The differences seen in transcriptional regulation of the gonadotropin subunits
indicates that differential roles of MAPK cascades in GnRH signalling can partly be
attributed to the use of different cell lines, promoters and species and suggests that
they may also provide a mechanism to differentially regulate subunit gene
expression. Multiple pathways of MAPK activation exist to generate redundancy in
signalling and any disrupting cellular changes or extrinsic factors may alter the
course by which MAPKs are stimulated and therefore change the transcriptional
effects of the MAPK. Figure 1.11 shows a simplified version of the MAP kinase
cascades activated in response to GnRH in L|3T2 cells.
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Figure 1.11 MAPK cascades initiated in L0T2 cells in response to
GnRH.
GnRH binds to and activates the GnRH receptor (GnRHr) releasing the a-subunit of
the coupled G protein. This activates protein kinase C (PKC), which in turns
activates various mitogen activated protein kinase (MAPK) cascades. Highest
activation is observed via the JNK MAPK cascade family with c-src, CDC42 and
MEK kinase 1 (MEKK1) being the main mediators of the GnRH-JNK pathway. JNKs
translocate to the nucleus where they phosphorylate and activate the transcription
factors c-Jun and c-Fos, which have been shown to regulate LHp and FSHp
transcription. GnRH also signals via the ERK MAPK family involving the sequential
activation of Raf and MEK. ERK phosphorylates Elk1, a factor that binds to the
aGSU promoter to control transcription. Diagram adapted from (Kraus et al., 2001).
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This section has described how the generation of a hypothalamic pulse ofGnRH and
subsequent binding of GnRH to its receptor on the surface of gonadotroph cells
results in the activation of distinct MAPK cascades to initiate the biosynthesis and
secretion of two disparate, but ultimately synergistic hormones, LH and FSH. The
trophic actions of LH and FSH are essential for gonadal function and regulation of
the HPG axis, as even a small alteration in the regulated release of these hormones
can have a significant impact on fertility.
30
Chapter One Literature Review
1.5 GnRH and cancer
In recent years, research has shown that GnRH, and its receptor, are expressed in
tissues other than the hypothalamus and pituitary including; the placenta (Kang et al.,
2000b), endometrium (Takeuchi et al., 1998), ovary (Peng et al., 1994; Kang et al.,
2000a), prostate (Tieva et al., 2001) and testis (Clayton et al., 1980; Bahk et al.,
1995). The presence of GnRH and GnRHR transcripts in cancers of the reproductive
tract has also been widely studied including those of the prostate (Limonta et al.,
1993; Bahk et al., 1998), endometrium (Imai et al., 1994; Irmer et al., 1994; Chatzaki
et al., 1996), breast (Harris et al., 1991; Kakar et al., 1994; Mangia et al., 2002) and
ovary (Ohno et al., 1993; Irmer et al., 1995) as well as non-hormonally regulated
tumours such as glioblastomas (van Groeninghen et al., 1998) and melanomas
(Moretti et al., 2002). Interestingly, in these tumours, activation ofGnRH receptors
has been shown to down regulate cell proliferation and reduce metastasis (See Figure
1.12), possibly by down regulating the tumour-promoting activity of growth factors
(Miller et al., 1985; Keri et al., 1991; Limonta et al., 1992; Emons et al., 1993; Dondi
et al., 1994; Yano et al., 1994; Kimura et al., 1999). If so, GnRH could prove a
useful tool in the treatment of reproductive cancers.
Figure 1.12 Proposed functions of GnRH in tumour progression.
Activation of GnRHR in cancer cells has been shown to decrease the proliferation
rate and metastatic capabilities of tumour cells.
GnRH
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1.6 Regulation of gene expression by GnRH
The molecular mechanisms by which GnRH achieves its functions remain unclear.
Within gonadotroph cells, a limited number of GnRH target genes have been
identified and further characterised. Microarray analysis of untreated and GnRH
treated gonadotroph cells has identified a large number of genes (>200) that
demonstrated a 2-fold or greater increase or decrease in expression after GnRH
treatment (Wurmbach et al., 2001; Kakar et al., 2003). These genes are involved in a
wide variety of cellular processes and include transcription factors, ion channel
proteins and cytoskeletal proteins, as well as proteins involved in controlling the cell
cycle, cell proliferation, apoptosis and signal transduction. Time course experiments
identified that several of these genes were highly regulated with elevated levels of
expression 1 h after treatment with GnRH, returning to baseline levels 3 h after
treatment. These experiments have allowed the identification of many genes that
were previously not known to be involved in the regulation of gonadotropin subunit
transcription by GnRH and suggest that signalling of GnRH through its receptor may
impact on processes other than gonadotropin biosynthesis within gonadotrophs.
However, confirmation that these genes are involved in GnRH signalling is required.
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1.7 Fanconi Anaemia
Fanconi Anaemia (FA) is a rare, autosomal recessive, chromosomal instability
syndrome (OMIM 227650) first described in 1927 by the Swiss paediatrician Guido
Fanconi (Fanconi, 1927). The incidence of FA is approximately 1 per 360,000 births
with a carrier frequency in the US and Europe calculated at ~1 in 300 persons (Swift,
1971; Schroeder et al., 1976). Founder effects mean that this is increased to ~ 1 in
89 in Ashkenazi Jews (Verlander et al., 1995) and 1 in 83 in the Afrikaans
population of South Africa (Rosendorff et al., 1987; Tipping et al., 2001). The
disorder has a complex genetic basis and variable phenotype as the same FA
mutation within a family can result in a wide variation in clinical symptoms (Alter,
1993; Koc et al., 1999). This section summarises the recent molecular advances that
have helped in the understanding of the cellular and clinical phenotypes associated
with FA.
1.7.1 Clinical phenotypes of Fanconi Anaemia
FA is a highly heterogeneous syndrome with many associated clinical features. In
general, the disease is characterised by bone marrow failure due to a progressive loss
of haematopoietic stem cells (Alter, 1998). With the advent of bone marrow
transplants, a cure for the haematopoietic aspects of the disease is now possible for
some patients. However, this does not alleviate the marked pre-disposition to
developing cancer associated with FA (Alter, 1996) including leukaemia and
tumours of the digestive system, reproductive tract and liver, which are all
commonly seen in older FA patients (Alter, 2003). A wide variety of congenital
abnormalities are also associated with FA, the most common of which are listed in
Table 1.1.
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Table 1.1 Frequency of abnormalities seen in Fanconi Anaemia
patients.
Data are percentage of patients (n=838) presenting with the abnormality taken from
(Young and Alter, 1994).
7.7.2 Cellular phenotypes of Fanconi Anaemia
FA patients are diagnosed using a lymphoblast assay system that detects spontaneous
chromosomal instability and hypersensitivity to DNA cross-linking agents such as
mitomycin C (MMC) and diepoxybutane (DEB) (Auerbach and Wolman, 1976;
Auerbach, 1993). These factors have led to FA being classified as a DNA repair
disorder (Buchwald and Moustacchi, 1998). Studies of lymphoblast cells from FA
patients reveal that an increased proportion have a 4n DNA content due to
spontaneous arrest and delay during the G2 stage of the cell cycle (Seyschab et al.,
1994; Heinrich et al., 1998). The bone marrow defects seen in FA patients suggest
that expression of growth factors involved in haematopoiesis could be altered since
studies have shown that interleukin-6 (IL6), a cytokine involved in various
processes, including B-cell differentiation, is decreased in cells from FA patients
(Rosselli et al., 1992; Bagnara et al., 1993).
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1.7.3 Genetics of Fanconi Anaemia
Cultured FA cells are sensitive to DNA cross-linking agents and this has been
exploited to develop a complementation cloning method. So far eight
complementation groups have been discovered (Joenje et al., 1997) indicating the
syndrome is genetically heterogeneous. To date, seven FA genes had been cloned:
FANCC (Strathdee et al., 1992), FANCA (Lo Ten Foe et al., 1996), FANCG (de
Winter et al., 1998), FANCF(de Winter et al., 2000b), FANCE (de Winter et al.,
2000a), FANCD2 (Timmers et al., 2001) and FANCL (Meetei et al., 2003a). FA only
occurs if an individual has two abnormal genes from the same complementation
group.
1.7.4 Fanconi Anaemia complementation group A (FANCA)
FANCA was the second FA gene to be cloned and maps to human chromosome
16q24.3 (Lo Ten Foe et al., 1996). Approximately 65% of all FA patients have
mutations in FANCA however there does not appear to be a common FANCA
mutation, instead point mutations and deletions are spread along the gene (Ianzano et
al., 1997; Levran et al., 1997; Morgan et al., 1999; Wijker et al., 1999). Murine
Fanca was cloned in 2000 (van de Vrugt et al., 2000; Wong et al., 2000) and maps to
the distal region of mouse chromosome 8, a region syntenic with human 16q. The
gene shares 74% nucleotide sequence identity with human FANCA and has an ORF
of 4365 bp. It is comprised of 43 exons and produces a protein of 1455 amino acids
(-160 kD) with 66% identity and 81% similarity to human FANCA. Analysis of
Fanca sequence reveals a bipartite nuclear localization signal (NLS) at the N-
terminus, a partial leucine zipper and several regions with weak homology to
putative SH2 and SH3 (Src-homology module 2 and 3) domains (See Figure 1.13)
suggesting FANCA protein can bind DNA and/or other proteins (Alber, 1992; Cohen
et al., 1995). These domains are conserved between mouse and human FANCA
sequence supporting a functional significance for these motifs. Expression of Fanca
in human FANCA deficient lymphoblast cells corrects hypersensitivity to DNA-
cross-linking agents, demonstrating functional conservation of the FANCA protein
between humans and mice. Expression analysis of Fanca using in situ hybridisation
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revealed that Fanca is expressed between mouse embryonic day (E) 8.5 and E16
within the developing brain, liver and kidney as well as in the mesenchyme,
primarily within cells that will give rise to the soft tissues of the fore and hind-limbs
(Abu-Issa et al., 1999). Northern analysis revealed that a predominant 4.5 kb band,
corresponding to full length Fanca, is expressed from E7.0 and maintained
throughout embryogenesis (Abu-Issa et ah, 1999). Fanca expression is also detected
in a wide range of adult tissues (van de Vrugt et ah, 2000; Wong et ah, 2000).
Interestingly, a novel zinc finger protein, Zfp276, is also located at the Fanca locus,
the 3' untranslated region (UTR) of Zfp276 overlaps with the last four exons of
Fanca (Wong et ah, 2000). Zinc finger proteins have been shown to be involved in
nucleic acid and protein-protein interactions and have been implicated in
oncogenesis, limb morphogenesis and proliferation (Ladomery and Dellaire, 2002)
however, there are no further reports in the literature that describe a specific role for
Zfp276.
N-terminus C-terminus
1 18 34 496 597 1069 1090 1500 Amino acids
1 54 102 1488 1781 3207 3270 4500 Nucleotides
Figure 1.13 FANCA genomic structure.
Bioinformatic analysis of Fanca nucleotide and amino acid sequence reveals the
presence of a nuclear localization signal (NLS) at the N-terminus of Fanca protein.
A partial leucine zipper is also predicted at the C-terminus. Several regions showing
weak homology to SH2 and SH3 domains are also predicted. Nucleotide positions
of the domains are given relative to the start codon.
1.7.4.1 Targeted disruption of the Fanca gene in mice
Two transgenic mouse models have been generated with a targeted knockout of the
Fanca gene. In the first mouse model, exons 4-7 of Fanca were replaced with a
lacZ-neo construct. Fancamice appeared normal, without obvious congenital
malformations or growth retardation although embryonic fibroblasts from the mice
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showed increased sensitivity to MMC and had higher levels of chromosomal
breakage, as seen in cells from human patients (Cheng et al., 2000). Recently,
another mouse model was generated where exons 1 -6 ofFanca were replaced with a
(3-galactosidase reporter construct (Wong et al., 2003). These mice displayed a FA-
like phenotype, showing growth retardation, microcephaly, craniofacial
malformations and tumour formation. In both mouse models the fertility of the
knockout mice was severely compromised. Female mice had reduced litter sizes and
stopped breeding by 21 weeks of age. Histological examination of the gonads
revealed hypogonadism in both sexes with Leydig cell hypoplasia and reduced
spermatogenesis in males and few or no follicles in females however, examination of
LH and FSH expression within the pituitary glands revealed no difference between
mutant and wildtype siblings (Cheng et al., 2000; Wong et al., 2003).
1.7.5 Fanconi anaemia complementation group C (FANCC)
FANCC was the first Fanconi Anaemia gene to be cloned and maps to human
chromosome 9q22.3 (Strathdee et al., 1992). The cDNA is 4566 bp long with an
ORF of 1674 bp comprised of 14 exons and producing a predicted protein of 557
amino acids. Murine Fancc maps to mouse chromosome 13 and shares 67% identity
with the human gene product (Wevrick et al., 1993a; Wevrick et al., 1993b).
Analysis of the protein reveals no known domains or motifs and databases searches
reveal no homology with any known proteins. In situ hybridisation studies reveal
that Fancc shares a similar expression pattern during embryogenesis to Fanca, but is
also expressed in the developing lungs and gut (Wevrick et al., 1993b; Krasnoshtein
and Buchwald, 1996). Two transgenic Fancc mouse models were generated in order
to study the function of the gene in more detail however, as with Fanca transgenic
mice, Fanemice showed no obvious phenotype other than increased cellular
sensitivity to DNA cross-linking agents and compromised fertility (Chen et al., 1996;
Whitney et al., 1996). Further examination of gonads from Fanccmice and
wildtype litter mates revealed that Fancc is expressed in the El2.5 developing gonad.
A lack of functional Fancc results in reduced numbers and slower proliferation of
germ cells demonstrating a role for Fancc in mitotic proliferation of primordial germ
cells (Nadler and Braun, 2000). Furthermore, histological examination of the gonads
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showed little or no follicles in female mice and reduced spermatogenesis in males.
Co-immunoprecipitation studies have shown that FANCC forms a complex with
FANCA (Kupfer et al., 1997a), FANCG (Garcia-Higuera et al., 1999) and FANCF
(de Winter et al., 2000c) and interacts strongly with FANCE (Medhurst et al., 2001).
Indirect immunofluorescence studies using FANCC antisera localizes FANCC
expression to both the cytoplasm and nucleus, though it is principally found in the
cytoplasm (Yamashita et al., 1994; Hoatlin et al., 1998). FANCC has also been
shown to interact with various proteins including the mitotic cyclin dependent kinase
CDC2 (Kupfer et al., 1997b), the molecular chaperone HSP70 (Pang et al., 2001) and
the signal transducer and activator of transcription, STAT1 (Pang et al., 2000).
Yeast two-hybrid screens identified that a novel BTB/POZ transcriptional repressor
protein, (FAZF), interacts with FANCC at amino acids 106-168 (Hoatlin et al., 1999)
a region deleted in patients showing a severe FA phenotype (Gillio et al., 1997).
1.7.6 Fanconi anaemia complementation group G (FANCG)
The gene mutated in FA patients assigned to complementation group G has been
identified as XRCC9 (de Winter et al., 1998), a gene involved in DNA repair and cell
cycle checkpoint control (Busch et al., 1996; Liu et al., 1997). The murine gene
shares 80% homology with human FANCG and has an ORF of 1872 bp comprised of
14 exons and producing a protein of ~ 69 kD. As with Fanca and Fancc transgenic
mice, targeted disruption of the Fancg gene generates mice with viable offspring and
no gross abnormalities other than an increased sensitivity to DNA cross-linking
agents, decreased fertility and abnormal gonadal histology (Yang et al., 2001). Co-
immunoprecipitation studies have shown that FANCG interacts with FANCA and
FANCC to form a complex (Waisfisz et al., 1999a). The N-terminus of FANCG
(amino acids 1-428) binds FANCA whilst the C-terminus binds FANCC (Kuang et
al., 2000).
1.7.7 Fanconi anaemia complementation group E (FANCE)
Using genetic linkage analysis, the gene mutated in patients assigned to
complementation group E was mapped to human chromosome 6p21-22 (Waisfisz et
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al., 1999b). FANCE was later cloned by complementation of a FANCE deficient cell
line using an episomal expression library. Human FANCE has an ORE of 1611 bp
comprised of 10 exons (de Winter et al., 2000a). The predicted 536 amino acid
protein (-60 kD) contains 2 nuclear localization signals (NLS) but lacks any
significant homology to other known proteins. Yeast two-hybrid analysis identified
that FANCE can weakly interact with both FANCA and FANCG whilst a relatively
strong interaction was detected between FANCE and FANCC (Medhurst et al.,
2001). The addition of functional FANCE protein to FANCK;' cells restores the
nuclear accumulation of FANCC and FANCA-FANCC complex formation (Pace et
al., 2002; Taniguchi and D'Andrea, 2002).
1.7.8 Fanconi anaemia complementation group F (FANCF)
The gene mutated in FA patients assigned to complementation group F was
identified by complementation of FA-F lymphoblasts with an episomal expression
library (de Winter et al., 2000b). FANCF genomic sequence contains no introns and
produces a protein product of 374 amino acids (~42 kD). Bioinformatic analysis
predicted a region of homology between FANCF and the prokaryotic RNA binding
protein ROM (Tomizawa and Som, 1984) suggesting a role for FANCF in binding
RNA/DNA. FANCF is localized predominantly to the nucleus and can be co-
precipitated from nuclear extracts using FANCA, FANCC or FANCG antisera (de
Winter et al., 2000c).
1.7.9 Fanconi anaemia complementation group D
The FA-D complementation group is distinct from other complementation groups,
because, although FA-D patients are phenotypically indistinguishable from other FA
subtypes, the FA protein complex assembles correctly in FA-D cells suggesting that
the FA-D gene product functions downstream or independently of the FA protein
complex (Yamashita et al., 1998). Complementation group D is genetically
heterogeneous with patients assigned to the group having mutations in one of two
genes, FANCD1 or FANCD2.
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1.7.9.1 FANCD2
FANCD2 is localized to chromosome 3p22-26 (Whitney et al., 1995; Hejna et al.,
2000). It has an ORF of 4358 bp comprising 44 exons, which produces a protein of
1451 amino acids (Timmers et al., 2001). FANCD2 protein is localized to the
nucleus and is present in two isoforms, long (L) and short (S), of 162 and 155 kD
respectively. Bioinformatic analysis of FANCD2 sequence revealed no known
functional domains or motifs but, unlike other FA proteins, FANCD2 homologs are
present in Arabidopsis thaliana, Caenorhabditis elegans and Drosophila
melanogaster (Timmers et al., 2001; Castillo et al., 2003). In response to DNA
damage, FANCD2-S is mono-ubiquitinated to form FANCD2-L, which then co-
localizes with the breast cancer susceptibility protein BRCA1 in nuclear foci
(Garcia-Higuera et al., 2001). Cells from other FA complementation groups lack
FANCD2-L suggesting that the FA complex is required for mono-ubiquitination of
FANCD2-S (Garcia-Higuera et al., 2001). Targeted disruption of the Fancd2 gene
in mice results in animals with a similar, but more severe, phenotype to that seen in
other FA knockouts. Fancd2~/~ mice show severe hypogonadism, microphthalmia,
perinatal lethality and tumour development (Houghtaling et al., 2003). Interestingly,
as well as interacting with BRCA1, FANCD2 has been shown to associate with
MENIN (Jin et al., 2003), the protein product of the MEN1 gene that is mutated in
multiple endocrine neoplasia type I (Chandrasekharappa et al., 1997).
1.7.9.2 FANCD1
As not all FA patients assigned to complementation group D have mutations in
FANCD2, it was concluded that another gene, now named FANCD1, may be mutated
in those patients (Timmers et al., 2001). Given that cells from FA patients and
BRCA2~/~ cells share sensitivity to MMC (Patel et al., 1998), and that targeted
inactivation of the Brca2 gene results in viable mice with a FA-like phenotype
(McAllister et al., 2002), investigators sequenced the BRCA1 and BRCA2 genes from
FA-D1 complementation group patients to determine if causal mutations were
present. Although no BRCA1 mutations were detected, bi-allelic mutations in
BRCA2 were observed. Taken together with the evidence that functional
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complementation of FA-D1 cells with wild-type BRCA2 restores MMC resistance
these results show that, in fact, FANCD1 is identical to BRCA2 (Howlett et al.,
2002).
1.7.10 Fanconi anaemia complementation group L (FANCL)
Recently, a novel component of the FA protein complex, with ubiquitin ligase
activity, has been identified. Several Fanconi anaemia associated polypeptides
(FAAPs) of unknown function were immuno-isolated from a complex containing the
five core FA proteins (Meetei et ah, 2003b). Mass spectrometry identified one of
these proteins as PHD finger protein 9 (PHF9) (Meetei et ah, 2003a). Plant
homeodomain (PHD) fingers confer E3 ubiquitin ligase activity, and indeed PHF9
demonstrated this function (Meetei et ah, 2003a). Levels of PHF9 protein were
decreased in cells from FA complementation groups A, E and B, and knockdown of
PHF9 expression, with a specific small interfering RNA (siRNA), decreased levels
ofmono-ubiquitinated FANCD2. This suggests that PHF9 is the E3 ubiquitin ligase
responsible for FANCD2 mono-ubiquitination and has been named FANCL. This
new member of the FA complex has been reported to be mutated in an individual
with FA previously unassigned to any complementation group (Meetei et ah, 2003a).
Interestingly, the mouse homolog of PHF9, Pog, is mutated in germ-cell deficient
(,gcd) mice, resulting in sub-fertile mice with defective germ cell proliferation
(Agoulnik et ah, 2002) a similar phenotype to that seen in FA knockout mice (Wong
et ah, 2003).
1.7.11 FA protein complex formation
Analysis of the FA proteins has shown that they interact with each other.
Immunoprecipitation studies demonstrated that FANCA binds both FANCC (Kupfer
et ah, 1997a) and FANCG (Waisfisz et ah, 1999a) and that FANCG is pivotal for the
interaction between FANCA and FANCC (Garcia-Higuera et ah, 1999). Yeast two-
hybrid studies confirmed these findings and demonstrated a strong interaction
between FANCA and FANCG, but a weak interaction between FANCA and
FANCC, indicating an indirect interaction between FANCA and FANCC, possibly
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involving other proteins (Huber et al., 2000; Reuter et al., 2000). The interaction of
FANCA with FANCC promotes phosphorylation of FANCA and its biological
activity (Naf et al., 1998; Yamashita et al., 1998). The NLS sequence present at the
N-terminus of FANCA is crucial for FANCA-FANCG binding (Kruyt et al., 1999).
Apart from interacting with FA complex members, FANCA also interacts, via its C-
terminus, with Sorting nexin 5 (SNX5) (Otsuki et al., 1999), a molecule belonging to
a family of proteins implicated in endocytosis of plasma-membrane receptors and/or
the trafficking of proteins from one membrane compartment to another (Worby and
Dixon, 2002). Overexpression of SNX5 in cells increases FANCA expression, but
the significance of this is unknown (Otsuki et al., 1999). A summary of the
interactions between FA family proteins is shown in Table 1.2 below.
FANCA FANCC FANCDl FANCD2 FANCE FANCF FANCG FANCL
FANCA - y X y y y
FANCC 1 - X x y y 7
FANCD1 ✓ X - ? x X y 7
FANCD2 X X 7 y X X 7
FANCE 7 y y X y 7 7 7
FANCF y // X x ? - y 7
FANCG y y y y X 7 ' 1 - 7
FANCL 7 7 7 9 7 7 9 —
Table 1.2 Interactions between FA proteins.
Yeast two-hybrid analysis and co-immunoprecipitation studies have determined
which FA proteins interact with each other. ✓ ✓ indicates strong binding, y
indicates binding, X indicates no binding, ? indicates that direct binding has not
been observed but interaction may be mediated via another protein.
The genes implicated in Fanconi Anaemia appear novel, and therefore unrelated to
one another, but the similarity of clinical symptoms and cellular features found in
patients with mutations in different genes indicates that they actually interact in a
common pathway. A model showing how the proteins cooperate as part of a
42
Chapter One Literature Review
common pathway is still being refined as research determines the specific role of this
multi-subunit complex in homology-directed DNA damage repair (Figure 1.14).
Cytoplasm Nucleus
Figure 1.14 A model of the Fanconi anaemia pathway.
Within the cytoplasm, FANCA binds FANCG then FANCC. These proteins then
move into the nucleus where FANCF and FANCE bind to form the FA complex.
FANCL and this complex are required for the mono-ubiquitination (Ub) of FANCD2.
Activated FANCD2 is then translocated to DNA-repair foci containing BRCA2 and
FANCD2/BRCA1 where it probably participates in homology directed DNA damage
repair. Diagram adapted from (Grompe, 2003).
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1.8 Fanconi anaemia and the HPG axis
The FA proteins function together in a common pathway required for repair ofDNA
damage and thus, bi-allelic mutations in any of the FA genes results in a marked
predisposition to cancer. How bone marrow failure, infertility, microcephaly and
short stature, are associated with mutations in the FANC genes has yet to be
determined. Studies of FA patients show that a relatively large percentage (43%)
have reproductive abnormalities (Young and Alter, 1994), but whether this
phenotype indicates a direct role for FANC genes in reproduction, or occurs as a
consequence of defective DNA damage repair has not been established. However,
patients with a mild FA phenotype survive to adulthood and provide insights into the
effects of the disease on reproductive capability. Fertility in FA males is severely
reduced due to hypogonadism and defective spermatogenesis (Bargman et al., 1977),
although from a cohort of 115 male FA patients, 4 (3%) fathered children (Alter et
al., 1991; Liu et al., 1991). Female FA patients have a high incidence of hypoplastic
ovaries, underdeveloped uteri, menstrual irregularities and premature menopause
(Alter et al., 1991). However, a relatively high number of female patients become
pregnant (15%). An analysis of gonadotropin levels has been reported for a few
cases of FA (Berkovitz et al., 1984; Schoof et al., 2000; Massa et al., 2002), all of
them had abnormal levels of LH and FSH. No research has established a link
between specific mutations in FA genes and an infertility phenotype but the
infertility phenotype is faithfully recapitulated in gene-targeted mice lacking Fanca,
Fancc, Fancg or Fancl (Chen et al., 1996; Whitney et al., 1996; Cheng et al., 2000;
Yang et al., 2001; Agoulnik et al., 2002; Wong et al., 2003). A recent paper
identified sixty-nine proteins that interacted with FANCA, FANCC or FANCG
which were involved in a wide range of cellular processes including transcription,
signalling, metabolism and cellular transport (Reuter et al., 2003). Thus FANCA,
and the other FA proteins, interact with proteins implicated in a number of diverse
and specialized pathways. Elucidating these pathways could explain the wide range
of clinical features associated with the disease and be informative when studying the
regulation of reproduction.
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1.9 Aims of this thesis
The body of research presented in this thesis aimed to address several questions
concerning the relationship between GnRH, and Fanca and the role of Fanca in
gonadotropin gene transcription. As the GnRH regulated transcript identified by
DD-RT-PCR could correspond to either one of two genes transcribed from the Fanca
locus, chapter three addresses the issue of whether it is the expression of Fanca,
Zfp276 or both genes, which is altered in response to GnRH. Then, having
established that it is expression of Fanca that is rapidly and transiently up-regulated
in L(3T2 cells in response to GnRH, chapter four analyses the expression of Fanca
protein within gonadotroph cells. It addresses whether addition ofGnRH promotes a
redistribution of Fanca protein within L(3T2 cells, in a bid to identify a mode of
Fanca action in these cells, and aims to determine by what specific mechanisms this
'shuttling' may be occurring. This chapter also addresses whether the introduction
of specific point mutations into the Fanca protein can alter the localization pattern of
Fanca within gonadotroph cells. Finally, chapter five compares the effects of
wildtype and mutant Fanca proteins on the control of GnRH induced gonadotropin
promoter activity to determine whether Fanca is an important molecule in the
regulation of gonadotropin gene expression. These mutant FANCA constructs are
genocopies of known FA probands, thus the cumulative aim of the experiments





It is common sense to take a method and try it. If it fails, admit it frankly and try
another. But above all, try something - Franklin D. Roosevelt.
Chapter 2 Materials and Methods
2 Materials and Methods
All solutions and buffers were made with deionised distilled water. All eppendorfs,




0.5 M EDTA (pH 8.0)
1 M Tris-HCl (pH 7.4/8.0)
1 x TE (10 mM Tris-HCl pH 7.4, 1
mMEDTA pH 8.0)
Low TE (10 mM Tris-HCl pH 7.4, 0.1
mMEDTA pH 8.0)
3 M Sodium acetate (pH 5.2)
186 g of EDTA (BDH) was dissolved
in 800 ml of dH20. The pH was
adjusted to 8.0 with concentrated
NaOH (BDH) then dH20 was added to
1 litre.
121 g of Tris (Roche) was dissolved in
800 ml dH20. The pH was adjusted to
7.4 or 8.0 by addition of HC1 (BDH)
then dH20 was added to 1 litre.
500 pi 1 M Tris-HCl (pH 7.4) and 100
pi 0.5 M EDTA (pH 8.0) were added
to 49.4 ml dH20.
500 pi 1 M Tris-HCl (pH 7.4) and 10
pi 0.5 M EDTA (pH 8.0) were added
to 49.4 ml dH20.
408.1 g sodium acetate (Sigma) was
dissolved in 800 ml dH20. The pH
was adjusted to 5.2 with acetic acid
(BDH) then dH20 was added to 1 litre.
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50 x TAE (2M Tris, 50 mMEDTA pH
8.0, 5.71% acetic acid)
10 x TBE (0.9 M Tris, 0.9 M
Orthoboric acid, 40 mM EDTA pH
8.0))
1% Agarose gel
10 x Loading Buffer (0.025% xylene
cyanol, 0.025% bromophenol blue,
40% sucrose)
242 g Tris, 100 ml 0.5 M EDTA (pH
8.0) and 57.1 ml acetic acid were
mixed in 1 litre of dH20.
108 g Tris and 55 g orthoboric acid
(BDH) were dissolved in 500 ml
dH20. 80 ml 0.5 M EDTA (pH 8.0)
was added and the pH adjusted to 8.3
with concentrated NaOH or orthoboric
acid (Roche) then dH20 added to 1
litre.
1.5 g agarose (Roche) was dissolved
in 150 ml of 1 x TAE/TBE buffer by
heating in a microwave. The agarose
was then allowed to cool to 50°C and
1.5 pi ethidium bromide (Sigma, 10
ug/pl) added before casting the gel.
25 mg xylene cyanol (Sigma), 25 mg
bromophenol blue (Sigma) and 4 g
sucrose (BDH) were dissolved in 10
ml dH20.
2.1.2 Primer design and oligonucleotide synthesis
Primers were designed either from sequences available in GenBank
(http://www.ncbi.nlm.nih.gov) or Celera (http://www.celeradiscoverysystem.com)
databases, or from our own sequence data obtained using vector primers. The major
aims when designing primer pairs were to ensure that they were unique to the
specific gene and that they had the same or similar annealing temperatures. The
annealing or melting temperature (Tm) of a primer can be estimated from its
sequence using the formula below:
Tm = (2 [A+T] + 4 [G+C]) - 5°C
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All primers were commercially synthesized by MWG (http://www.mwg-biotech.com)
using the 0.01 pmol synthesis scale. Table 2.1 shows primers used to analyze the
expression of various genes.
2.1.3 Reverse Transcription-PCR
2.1.3.1 cDNA synthesis
An expression profde for members of the Fanconi Anaemia complex was performed
using reverse transcriptase (RT) PCR. First strand cDNA was synthesized by
extension with murine reverse transcriptase (RT) and an oligo(dT) primer using
RNA harvested from various hormone treated and untreated cell lines. This cDNA
was then used as a template for a PCR reaction with gene specific primers to
determine the presence or absence of the gene of interest. First strand cDNA was
synthesized using the Bulk First-Strand cDNA Synthesis Kit (Amersham
Biosciences). Approximately 1 pg of total RNA extracted from cells (as described
in Section 2.6.2) was used in each reaction in accordance with manufacturer's
instructions. The resulting cDNA was stored at -20°C until required.
2.1.3.2 PCR conditions
Primers were used at a concentration of 100 ng/pl and 1 pi of each was added to 7 pi
dH20 in an eppendorf. 1 pi of cDNA was added to this and the tube incubated at
95°C for 5 minutes. Tubes were snap cooled on ice then 10 pi of 2x High Fidelity
Taq Master Mix Buffer 2 (AbGene) added. Unless stated otherwise, thirty-five
cycles ofPCR amplification were performed as detailed below:
Initial denaturation 94°C 2 minutes
Denaturation 94°C 30 seconds
Specific primer annealing temperature X°C 30 seconds
Extension 72°C lmin/kb of product
Final extension 72°C 10 minutes
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2.1.4 Agarose gel electrophoresis
Agarose gel electrophoresis was used to analyze DNA fragments after PCR or
restriction endonuclease digestion. Typically, 1 x TBE buffer was used for DNA
fragments below 1 kb in size whilst 1 x TAE buffer was used in all other situations.
The percentage agarose used was typically 1 % (w/v) and the gels were
electrophoresed at 10 volts/cm. Ethidium bromide, a powerful carcinogen, which
intercalates between DNA bases and fluoresces under UV light, was added at a final
concentration of 0.1 ng/ul. To visualize the DNA, the gel was transilluminated with
UV light (UV transilluminator 2000, BioRad) and gel images captured using a
GENEFLASH Imaging System (Sygene Bioimaging).
2.1.5 Cloning of RT-PCR products
To confirm their identity, PCR products were cloned into TOPO-pCRII Vector
(Invitrogen) according to manufacturer's instructions then plasmid inserts sequenced
as described in Section 2.3.6. Approximately 100 ng of PCR product was mixed
with 1 pi salt solution, 1 pi TOPO Vector and 2 pi sterile H20. The contents of the
tube were mixed gently and incubated at room temperature for 10 minutes and 2 pi
of this mixture was then transformed into 30 pi electrocompetent TOP 10 cells
(Invitrogen) as described in Section 2.2.2. The transformation reaction was then
plated out onto Luria Bertoni (LB) Agar/Amp plates and incubated at 37°C
overnight.
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2.2 Microbiology
2.2.1 Bacterial solutions
Luria Bertoni (LB) Broth
Luria Bertoni (LB) Agar
Ampicillin stock (50 mg/ml)
Kanamycin stock (30 mg/ml)
Chloramphenicol stock (30 mg/ml)
25 pellets of LB Broth (Q-Biogene)
were dissolved in 1 litre dLLO then
autoclaved.
31 pellets of LB Agar (Q-Biogene)
were dissolved in 1 litre dtLO then
autoclaved.
500 mg ampicillin (Sigma) was
dissolved in 10 ml dTLO then
sterilized by filtration through a 0.22-
micron filter (Sartorius). This stock
solution was aliquoted and stored at
-20°C until required. Working
concentration was 50 ug/ml
300 mg kanamycin (Sigma) was
dissolved in 10 ml dELO then
sterilized by filtration through a 0.22-
micron filter (Sartorius). This stock
solution was aliquoted and stored at
-20°C until required. Working
concentration was 30 pg/ml
300 mg chloramphenicol (Sigma) was
dissolved in 10 ml 100% EtOH
(BDH). This stock solution was
aliquoted and stored at -20°C until
required. Working concentration was
30 pg/ml.
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2.2.2 Transformation of competent cells
Various strains of chemically competent cells (Table 2.2) were used during this
project.




Invitrogen F- mcrA A(mrr-hsdRMS-mcrBC)
(p80lacZAM15 AlacX74deoR
recAl araD139 A(ara-leu)7697
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Table 2.2 Chemically competent cells.
Genotypes and supplier information for chemically competent cells using during the
course of this research.
Cells were thawed on ice (|3-mercaptoethanol was added according to
manufacturer's instructions for Solopack cells) then 2 pi ligation reaction added and
the tube tapped gently to mix. Cells were incubated on ice for 30 minutes then heat
shocked at 42°C for 30 seconds (Solopack cells were heat shocked at 54°C for 60
seconds) before being returned to ice for 2 minutes. A 250 pi volume of SOC media
(GibcoBRL) was added and the cells incubated at 37°C, whilst shaking at 150 rpm,
for at least 30 minutes. Between 50 pil and 250 pi of the transformation reaction was
plated out onto LB-agar plates containing the appropriate antibiotic and incubated
overnight at 37°C.
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2.3 Nucleic acid analysis
2.3.1 Solutions
DNA maxi-preparation solution PI
(50 mM Glucose, 25 mM Tris-HClpH
8.0, 10 mMEDTA pH 8.0)
DNA maxi-preparation solution P2
(0.2 MNaOH, 1% SDS)
DNA maxi-preparation solution P3
(3MKOAcpH 4.8)
Denaturing Solution (1.5 MNaCl, 0.5
MNaOH)
Neutralizing Solution (1.5 MNaCl. 1
M Tris)




9 g glucose, 40 ml 1 M Tris-HCl (pH
8.0) and 20 ml 0.5 M EDTA (pH 8.0)
were mixed together in 1 litre of
dH20.
8 g NaOH and 10 g SDS (Roche) were
dissolved in 1 litre of dH20.
249 g potassium acetate (Sigma) was
dissolved in 400 ml dH20. The pH
was adjusted to 4.8 by adding ~ 500
ml acetic acid then made up to 1 litre
with dH20. The solution was stored at
4°C until required.
87.7 g NaCl (BDH) and 20 g NaOH
were dissolved in 1 litre of dH20.
87.7 g NaCl and 121 g Tris were
dissolved in 1 litre of dH20.
175 g NaCl and 88 g sodium citrate
were dissolved in 1 litre of dH20.
100 g SDS was carefully weighed out
in a fume hood then dissolved in 1
litre of dH20. This solution was then
fdtered using pre-assembled and pre-
sterilized 1 litre filter units (Nalgene).
120 g of NaH2P04 (Sigma) was
dissolved in 1 litre of dH20.
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lMNa2HP04 142 g of NaH2P04 (Sigma) was
dissolved in 1 litre of dH20.
1 M NaH2P04 was added drop wise to
1 M Na2HP04 until the pH reached
7.2.
1 M NaP04 (pH 7.2)
Modified Church and Gilbert
Hybridization Solution (0.5 MNaP04
pH 7.2, 1 % BSA, 15 % formamide,
7% SDS, 2 mMEDTA pH 8.0)
50 ml of 0.5 M NaP04 (pH 7.2); 15 ml
deionised formamide (BDH); 35 ml of
10% SDS; 0.4 ml 0.5 M EDTA (pH
8.0) and 1 g bovine serum albumin
(BSA, Sigma) were mixed together.
2.3.2 Small scale DNA preparation
Single bacterial colonies were picked from a pre-streaked plate and innoculated into
5 ml LB Broth containing the appropriate antibiotic and grown overnight with
shaking (150 rpm) at 37°C. The next day plasmid DNA mini-preparations were
made using the Boerhinger Mannheim High Pure Plasmid Isolation Kit according to
manufacturer's instructions. An aliquot was then analysed to determine
concentration of plasmid DNA using a GeneQuant spectrometer (Pharmacia
Biotech, See Section 2.3.4). Yield was typically 100 ng/ul and plasmid preparations
were stored at -20°C until required.
2.3.3 Preparation of DNA over a caesium chloride gradient
For large scale preparation of plasmid DNA, 500 ml LB-Broth containing the
appropriate antibiotic, was seeded with 1 ml mini-prep culture and grown overnight
with shaking at 37°C. The following morning the culture was split between two 250
ml plastic centrifuge tubes and centrifuged in a J2-21 Beckman centrifuge using a
JA-14 rotor at 6000 rpm for 10 minutes at 4°C to pellet the bacteria. The supernatant
was discarded and the pellet carefully resuspended by gentle shaking in 60 ml of
Solution PI. An equal volume of Solution P2 was added whilst gently mixing and
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the contents incubated at room temperature for exactly 5 minutes, this was then
mixed with 80 ml chilled Solution P3 and the contents incubated on ice for 1 h. The
tubes were then centrifuged at 7,000 rpm for 30 minutes. The supernatant was
filtered through miracloth (CamLab) to remove any precipitate and split equally over
three 250ml centrifuge tubes. To each tube, 0.7 volumes of isopropanol (BDH) was
added and the contents gently mixed. The tubes were then centrifuged at 7,000 rpm
for 15 minutes at 4°C. The supernatant was discarded and all 3 pellets re-suspended
in TE buffer to give a total volume of 8 ml. To purify plasmid DNA from genomic
bacterial DNA a caesium chloride (CsCl) gradient was used. A 1 x gradient was
prepared by adding 11.82 g CsCl (Roche) to 8 ml DNA solution. To this, 500 pi
ethidium bromide solution (10 mg/ml, Sigma) was added and the final volume
adjusted to 14 ml with TE buffer. This was centrifuged at 3000 rpm for 10 minutes.
The supernatant was removed and split between two 6 ml Ultra centrifugation tubes
(Sorvall). The tubes were weighed, balanced against each other and sealed with
metal caps. Samples were then centrifuged in a Sorvall Ultra Pro 80 using a TV
1665 upright rotor at 50,000 rpm for at least 16 h at 20°C. After ultra-centrifugation
two bands were visible. The lower, thicker band corresponded to plasmid DNA
whilst the upper, thin band represented contaminating, genomic bacterial DNA.
Bands were visualized using a long wavelength 302 nm UV lamp in a dark room and
the plasmid DNA band removed into a falcon tube (Costar) using an 18 gauge needle
(Kendal) and syringe (BDPlastipak). To remove the ethidium bromide an equal
volume of caesium chloride saturated with isopropanol was added and mixed by
shaking. When allowed to settle, two phases appeared and the upper, pink, phase
was removed and discarded using a pasteur pipette. TE buffer was added as
necessary to ensure the lower phase remained at 2 ml volume. This process was
repeated until both phases appeared clear. The bottom phase was then removed into
a new tube and l/10th volume 3 M NaAc (pH 5.2) and 3 volumes of 70% EtOH
(BDH) added. This was mixed, then stored at -20°C for at least 1 h. The tube and
its contents were warmed to room temperature then centrifuged at 7,000 rpm for 15
minutes. The supernatant was discarded and 500 p,l 70% EtOH added. The pellet
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and 70% ethanol was transferred to a clean eppendorf tube, the tube was washed out
with a further 500 pi 70% EtOH and this was added to the eppendorf to give a final
volume of 1 ml. The DNA pellet was centrifuged at 13,000 rpm for 10 minutes, the
supernatant was discarded and the pellet allowed to air-dry before being resuspended
in an appropriate amount of TE buffer, usually 900 ptl. Contaminating protein was
removed by adding a 1/2 volume of phenol (BDH) to the DNA solution. The
contents were briefly mixed and centrifuged for 10 seconds at 13,000 rpm. A 1/2
volume of chloroform (BDH) was added and the contents mixed by shaking.
Eppendorfs were then centrifuged at 13,000 rpm for 1 minute. The top aqueous layer
was removed into a new eppendorf and a 1/2 volume of chloroform added. This was
centrifuged again at 13,000 rpm for 1 minute and the top layer removed into a new
eppendorf. A l/10th volume of 3 M NaAc (pH 5.2) and 3 x volume EtOH was added
and the contents mixed by shaking. Eppendorfs were then incubated at -20°C for at
least 1 h. Eppendorfs were centrifuged at 13,000 rpm for 10 minutes, the supernatant
was discarded and the pellet washed in 150 pi 70% EtOH by centrifugation at 13,000
rpm for 10 minutes. The supernatant was discarded and the DNA pellet allowed to
air-dry before being resuspended in 100 pi low TE.
2.3.4 Spectrophotometrical analysis of nucleic acids
Quantification of nucleic acids was performed using a GeneQuant
spectrophotometer (Pharmacia Biotech). At 260 nm, an OD reading of 1 is
equivalent to 50 pg/ml of double stranded DNA or 40 pg/ml of single stranded DNA
or RNA. An OD reading at 280 nm indicates the presence of high molecular weight
molecules i.e. proteins. A 260 nm:280 nm ratio of 1.7 for DNA or 2.0 for RNA
indicates an acceptably pure sample.
2.3.5 Restriction digest analysis ofplasmid DNA
All restriction enzymes were purchased from Roche or New England Biolabs
(NEB). To identify positive clones, mini-prepped plasmid DNA (See Section 2.3.2)
was digested with the appropriate restriction enzyme(s). The cloning site of TOPO-
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pCRII (Invitrogen) is flanked by EcoRI sites to allow liberation of the cloned PCR
insert. A typical restriction enzyme digest contained 10 pi plasmid DNA (-0.8 pg)
mixed in an eppendorf with 16 pi dH20, 3 pi appropriate enzyme buffer and 1 pi
enzyme. Digests were incubated at 37°C for at least 2 h then analysed by running 20
pi of each digest on a 1 % agarose gel in 1 x TAE/TBE buffer.
2.3.6 Sequencing analysis
All sequencing was performed by technical staff at the MRC Human Reproductive
Sciences Unit or MRC Human Genetics Unit (Edinburgh). Sequences were
analysed and contigs constructed from overlapping DNA sequence using either
GeneJockey (Oxford Molecular) or Contig Express (Vector NTI, Informax)
computer software. Sequence information was compared against the Genbank
databases on the NCBI website (http://www.ncbi.nih.nlm.gov) using BLAST (Altschul
etal., 1990).
2.3.7 Restriction enzyme digest ofplasmid DNA for cloning
In general, when cloning fragments of DNA from one plasmid vector to another,
-50 pg of DNA from each plasmid vector was digested using the appropriate
restriction endonucleases. In an eppendorf, 50 pg plasmid was mixed with 10 pi
enzyme buffer, and 5 pi enzyme(s) and then made up to 100 pi with dH20. Digests
were incubated at 37°C for at least 2 h then frozen to inactivate the enzyme.
Approximately 2 pi of this reaction was then electrophoresed on an agarose gel to
check for complete digestion before proceeding to the next stage. In cases where the
vector may be able to re-ligate to itself, digests were then treated with shrimp
alkaline phosphatase (SAP, Roche). 40 pi SAP buffer and 30 pi SAP were added to
the digested DNA and the final volume increased to 400 pi by addition of dH20.
Digests were SAP treated at 37°C for at least 2 h and then frozen. All 400 pi of the
SAP treated digest was electrophoresed on a 1 % agarose gel at 35 volts/cm
overnight. The next morning the appropriate bands were excised from the gel using
a scalpel blade and DNA extracted from them as desrcibed in Section 2.3.8.
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2.3.8 Extraction of DNA from agarose gel fragments
DNA was extracted from agarose gel slices using the GENECLEAN SPIN Kit
(Hybaid) according to manufacturer's instructions. Briefly, 0.3 g agarose was
melted in 400 pi binding buffer, by heating at 55°C for 10 minutes, then centrifuged
through a column for 30 seconds. The columns were rinsed with 500 pi of wash
solution for 30 seconds then spun dry. DNA was recovered by addition of 2 x 15 pi
aliquots of elution buffer to the column and 2 pi of this was electrophoresed on a
1 % agarose gel against a Lambda/Hindlll DNA marker (Promega) to quantify the
amount ofDNA present before ligation.
2.3.9 Ligation of DNA inserts into other vectors
After liberation of the DNA insert from its cloning vector, DNA fragments were
cloned into the appropriate plasmid vector using compatible overhanging DNA ends
and Ready-To-Go ligation tubes (Amersham Biosciences). The amount of insert
required was calculated using the following equation:
X ng insert = (Y basepairs of inserf)t50 ng vector)
base pairs of vector
To facilitate cloning, the insert to vector ratio was then adjusted to 3:1. The
appropriate amounts of insert and vector were mixed together in the ligation tube,
with dH20 up to 20 pi, and incubated at room temperature for 5 minutes. The
ligation was then incubated at 16°C overnight and 2 pi of this was transformed into
50 pi competent cells as previously described (See Section 2.2.2).
2.3.10 Southern blotting ofRT-PCR products
Southern blotting (Southern, 1975) was used to verify the identity and presence of
PCR products. PCR products were electrophoresed on a 1% agarose gel as
described in Section 2.1.4. The gel was denatured by washing for 20 minutes in
denaturing solution, rinsed twice in dTBO, then washed for 20 minutes in
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neutralizing solution. The gel was blotted on to Hybond-N+ (Amersham
Biosciences), pre-soaked in 3 x SSC, according to manufacturer's instructions and
transferred for 4 h in 20 x SSC. The next morning the membrane was wet in 3 x
SSC and the DNA crosslinked by treating for 30 seconds in a SpectroLinker XL-
1000 machine. The blot was re-washed in 3 x SSC, excess liquid blotted off, then
wrapped in Saran wrap and stored at 4°C until required.
2.3.10.1 Probe design to verify Fanca PCR products
For Southern blots to verify Fanca PCR products a labeled probe was generated
corresponding to exons 14 to 18 ofFanca cDNA that had been amplified from L-cell
cDNA, cloned into TOPO-pCRII and verified by DNA sequencing. The probe
template was liberated from the vector by digestion with EcoRI, purified on an
agarose gel and labelled as described below.
2.3.10.2 Radiolabelling ofprobes
All work with radioactive material was performed with appropriate care to ensure no
accidental over exposure to the potentially harmful effects of radiation. Probes were
labeled with oc32P-dCTP (ICN) using the Rediprime Labelling Kit (Amersham
Biosciences) according to manufacturer's instructions. Briefly, 30 ng of probe DNA
was mixed with dH20 to a final volume of 45 pi then boiled for 5 minutes in a
waterbath. The DNA was snap-cooled on ice for 5 minutes then added to a Redi¬
prime reaction tube containing the Klenow subunit ofDNA polymerase I. Contents
were mixed gently by tapping and 50 pCi of oc32P-dCTP added. The template was
then incubated at 37°C for at least 1 h to allow incorporation of radioactivity. The
amount of incorporated activity was measured using a scintillation counter by
spotting 2 pi of radioactive probe onto a glass filter disc (Whatmann). Any
unincorporated radioactivity was removed by washing 3 times in 5% Trichloroacetic
acid/20 mM PPi then once in 70% EtOH. Excess liquid was drained off and the disc
placed in a scintillation vial. Counts were read using a Trilux 1450 Microbeta
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scintillation counter and the amount of incorporated radioactivity was calculated
using the following equation:
Specific activity (DPM)/pg = (CCPMI) x (dilution volume) x (3) x (dilution for 1 pg)
Probes were used if the specific activity (DPM/pg) was > 1 x 109.
2.3.10.3 Hybridisation and washing conditions
The radiolabeled probe was denatured by addition of 750 pi dH20 and 250 pi, 2 M
NaOH then incubated on ice for 5 minutes and neutralized by addition of 125 pi,
3 M NaAc (pH 5.2). Pre-hybridisation was carried out at 65°C in a Techne
hybridisation oven in modified Church and Gilbert Hybridization solution for a
minimum of 30 minutes. Denatured, labeled probe was added to fresh Church and
Gilbert hybridization solution and the blot incubated overnight at 65°C. The
membrane was then washed with 2 x SSC, 0.5% SDS at 65°C for 30 minutes
followed by 0.1 x SSC, 0.1% SDS at 50°C for 30 minutes. The blot was sealed in
Saran wrap and exposed to X-OMAT (Kodak) x-ray film at -70°C overnight.
2.3.11 Site directed mutagenesis of human FANCA
Mutagenesis was performed using the QuikChange XL Site Directed Mutagenesis
Kit (Stratagene) according to manufacturer's instructions. This kit allows site
specific mutation of double-stranded plasmid through the use of mutagenic
oligonucleotide primers and PfuTurbo DNA polymerase (See Figure 2.1).
Mutagenic primers are designed so that both primers contain the desired mutation
and anneal to the same DNA sequence on opposite strands of the plasmid. Specific
mutagenic primers used to mutate FANCA are shown in Table 2.3.
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Primer HIHOP point mutation Position (bp)
Sense 5' -GCGAGCAGTTCTTCCCCTTGGTCAACTCTG-3' 3313-3343
Antisense 5 '-CAGAGTTGACCAAGGGGAAGAACTGCTCGC-3' 3343-3313
Primer Q1128E point mutation Position(bp)
Sense 5 '-GAGGTGCCCTGACAGAGGACATGACTGCCC-3' 3367-3397
Antisense 5' -GGGCAGTGATGTCCTCTGTCAGGGCACCTC-3' 3397-3367
Table 2.3 DNA sequence of primers used for site directed mutagenesis
of FANCA.
Mutated bases are highlighted in red. Position of primers (bp) is given relative to
ATG of FANCA (Accession N° NM_000135).
The FANCA/enhanced green fluorescent protein (EGFP) vector was a kind gift from
Manuel Buchwald (Toronto, Canada). This vector is large (10 kb) and proved
difficult to mutagenise by PCR, so to facilitate easy mutagenesis, a 1.8 kb region
containing the sequence to be mutated was sub-cloned into pBluescriptSK+
(Stratagene) using EcoRV restriction sites (See Section 2.3.7 for protocol. See
Appendix I for vector map). This smaller sized, more malleable, vector of ~ 4 kb
(pBluSKP-FANCA-EcoRV) was mutagenised, and the inserts then cloned back into
the pEGFP/FANCA vector, using EcoRV sites, to give a full length, mutated, human
FANCA clone tagged with EGFP (pEGFP-FANCA-Hl 110P/Q1128E).
To perform the PCR mutagenesis the following were mixed together:
5 pi 10 x Reaction Buffer
2 pi pBluescript/EcoRVFANCA (10 ng/pl)
1.5 pi Sense primer (100 ng/pl)
1.5pl Antisense primer (100 ng/pl)
1 pi dNTP mix
3 pi QuikSolution
39 pi dH20
1 pi Pfu Turbo Taq DNA polymerase
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to repair the nicked,
mutated plasmid
Figure 2.1 Overview of the QuikChange site-directed mutagenesis
method.
PCR amplification with oligonucleotide primers containing the desired mutation
results in incorporation of the mutation into circular, nicked DNA. Parental,
methylated non-mutated DNA is removed by digestion with Dpnl and nicks in the
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18 cycles ofPCR amplification were then performed under the following conditions
Initial denaturation 95°C 1 minute
Denaturation 95°C 50 seconds
Specific primer annealing temperature 60°C 50 seconds
Extension 68°C 7 minutes
Final extension 68°C 7 minutes
] 18 cycles
The PCR reaction was chilled on ice before any methylated, non-mutated parental
DNA template was removed by digestion with 1 pi ofDpnl (Stratagene) at 37°C for
at least 1 h. A 3 pi aliquot of this reaction was transformed into 45 pi XLIO-Gold
competent cells (See Section 2.2.2), plated onto LB-Agar/Amp plates and grown
overnight at 37°C. Colonies were mini-prepped as described in Section 2.3.2 then
sequenced (see Section 2.3.6) to check for the introduced mutation and ensure that
no non-specific mutations had been added. Table 2.4 lists all sequencing primers
used.
Primer name DNA sequence 5' => 3' Position (bp)
HFAA-1F CAAGGCCATGTCCGACTCGT 25-44
HFAA-2F ATCCTGCCAGCATGCTGACG 700 - 720
HFAA-3F TGATGTTATATCGGCACAGG 2039 - 2060
HFAA-4F GGATTCCTTGTTCTTCTGCCC 2412-2529
HFAA-5F AGAGGAGCTGCTAATGTAC 3246 - 3265
HFAA-6F GTCTTCTCTCCTACTTCCAT 4041 -4060
HFAA-1R TCAGGAGGCCCCTGAAGAAG 810-791
HFAA-2R CTGCTGTCATCCTCATTGTG 2118-2099
HFAA-3R TCAGGAGGCCCCTGAAGAAG 3449 - 3430
HFAA-4R GGCACTTGGCCAGTATGAAG 3509 - 3490
HFAA-5R ATGGAAGTAGGAGAGAAGAC 4060 - 4041
HFAA-6R ACAGCTGATGAAGCCACGTG 5400- 5381
Table 2.4 DNA sequence of FANCA sequencing primers.
Primers were designed based on FANCA sequence available on Genbank
Database (Accession number NM_000135). Position of primers, specified in
basepairs (bp) is given relative to the start codon (ATG).
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2.4 Tissue Culture
2.4.1 Cell lines
Various cell lines were used during the course of this research. HeLa cells, HEK293
cells and L-cells were purchased from the European Collection of Cell Cultures
(ECACC). GH3 cells were a kind gift from Alan McNeilly (Edinburgh). Cell lines
derived from developing pituitary gonadotrophs (L|3T2 and aT3-l cells) were a kind
gift from Pamela Mellon (San Diego, USA).
2.4.2 Cell growth conditions
LPT2, aT3-l, HeLa and L-cells were grown in DMEM (Sigma) containing 10%
Fetal Calf Serum (Sigma) and 0.1% penicillin-streptomycin (Sigma) which will
hereafter be referred to as media. LPT2 and a-T31 cells were grown on Matrigel, a
basement membrane matrix (See Section 2.4.6). All tissue culture work was carried
out under sterile conditions. All media and Phosphate Buffered Saline (PBS, Sigma)
were heated to 37°C before use.
2.4.3 Solutions
1 x trypsin 10 ml trypsin (Sigma) was diluted in
100 ml PBS and stored, in aliquots at
-20°C until required.
100 qM GnRH GnRH (Peninsula) was dissolved in
PBS to achieve a concentration of 100
|xM and stored, in aliquots, at -20°C
until required. A working
concentration of 1 [xM was achieved
by diluting 500 [xl GnRH in 50 ml
media.
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Cycloheximide (10 mg/ml) 100 mg cycloheximide (Calbiochem)
was dissolved in 10 ml dt^O. This
stock solution was aliquoted and
stored at -20°C until required.
Working concentration was 15 qg/ml.
5 mg actinomycin D (Calbiochem)
was dissolved in 5 ml 95% EtOH.
This stock solution was aliquoted and
stored at -20°C, protected from light,
until required. Working concentration
was 5 pg/ml.
ActinomycinD (1 mg/ml)
2.4.4 Resuscitation of cell lines from liquid nitrogen storage
Cells were removed from liquid nitrogen storage onto ice and thawed rapidly by
hand. A 1 ml aliquot of cells was added to 4 ml media and plated in a T-25 cell
culture flask (Costar).
2.4.5 Passaging of cell lines
Media was removed from the cells using a 10 ml pipette (Costar) and each flask
washed twice with 5 ml of PBS. All PBS was removed and 1.5 ml of 1 x trypsin
added per T-75 flask. Flasks were laid flat and incubated at 37°C for 2 minutes, then
removed from the incubator and tapped against the hand to dislodge cells from the
growing surface. Immediately, 14 ml ofmedia was added to each flask to inactivate
the trypsin and using a pasteur pipette, the growing surface was washed with the
media then cells were agitated twice to break up any 'clumps' of cells. Flask
contents were then pooled and a small aliquot was removed for counting using a
haemocytometer (Sigma). Cells were diluted appropriately with media to the
required density and plated in new tissue culture flasks.
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2.4.6 Matrigel coating of tissue-culture flasks
All cell culture plasticware required for growing L|3T2 or aT3-l cells was coated
with a 1/30 dilution of a basement membrane matrix (Matrigel, Beckton Dickinson
Labware). Concentrated matrigel is a solid at room temperature and liquid at 4°C
therefore, before dilution, all apparatus and solutions must be chilled to below 4°C.
Matrigel was thawed overnight on ice, then 400 pi was added to 14.6 ml of pre-
chilled PBS. Aliquots were stored at -20°C until required. To coat flasks, Matrigel
was pipetted onto the base of the flask or plate, ensuring the whole area was covered.
Excess Matrigel was removed and the plasticware allowed to air-dry before plating
cells as described.
2.4.7 GnRH treatment of cells
aT3-l and L(3T2 cells were grown until 80% confluence in T-75 flasks. To treat
cells, media was removed and replaced with fresh media containing GnRH to a final
concentration of 1 pM. After incubation for the appropriate amount of time, cells
were harvested for further analysis.
2.4.8 Treatment of L/3T2 cells with inhibitor chemicals
L|3T2 cells were grown until 80% confluence in T-75 flasks. To treat cells, media
was removed and replaced with fresh media containing the appropriate inhibitor.
Cycloheximide (CHX) was added to a final concentration of 15 pg/ml, actinomycin
D (AMD) was added to a final concentration of 5 u,g/ml and leptomycin B (LMB,
Sigma) was added to a final concentration of 2 ng/ml. Flasks were returned to the
incubator for 30 minutes then 150 pi of 100 pM GnRH was added, to give a final
concentration of 1 pM. Flasks were then returned to the incubator for a further 2 h.
Cells were harvested for protein extracts as described in Section 2.7.2.
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2.5 Transient transfection ofDNA into in vitro cultured cells
For LPT2, HeLa and L-cells, Fugene transfection reagent was used at a ratio of 3 [a.1
of Fugene to 1 pg DNA. For aT3-l cells, GenePorter transfection reagent was used
at a ratio of 5 pi of GenePorter to 1 pg DNA.
2.5.1 Transient transfection of GFP expressing plasmids into cultured cells
Cells to be transfected (LPT2 or HeLa) were plated on 2-well glass slides (Nunc) at a
density of 100,000/ ml. The following day, 2 h prior to transfection, fresh media was
added to the cells. For each well, 1.5 pg DNA was diluted in 50 pi Optimem
(GibcoBRL) in a 5 ml culture tube (Elkay Laboratory products, UK). Into a separate
tube, 4.5 pi Fugene was diluted in 50 pi Optimem. The DNA/Optimem mix was
pipetted into the Fugene/Optimem mix, thoroughly mixed and incubated at room
temperature for 15 minutes. The 100 pi transfection mix was added drop-wise to
each well and the cells returned to the incubator for 48 h.
2.5.1.1 Preparation of EGFP transfected cells prior to image analysis
Localization of EGFP-tagged proteins was determined by comparison of GFP
expression with the expression of known nuclear stains. Media was discarded from
the transfected cells, and cells were washed twice in PBS. They were then fixed in 1
ml Methanol (MeOH, BDH) at -20°C for 10 minutes. The MeOH was removed and
the cells washed again in PBS. At this point the chambers were removed from the
top of the slides and a few drops of Topro-3 (Cambridge Biosciences, UK) nuclear
stain (1:2000 in PBS) were added to the fixed cells and the slides incubated, in the
dark, for 2 minutes. Slides were kept in the dark whilst washing in PBS for 5
minutes then coverslips were mounted using Permafluor mounting medium
(Immunotech, Beckman Coulter). Slides were viewed by confocal microscopy and
stored, in the dark, at 4°C.
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2.5.1.2 Image analysis of EGFP tagged proteins in mammalian cell culture
Analysis of direct immunofluorescence within cells was undertaken using a Zeiss
Axiovert 100m microscope and LSM510 scanning module with an oil immersion
x40 objective (Zeiss). Single scans and Z-stack analysis were performed at 1024 x
1024 pixels resolution according to manufacturer's instructions. To visualize GFP
and Topro-3, fluorescence excitation was performed using the Argon 488 nm and
HeNe 633 nm lasers (FITC/Cy5 multitrack).
2.5.2 Transient transfection of constructs for reporter gene assays
Luciferase assays were used to determine the effect a particular protein may have on
gene promoter activity. All constructs are detailed in Table 2.5 below. See Section
2.3.7 for information regarding cloning.
Vector Construct From/constructed by Size (basepairs)
pBluescriptSK+ Stratagene 2961 bp
pcDNA4HisMax Invitrogen 5222 bp
pcDNA4HisMax-LacZ P.Brown 8321 bp
pA3LUC D.Gordon, Denver 6356 bp
-480 alpha-pA3LUC P.Brown 6840 bp
-692 LH(3-pA3LUC P.Brown 7038 bp
-4741 FSH(3-pXP2LUC W.Miller 10227 bp
pCEP4 Invitrogen 10188 bp
pCEP4-Fanc.i H. van de Vrugt, Amsterdam 14879 bp
pEGFP-Cl Clontech 4700 bp
pEGFP-FANCA M.Buchwald, Ontario 10205 bp
pEGFP-FANCA-Hl 110P R.Larder 10205 bp
pEGFP-FANCA-Ql 128E R.Larder 10205 bp
pCDNA4-HisMaxB Invitrogen 5259 bp
pREP4-FancC M.Buchwald, Ontario 12192 bp
Table 2.5 Expression constructs used during the course of this thesis.
For all transfections, other than those analysing FSHfi promoter activity (See
Section 2.5.2.2), cells were plated into 12 well plates (Costar) at a density of
100,000/ml 24 h prior to use. The total plasmid DNA transfected into each well was
2 p,g, 1.5 pg of this corresponded to the promoter construct, the remainder was
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comprised of effector or control pBluescriptSK+ plasmid. The ratio of gene
promoter/reporter construct to effector plasmid DNA was always 12:1. A |3-
galactosidase (Lacz) reporter construct (pcDNA4HisMax-LacZ) was co-transfected
at 100 ng per well to control for transfection efficiency. Each transfection was
carried out in triplicate and each experiment repeated at least three times.
2.5.2.1 Transient transfection of L[3T2 cells using Fugene
L|3T2 cells were transfected using Fugene according to the manufacturer's
instructions. At least 2 h prior to transfection, media was removed and fresh media
added to the cells. The DNA to be transfected and the Fugene reagent were diluted
in Optimem serum free media (GibcoBRL). Optimem was pipetted to give a final
transfection volume of 100 pi per well and was split over two 5ml culture tubes. The
appropriate DNA plasmids were added to one tube whilst 3 pi of Fugene reagent per
1 pg DNA was added to the other. The diluted DNA was then added to the
Fugene/Optimem mix and the two solutions mixed. After incubating at room
temperature for 15 minutes, 100 pi of transfection mix was added drop-wise to each
well. The plate was swirled gently to mix and the cells incubated at 37°C for 48 h.
Cells were harvested for luciferase assays 6 h post GnRFI treatment. (See Section
2.5.3).
2.5.2.2 Transient transfection of FSH/3 promoter constructs
For analysis of FSH|3 promoter activity, cells were plated into 6 well plates (Costar)
at a density of 150,000/ml 24 h prior to use. As these wells hold 2.5 ml rather than 1
ml, each transfection was performed as for 12 well plates but was scaled up 2.5 times
(See Section 2.5.2.1). Approximately 16 h after transfection, cells were serum
starved by incubating for 24 h in DMEM containing 0.5% FCS and 0.1% Pen/Strep.
The following morning, activin (Sigma) was added to all wells at a final
concentration of 25 ng/pl whilst GnRH was added to the appropriate wells at a final
concentration of 100 nM. After 8 h cells were harvested for luciferase assays as
described in Section 2.5.3.
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2.5.2.3 Transient transfection of aT3-1 cells using Geneporter
aT3-l cells were transfected using Geneporter according to the manufacturer's
instructions. At least 2 h prior to transfection, the media was replaced with Optimem
serum free media (GibcoBRL). Transfection reactions were set up as described for
Fugene except that 5 pi ofGenePorter was added per 1 pg DNA. A 100 pi aliquot of
transfection mix was added drop-wise to each well. The plate was swirled gently to
mix and the cells incubated at 37°C for 4 h. The Optimem/transfection mix was
removed, fresh media added, and the cells were returned to the incubator for a further
48 h then harvested (as described in Section 2.5.3), 6 h post GnRH treatment.
2.5.3 Luciferase/(3-galactosidase chemiluminescent reporter gene assay
Luciferase assays for promoter activity were carried out using the Dual Light Assay
Kit (Tropix). This kit allows luciferase and Lacz activity to be read from the same
sample allowing the luciferase activity to be corrected for the transfection efficiency
of the cells. Media was removed from untreated or GnRH treated cells, and the cells
were washed 3 times in ice cold PBS. The cells were lysed in 250 pi lysis buffer
(Tropix) containing protease inhibitors (Roche) by shaking at 1000 rpm for 30
minutes. The supernatant from each well was transferred to a 1.5 ml eppendorf tube
and centrifuged at 5,000 rpm for 2 minutes at 4°C. A 10 pi aliquot of each sample
was pipetted in duplicate into a white, 96 well plate (Nunc). The luciferase activity
was determined using an automatic injection microplate luminometer (FLUOstar
Optima, BMG Labtechnologies). After incubation for 30 minutes at room
temperature p-galactosidase activity was measured. Luciferase activity was then
normalized against the relative amount of |3-galactosidase activity in each sample.
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2.6 RNA expression analysis
2.6.1 Solutions
Solutions and buffers for protocols involving RNA were made as described in
Sections 2.1 and 2.3 except they were pre-treated with 0.1% DEPC (Sigma)
overnight, to remove RNases, before autoclaving.
10 x MOPS, pH 7.0 (0.4 MMOPS, pH 20.9 g of 3-[N-Morpholino]
7.0, 0.1 MNaAc, 10 mMEDTA) propanesulfonic acid (MOPS, Sigma)
and 2.05 g NaAc were dissolved in
490 ml DEPC dH20. To this 10 ml of
0.5M EDTA (pH 8.0) was added
2.6.2 RNA extraction
All reverse transcriptase (RT) PCR was performed using total RNA harvested from
cells grown in culture media. RNA is easily degraded by RNases so extreme care
was taken during extraction. All equipment and bench areas were cleaned with
RNaseZap (Ambion) to remove any enzymes that could degrade RNA. All
plasticware was certified RNase free and all solutions were DEPC treated. RNA
was extracted by harvesting cells into RNAzol-B (AMS Biotechnology). Cells were
washed twice in PBS then removed from the flasks by lysing in 3 ml of RNAzol-B
solution for a T-25 flask and 7 ml ofRNAzol-B solution for a T-75 flask. RNAzol-
B/lysed cell suspensions were stored at -70°C until required. Total RNA was
extracted following manufacturer's instructions. Pelleted RNA was resuspended in
RNase free water and stored at -70°C until required.
2.6.3 Northern blot analysis
To analyze expression of Fanca and Zfp276 within L|3T2 cells, and the effects
hormone treatment may have on expression levels, northern blot analysis was
performed.
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2.6.3.1 Preparation of northern blot
A 1% agarose gel was prepared by boiling 3 g agarose in 30 ml 10 x MOPS mixed
with 220 ml DEPC H20. Once the gel had cooled to ~50°C, 51 ml formaldehyde
was added and the gel cast in a tray that had been thoroughly cleaned with
RnaseZap. A 30 jig aliquot ofRNA sample was made up to a final volume of 12 (il
with DEPC H20 then adjusted to a final volume of 50 pi by adding 25 pi
formamide, 5 pi 10 x MOPS and 8 pi formaldehyde (BDH). This mix was then
incubated at 65°C for 10 minutes then chilled on ice and 5 pi 50% (v/v) glycerol/0.1
mg/ml bromophenol blue loading dye added. Samples were loaded onto the gel and
electrophoresed overnight at 35 volts/cm in 1 x MOPS buffer. The next day the
marker lane, containing L-cell control RNA, was removed and stained in ethidium
bromide (5 pg/ml) for 15 minutes. Following de-staining in DEPC H20 for 15
minutes the RNA was visualized using UV light and photographed to record the
distance traveled by 28s and 18s RNA. The rest of the gel was blotted onto
Hybond-N+ (Amersham Biosciences), pre-wet in 3 x SSC, according to
manufacturer's instructions and left to transfer overnight in 20 x SSC. The next
morning the blot was crosslinked, as described in Section 2.3.10, then re-washed in
3 x SSC, excess liquid removed and the membrane wrapped in Saran wrap and
stored at 4°C until required.
2.6.3.2 Probe design for detecting Fanca and Zfp276 transcripts by northern
blotting
To analyze the expression and size of Fanca and Zfp276 mRNA transcripts two
probes were designed from mouse Fanca cDNA sequence for hybridization to a
northern blot containing L|3T2 total RNA. A 5' probe corresponding to exons 1-11
of Fanca was generated by digestion of pCEP4-Fanca (See Appendix I for vector
map) with Hindlll (Roche) and Asp700 (NEB). This generated three fragments, the
smallest 965 bp fragment, corresponding to exons 1-11 of Fanca, was gel purified
and labelled as previously described in Section 2.3.10.2. As exons 40-43 of Fanca
overlap with the 3'UTR of Zfp276, a probe corresponding to this region should
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hybridize to both transcripts. A labelled probe was generated, by amplification of L-
cell cDNA, which matched exon 43 of Fanca sequence and 1441 - 1949 bp of
Zfp276 cDNA sequence. Table 2.6 shows the DNA sequence of primers used to
generate this fragment. This 508 bp PCR product was cloned into TOPO-pCRII and
verified by DNA sequencing. The probe template was liberated from the vector by















Table 2.6 DNA sequence of primers used to generate probes for
northern blotting analysis.
Sequence of primers used to generate a 3' northern probe corresponding to both
Fanca and Zfp276 cDNA sequence.
2.6.3.3 Hybridisation and washing conditions
The probe was prepared and overnight hybridization performed as described in
Section 2.3.10.3. The following morning the blot was washed three times with 2 x
SSC, 0.1% SDS at room temperature for 30 minutes. The membrane was sealed in
Saran wrap and exposed to X-OMAT (Kodak) x-ray film at -70°C for 3 days. To
control for even loading, the blot was stripped in 1 litre of freshly boiled 0.5% SDS
solution and re-hybridized with an 18s probe using the same hybridization and
washing conditions as above.
2.6.4 Quantitative RT-PCR
Quantitative RT-PCR (Q-RT-PCR) was performed using a LightCycler Instrument
(Roche) and FastStart DNA Master SYBR Green I (Roche). This is a 'hot start'
reaction mix for PCR, containing FastStart Taq DNA polymerase and a dye for
detection of double-stranded DNA. During each round of amplification the dye
binds to the amplified PCR products and the amplicon is then detected by
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fluorescence. Quantification of real time PCR is based on calculations taking into
account the expression of a house keeping gene, in this case (3eta-2-microglobulin
(B2m), and the gene of interest (Fanca). The internal control gene must be
quantifiable over the same number of PCR cycles, expressed at the same levels
regardless of any cell treatments and be optimally synthesized at the same primer
annealing temperature and magnesium concentration as the gene of interest. Fanca
and B2m reaction conditions were optimized taking these factors into account and
primers were designed to amplify a product of between 100 and 200 bp. Prior to
using the LightCycler a check for genomic contamination in the sample was
performed using these primers in an RT-PCR reaction. If a single band was visible
when the product was analysed on a 1% agarose gel then the RNA was free from
contamination. Contaminated genomic DNA would generate 2 bands and therefore 2
melt curves and invalidate the results. The specific DNA primer sequences for
amplification ofFanca and B2m are shown in Table 2.7.



















102 bp ATG-102 |
Table 2.7 DNA sequence of primers used for LightCycler quantitative
RT-PCR.
DNA sequence of primers used to amplify Fanca and B2m for quantification of
mRNA levels using the LightCycler. Positions are specified in basepairs (bp) and
are qiven relative to the start codon (ATG) of mouse Fanca sequence (Accession N°
AF178934).
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Primer PairMix (25 pM each)
LightCycler DNA Master SYBR Green I (Roche)
cDNA
Specific PCR conditions were as follows:














A melt curve analysis is performed to determine the optimum temperature at which
to measure fluorescence, which in this case, was determined to be 80°C. This
temperature was chosen to ensure that only fluorescence measurements of specific
products were taken and fluorescence of non-specific products e.g. primer-dimers
was avoided. Any primer-dimers that may have formed during the PCR reaction
were denatured at this temperature and could therefore no longer bind SYBR Green
I.
A standard curve ofFanca and B2m expression was determined using serially diluted
cDNA made from mouse L-cell or HeLa cell RNA. Results are expressed as
arbitrary units of Fanca mRNA expression normalized against B2m mRNA
expression levels and are a mean of three separate experiments performed in
duplicate.
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2.7 Protein Expression Analysis
2.7.1 Solutions
1 M Tris-HCl (pH 8.0)
1 M Tris-HCl (pH 6.8)
1 M HEPES (pH 7.6)
0.5 M EGTA
3 M Potassium Chloride
10 % Ammonium persulphate (APS)
1 MDTT
121.1 g Tris was dissolved in 800 ml
dH20. The pH of the solution was
adjusted to pH 8.0 by adding ~ 42 ml
HC1 (BDH) then made up to 1 litre
with dH20.
121.1 g Tris was dissolved in 800 ml
dH20. The pH of the solution was
adjusted to pH 6.8 by adding ~ 100 ml
HC1 then made up to 1 litre with
dH20.
0.48 g of HEPES (Calbiochem) was
dissolved in 100 ml dH20, aliquoted
and stored at -20°C until required.
1.9 g EGTA (BDH) was dissolved in
100 ml dH20.
15 g KC1 (BDH) was dissolved in 100
ml dH20.
10 g of APS (Sigma) was dissolved in
100 ml of dH20, aliquoted and stored
at -20°C until required.
0.015 g of DTT was dissolved in 100




Phosphate Buffer Saline (PBS)
1 x Tris/Glycine/SDS (TGS)
5 x western loading dye (62.5 mM
Tris-HCl pH 6.8, 2% SDS, 10%
glycerol, 0.01% bromophenol blue,
1% /3-mercaptoethanol)
Western transfer buffer (7 x TGS, 20%
MeOH)
1 x TBST (i0.14 MNaCl, 20 mM Tris-
HClpH 7.4, 0.05 %> Tween 20)
Western blocking buffer (2% milk
powder, 1% BSA in 1 x TBST)
Western stripping buffer (2% SDS, 50
mM Tris-HCl pH 6.8, 0.7% /%
mercaptoethanol)
Protein extraction Buffer A (10 mM
Hepes pH 7.6, 10 mM KCl, 0.1 mM
EDTA, 0.1 mMEGTA, 1 mMDTT)
Materials and Methods
8 g NaCl; 800 mg KCl (BDH); 610
mg Na2HP04 and 200 mg KH2PO4
(Sigma) were dissolved in dH20. The
pH was adjusted to pH 7.4 with
concentrated NaOH or HC1 then made
up to 1 litre with dH20.
50 ml 10 x TGS (BioRad) was diluted
in 450 ml dH20.
1.25 ml 0.5 M Tris-HCl pH 6.8, 2 ml
10% SDS, 1 ml glycerol (BDH) and 1
mg bromophenol blue were mixed
together in 5.75 ml dH20. the dye was
then aliquoted and stored at -20°C
until required. Immediately prior to
use 10 pi |3-mercaptoethanol (Sigma)
was added to 1 ml of dye.
400 ml of 1 x TGS and 100 ml of
100% MeOH were mixed together.
8 g NaCl; 20 ml, 1M Tris-HCl pH 7.4
and 500 pi Tween 20 (Sigma) were
dissolved in 1 litre of dH20.
2 g milk powder and 1 g BSA were
dissolved in 100 ml of 1 x TBST.
2 ml 10% SDS, 4 ml 1.25 M Tris-HCl
pH 6.8 and 700 pi (3-mercaptoethanol
were dissolved in 100 ml dH20.
100 pi 1M HEPES, 33 pi 3 M KCl, 2
pi 0.5 M EDTA, 2 pi 0.5 M EGTA
and 10 pi 1 M DTT were diluted in
9.85 ml dH20.
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Protein extraction Buffer B (20 mM
Hepes pH 7.6, 0.4 M NaCl, 1 mM
EDTA, 1 mMEGTA, 1 mMDTT)
200 pi 1 M HEPES, 1.33 ml 3 M
NaCl, 20 pi 0.5 M EDTA, 20 pi 0.5 M
EGTA and 10 pi 1 M DTT were
diluted in 8.42 ml dH20.
2.7.2 Protein extraction from cells grown in culture
2.7.2.1 Whole cell extracts
Cells were grown in T-75 flasks until confluent. All media was removed and the
cells washed twice in chilled PBS. Cells were then scraped into 100 pi PBS
containing protease inhibitor tablets (Roche) and transferred to an eppendorf. After
three freeze-thaw cycles on dry-ice, cells were centrifuged at 13,000 rpm for 1
minute to pellet cell debris. The supernatant was aliquoted into new eppendorfs and
snap-cooled on dry ice. Extracts were stored at -70°C until required and were not re-
frozen once thawed.
2.7.2.2 Nuclear and cytoplasmic cell extracts
Cells to be harvested were grown in T-75 flasks until confluent. All media was
removed and the cells washed twice in chilled PBS. Cells were scraped into 1 ml
PBS containing protease inhibitor tablets and transferred to an eppendorf. After
centrifugation at 1500 rcf for 5 minutes at 4°C, the supernatant was removed and
each pellet (representing 1 x T-75 flask) resuspended in 400 pi chilled Buffer A (See
Section 2.7.1). After incubation on ice for 15 minutes, 25 pi 10% NP40 (Sigma) was
added to each eppendorf and cells vortexed for 10 seconds. Tubes were then
centrifuged at 13,000 rpm for 45 seconds. The supernatant, representing the
cytoplasmic fraction, was removed into new eppendorfs and snap-cooled on dry ice.
The remaining pellet was resuspended gently in 25 pi Buffer B (See Section 2.7.1)
and incubated on ice for 15 minutes. Eppendorfs were then centrifuged at 12,000
rpm for 5 minutes at 4°C. Supernatant, representing the nuclear fraction, was
transferred into new eppendorfs and snap-cooled on dry ice. Extracts were stored at
-70°C until required and were not re-frozen once thawed.
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2.7.3 Bradford assay ofprotein extracts
The concentration of protein extracts was determined using Bradford Assay Dye
(BioRad). A standard curve of BSA was used to calculate the amount of protein
present in each sample. BSA was diluted in PBS to give a range of protein
concentrations from 1 pig/pil to 30 pg/ul. To formulate the standard curve, 800 u.1 of
BSA standard was mixed with 200 [xl Bradford Assay dye and the OD at 595 X
measured using a WPA Lightwave S2000 UV/Vis Spectrophotometer (SLS, UK).
These results were plotted graphically and the linear regression formula of the best
fitting line then used to calculate the protein concentration of the samples. To
determine levels of protein present in each sample, 5 p,l of extract was mixed with
800 [xl dFLO and 200 ul dye and an OD measurement taken.
2.7.4 Preparation of SDS-polyacrylamide gels
All SDS-polyacrylamide (SDS-PAGE) gels were run using a Biorad PROTEAN II
cell or a Biorad MINI-PROTEAN III cell. All glass plates, spacers and combs were
cleaned thoroughly in detergent before use. After rinsing with dE^O and EtOH the
gel rig was assembled as per manufacturer's instructions.
2.7.4.1 SDS-polyacrylamide gel electrophoresis
In general, SDS-PAGE gels were cast and electrophoresed using a Biorad mini-
Protean III gel rig. A 20 ml volume of acrylamide gel mixture was adequate for
pouring two mini gels (See Table 2.8). To pour the gel, all components, apart from
the SDS and TEMED (Sigma), were mixed together then filtered and de-gassed
using a Nalgene filter sterilization unit (Fisher Scientific). The remaining
components were added, the gel poured immediately using a pasteur pipette and a
clean comb inserted. The gel was left to set at room temperature for at least 30
minutes then the comb was removed and the wells washed out with 1 x TGS running
buffer (Biorad). The gel rig was assembled as per manufacturer's instructions and
samples loaded as described in Section 2.7.5. Occasionally a Biorad PROTEAN II
gel rig was used to pour and electrophorese larger gels (16 cm x 16 cm). The process
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was essentially the same as for pouring mini-gels except 100 ml of acrylamide gel
mixture was required to pour two large gels and a 3% stacking gel was poured on top
of the resolving gel. (5 ml, 30% 37.5:1 acrylamide; 5 ml, 1.25M Tris pH6.8; 39.5 ml
dH20, 300 pi 10% APS, 500 pi 10% SDS and 25 pi TEMED)
Percentage of resolving gel
6% 12% 16%
20 ml 40 ml 53 ml 30% Acrylamide (37.5:1)
25 ml 25 ml 25 ml 1.5M Tris pH 8.8
53.4 ml 40 ml 21 ml h2o
600 pi 600 pi 600 pi 10% APS
1 ml 1 ml 1 ml 10% SDS j
50 pi 50 pi 50 pi TEMED
~ 50 - 220 kD ~ 15- 100 kD ~ 5 - 50 kD Resolution
Table 2.8 Components required to make 100ml SDS-Page acrylamide
gel.
2.7.5 Western analysis ofprotein extracts
All protein extracts were denatured by boiling for 5 minutes before loading on a
SDS-PAGE gel. An appropriate amount of protein extract was mixed with PBS and
5 x western loading dye to make a final loading volume of 25 pi or 40 pi depending
on the gel size. In general, 30 pg of whole cell extract and 50 pg of either
cytoplasmic or nuclear extract was loaded using duck-billed tips (Anachem). On
each gel, at least one well was loaded with Kaleidoscope Protein Marker (BioRad) so
the size of protein products could be determined after probing with an antibody.
Proteins were electrophoresed in 1 x TGS buffer at 10 volts/cm until they reached the
resolving gel, when the voltage was increased to 15 volts/cm. Samples were
electrophoresed until the dye front reached the bottom of the glass plates.
2.7.6 Transfer ofproteins to PVDF membrane
The gel rig was dismantled, gel plates pulled apart and the gel equilibrated in wet
blot transfer buffer for 10 minutes (See Section 2.7.1). Prior to use, PVDF
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(Millipore) membrane was rinsed in 100 % MeOH, followed by water then wet
transfer buffer to equilibrate the membrane. All blotting was done using a BioRad
wet blotter or a BioRad semi-dry blotter according to manufacturer's instructions.
Wet blotting was performed overnight at 25 volts, semi-dry blotting was performed
for 30 minutes at 10 volts for mini-gels (maximum current 5.5 mA/cm2) or for 1 h at
15 volts for large gels (maximum current 3 mA/cm2). After blotting the PVDF
membrane was rinsed in 1 x TBST and blots stored at 4°C in 1 x TBST until ready
for probing.
2.7.7 Immuno-blotting
Immunofluorescent detection ofprotein expression was performed using a secondary
antibody conjugated to horseradish peroxidase (HRP) and visualized with an ECL
Plus western blotting detection kit (Amerhsam Biosciences). Figure 2.1 shows a
schematic of how the detection system works.
Figure 2.2 Method of detection of Fanca protein by ECL Pius Detection
Kit.
All membranes were blocked in 2% milk powder/1% BSA/1 x TBST for at least 2 h
at room temperature or at 4°C overnight, with shaking. Blots were then incubated
with the appropriate antisera, diluted in blocking solution, for at least 2 h at room
temperature with shaking. The anti-serum was recovered and the blots were washed
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appropriate HRP conjugated secondary antibody at a 1:50,000 dilution in 1 x TBST
for at least 1 h. The blots were then washed in several changes of 1 x TBST for at
least 45 minutes. ECL Plus detection reagent was added according to manufacturer's
instructions and the blots incubated at room temperature for 5 minutes. Excess
solution was dried off and they were sandwiched between 2 sheets of acetate before
being exposed to X-AR Kodak x-ray fdm (Sigma) or scanned using a Typhoon
Phosphoimager (Amersham Biosciences) according to manufacturer's instructions.
Table 2.8 shows full details of antibodies used and conditions required.
Antibody Supplier Info Dilution 2° antibody
Fanca N-terminus Fre Arwert Polyclonal rabbit
anti-mouse


































Table 2.9 Antisera and conditions used for western blotting analysis of
cell extracts.
2.7.8 Quantification ofprotein expression
Levels of protein expression were determined using the ImageQuant Toolbox
computer program (Amersham Biosciences). Results are expressed as arbitrary units
of Fanca protein expression, normalized against |3-tubulin protein expression levels
where appropriate, and are a mean of at least three separate experiments.
2.7.9 Crude purification of Fanca antisera
Rabbit anti-mouse Fanca antiserum, collected from three inoculated rabbits, was
provided by Dr. Fre Arwert. To remove fat and serum proteins 30 ml of 60 mM
sodium acetate (pH 4.0) was added to 15 ml of antiserum and the solution mixed. To
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this, 10.5 ml of capryllic acid (Sigma) was added, a few drops at a time, whilst
stirring vigorously at room temperature. The serum protein precipitate was removed
by centrifugation at 3,000 rpm for 30 minutes at 4°C and any fat present solidified as
a disc on top of the partly purified antiserum. Partly purified antiserum was then
filtered through 1 MM Whatmann paper (Fisher Scientific) and dialysed overnight in
PBS. Dialysis tubing was prepared by boiling for 10 minutes in 1% sodium
hydrogen carbonate/1 mM EDTA/dFEO; rinsing in water; boiling for 10 minutes in 1
mM EDTA/dFEO then washing in PBS. After dialysis, the protein concentration of
the antisera was determined by Bradford assay and antisera was stored in aliquots at
-20°C until required.
2.7.10 Immunohistochemistry ofmammalian cells cultured in vitro
Immunohistochemistry was performed on LPT2 cells using antisera against Fanca.
Figure 2.3 shows how Fanca protein expression is detected by indirect
immunofluorescence.
Figure 2.3 Detection of Fanca protein expression by indirect
immunofluorescence.
Cells were plated on Matrigel coated 8-well glass slides (Nunc) at a density of
100,000/ml. The next day, media was discarded and the cells were washed twice in
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otherwise stated. Cells were fixed in 1 ml MeOH at -20°C for 10 minutes. MeOH
was removed and the cells were washed in PBS. Cells were permeabilised by
incubating in PBS containing 0.2% NP40 (Sigma), 1% BSA (Sigma) and 10%
normal goat serum (Diagnostics Scotland, Edinburgh, UK) for 20 minutes. Two
washes in PBS removed any remaining detergent. The cells were then incubated in
blocking solution (PBS containing 20% normal goat serum, 5% BSA, 4 drops/ml
Avidin (Vector laboratories, California), for 30 minutes. After two washes with
PBS, cells were incubated in biotin (Vector laboratories, California) diluted in PBS
(4 drops/ml) for 30 minutes. Cells were washed a further two times in PBS then
incubated overnight at 4°C in Fanca antisera diluted 1:200 in 20% normal goat
serum/5% BSA/PBS. The following day, excess primary antisera was removed by a
5 minute wash in PBS containing 0.05% Tween 20 (Sigma, PBST) followed by a 5
minute wash in PBS. Chambers were removed from the slides and a biotinylated
secondary antibody, goat-anti-rabbit-biotin, was applied at a 1:500 dilution in 20%
normal goat serum/5% BSA/PBS for 30 minutes at room temperature. Excess
secondary antibody was removed by washing for 5 minutes in PBST then 5 minutes
in PBS. Slides were maintained in the dark for the remaining treatments. A few
drops of a 1:200 dilution of Alexa 488 streptavidin conjugate (Cambridge
Biosciences) were applied to each slide and slides were then incubated for 1 h at
room temperature. Excess fluorescent probe was removed by washing for 5 minutes
in PBST then PBS. Cells were counterstained to visualize nuclei by application of a
few drops of Topro-3 (1:2000 in PBS, Cambridge Biosciences) to the top of each
slide and incubating for 2 minutes. Slides were then washed in PBS for 5 minutes
and coverslips mounted using Permafluor (Immunotech, Beckman Coulter)
mounting medium. Cells were viewed by confocal microscopy or stored in the dark
at 4°C.
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2.8 'Knockdown' of Fanca gene expression using siRNAs
RNA interference (RNAi) is the process by which dsRNA silences gene expression
by the sequence specific degradation of complementary mRNA (Harmon, 2002). In
principle, any gene can be silenced providing a rapid means to assess what
consequences loss of specific gene function may have on a cell line or on organ
function. Chemically synthesized short double stranded RNA (dsRNA) molecules of
21 nucleotides (nt), commonly known as short interfering RNAs (siRNAs), are used
to target mammalian mRNA without eliciting the interferon response associated with
introduction of long dsRNAs (Elbashir et al., 2001).
2.8.1 siRNA design and production
Specific siRNAs against mouse Fanca sequence (Accession Number: AF178934)
were designed using publicly available siRNA design programs on the websites of
MWG (http://www.mwg-biotech.com); Ambion (http://www.ambion.com) and Dharmacon
(http://www.dharmacon.com). Results from all three programs were analysed and three
sequences were chosen that were held in common between all three programs.
BLAST analysis was performed on these sequences to ensure that they matched no
other transcripts within the database. As a consequence, one sequence was
discarded, as it matched sequence on mouse chromosome 2, whilst Fanca is located
on chromosome 8. The remaining siRNA sequences, meeting all of the match
criteria, are shown in Table 2.10.
All siRNAs were synthesized by MWG using the 0.02 qmole synthesis scale as
duplexes in desalted form. They were resuspended in 750 ql 5 x Dharmacon
Universal Buffer (0.1 m KC1, 0.03M HEPES, 1 mM MgCb, 0.04 M KOH) to give a
final concentration of 20 qM then aliquoted under RNase free conditions and stored
at -70°C until required.
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Base-pairs (bp) 1644 - 1663 2979-2999 n/a
Table 2.10 DNA sequence of Fanca and scrambled siRNAs.
Sense and antisense sequence of siRNAs designed against mouse Fanca. Position
of siRNA sequence, given in basepairs (bp), is relative to the start codon (ATG) for
mouse Fanca (Accession N° AF 178934).
2.8.2 Transfection of siRNAs into L/3T2 cells using Fugene
LPT2 cells were transfected using Fugene according to the manufacturer's
instructions. Cells were plated in T-75 flasks 24 h prior to transfection at 100,000
cells/ml. At least 2 h prior to transfection, media was removed and 5 ml fresh media
added to the cells. The siRNA to be transfected and the Fugene reagent were diluted
in Optimem serum free media (GibcoBRL). Optimem was pipetted to give a final
transfection volume of 500 pi per flask and was split over two 5ml culture tubes. An
appropriate amount of siRNA was added to one tube containing Optimem to achieve
a final concentration of either 200 or 400 nM in the T-75 flask. A 3 pi aliquot of
Fugene reagent was used per 1 pg siRNA and added to a separate tube. The diluted
siRNA was added to the Fugene/Optimem mix and the two solutions mixed by
gentle tapping. After incubating at room temperature for 15 minutes, 500 pi
transfection mix was added to each T-75 flask to be transfected. Flasks were
incubated at 37°C for 24 h then whole cell protein extracts were made, as described
in Section 2.7.2.1.
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2.8.3 Analysis of Fanca mRNA levels after siRNA treatment
Analysis of mRNA expression levels in cells transfected with siRNAs was
performed using RT-PCR analysis as described in Section 2.1.3. Table 2.1 details
the primers used for amplification ofFanca, Zfp276 and Gapdh.
2.8.4 Analysis of Fanca protein levels after siRNA treatment
Western blotting ofwhole cell extracts from untreated cells and cells transfected with
siRNA was performed as previously described (See Section 2.7). Blots were probed
with Fanca antisera then stripped and re-probed with (3-tubulin antisera to check for
specific knockdown of Fanca protein. Results are expressed as arbitrary units of
Fanca protein expression normalized against (3-tubulin protein expression levels and
are the mean of at least three separate experiments.
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2.9 Construction of recombinant adenoviral vectors
expressing FANCA
Recent advances in adenoviral technology have made it possible to clone a gene of
interest into an adenoviral vector, propagate the virus in HEK293 cells then infect
target cells to achieve efficient transfer of the gene and produce high levels of protein
expression under standard laboratory conditions (Imperiale and Kochanek, 2004).
BD-Adeno-X Expression Systems 2 with BD Creator Technology (Clontech) was
used to clone FANCA into an adenoviral vector. This system uses Crt-loxP site-
specific recombination to create recombinant adenoviral vectors. (See Figure 2.4).
Adenoviral genome





Figure 2.4 Construction of recombinant adenovirus with BD Creator
Technology.
Cre-loxP mediated recombination allows the production of a recombinant adenoviral
vector containing your gene of interest. Digestion with Pad linearizes the DNA and
exposes the inverted terminal repeats (ITR) allowing viral replication when
transfected into HEK293 cells. Viral particles can then be purified and used to infect
target cell lines.
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2.9.1 Materials and solutions
Sucrose/Chloramphenicol/LB plates
( 7% sucrose, 30 p g / m I
chloramphenicol)
Buffer 1 (25 mM Tris-HCl pH 8.0, 10
mMEDTA, 50 mMglucose)
Buffer 2 (0.2 MNaOH, 1% SDS)
Buffer 3 (5MKOAc pH 4.8)
Buffer 4 (10 mM Tris-HCl pH 8.0, 1
mMEDTA, 20 tig/ml RNase)
70 g sucrose (BDH) was dissolved in
1 litre of dH20. 31 pellets of LB-Agar
(Q-Biogene) were added to this and
the solution autoclaved. To pour the
plates, the agar was melted in the
microwave, 1 ml chloramphenicol (30
mg/ml) added and the agar poured into
Petri dishes
2.5 ml 1 M Tris-HCl pH 8.0, 2 ml 0.5
M EDTA and 0.9 g glucose were
mixed together in 100 ml of dH20
0.8 g NaOH and 1 g SDS were
dissolved in 100 ml dH20
24.9 g potassium acetate was
dissolved in 40 ml dH20. The pH was
adjusted to 4.8 by adding ~ 50 ml
acetic acid then made up to 100 ml
with dH20
500 1 M Tris-HCl pH 8.0 and 100
pi 0.5M EDTA were diluted in 50 ml
dH20. RNase was added to a final
concentration of 20 pg/ml
2.9.2 Cloning FANCA into 'donor' vector
FANCA insert was liberated from pEGFP-FANCA by digestion with Nhel as
described in Section 2.3.7. Donor vector (pDNR-CMV) was linearized by digestion
with Xbal and SAP treated to prevent self re-ligation. The 6.2 kb FANCA insert
with Nhel overhangs was then ligated into the pDNR-CMV compatible Xbal sites to
produce pDNR-CMV-FANCA. Figations were transformed into E.coli as described
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in Section 2.2.2, plated onto LB-Agar/Amp plates and grown overnight at 37°C. The
following day, plasmid DNA was prepared from single colonies as described in 2.9.4
and diagnostic restriction digests performed using EcoRI to check for correct
orientation of the insert (See Section 2.3.5).
2.9.3 Cloning of FANCA into adenoviral 'acceptor' vector
In an eppendorf, 1 pi pDNR-CMV-FANCA (200 ng/ul), 1 pi Cre Recombinase and
18 pi of BD Adeno-X-LP Reaction Mix were mixed together by gentle tapping.
After incubating at room temperature for exactly 15 minutes the reaction was
stopped by heating to 70°C for 5 minutes and 2 pi was then transformed into SURE
competent cells (Stratagene) as described in Section 2.2.2. A 150 pi aliquot of the
transformation reaction was plated out onto LB-Agar/sucrose/chloramphenicol plates
and the plates incubated at 37°C for 24-32 h.
2.9.4 Small scale preparation of recombinant adenoviral vectors
pLP-Adeno-X is a large vector (34 kb) that is susceptible to damage and
rearrangement. Cultures were not left at room temperature or 4°C for >24 h before
starting purification of DNA or inoculating a second culture. To ensure strict
propagation of recombinant clones, colonies were grown overnight at 37°C in LB
containing both ampicillin (50 pg/ml) and chloramphenicol (30 pg/ml). The
following day, cultures were centrifuged at 10,000 rpm for 1 minute and the pellet
resuspended in 150 pi buffer 1. A 150 pi aliquot of buffer 2 was added, the solution
mixed gently and incubated at room temperature for 5 minutes before adding 150 pi
of buffer 3, mixing gently and incubating on ice for a further 5 minutes. This mix
was then centrifuged at 14,000 rpm for 5 minutes at 4°C and the supernatant
removed to a fresh eppendorf tube. To this, 450 pi phenokchloroform (50:50) was
added, the solution carefully mixed and then centrifuged at 14,000 rpm for 5 minutes
at 4°C. The top layer was removed to a fresh eppendorf and 1 ml of 100% EtOH
added to precipitate the DNA. DNA was pelleted by centrifugation at 14,000 rpm
for 10 minutes at 4°C and the pellet was washed in 1 ml of 70% EtOH. The DNA
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pellet was dried then resuspended in 20 pi buffer 4 and incubated at 37°C for 10
minutes. The adenoviral DNA was stored at -20°C until required.
2.9.5 Confirmation ofpositive clones by PCR
E.coli clones containing recombinant pLP-Adeno-X Viral DNA were identified by
PCR using the BD Adeno-X LP Primer Mix (Clontech). A diagnostic PCR fragment
of 660 bp indicates the gene fragment has cloned successfully, whilst a 296 bp
fragment indicates failure to insert the gene of interest.
To perform the PCR the following components were mixed together:
1 pi DNA
1 pi BD-Adeno-X LP Primer Mix
8 pi dH20
10 pi Abgene High Fidelity Master Mix Taq
30 cycles of PCR amplification were performed under the following conditions:
Initial denaturation 95°C 2 minutes
Denaturation 94°C 1 minute
Specific primer annealing temperature 64°C 1 minute
Extension 72°C 1 minute
Final extension 72°C 10 minutes
30 cycles
PCR products were electrophoresed on a 1% agarose gel and visualised by UV light.
2.9.6 Large scale preparation of recombinant adenoviral vectors
Once a positive clone had been identified by PCR, the clone was amplified by
inoculating 100 ml of LB-Broth containing ampicillin (50 pg/ml) and
chloramphenicol (30 pg/ml) with 2-5 ml of fresh log-phase culture. This culture was
incubated at 37°C until it reached log-phase then plasmid purified using the
NucleoBond Plasmid Midi Kit (Clontech) according to the manufacturer's
instructions (Low copy plasmid purification method). The identity of the purified
plasmid was then re-confirmed by PCR as described in Section 2.9.5.
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2.9.7 Producing recombinant adenovirus
2.9.7.1 Pad digestion of recombinant plasmid
Before the recombinant adenoviral DNA can be packaged, the plasmid must be
digested with PacI to expose the inverted tandem repeats (ITRs) located at either end
of the adenoviral genome. The ITRs contain the origins of adenovirus DNA
replication and must be positioned at the ends of the linear adenovirus DNA
molecule to allow formation of the replication complex (Tamanoi and Stillman,
1982).
The following components were mixed together in an eppendorf tube and incubated
at 37°C for 2 h:
Sterile H20 20 pi
Recombinant adenoviral plasmid DNA (500 ng/pl) 10 pi
10 x Pad digestion buffer 4 pi
lOxBSA 4 pi
Pad restriction enzyme (1 unit/pi) 2 pi
To this, 60 pi of 1 x TE buffer and 100 pi phenokchloroform (50:50) were added and
the contents gently mixed. Following centrifugation at 14,000 rpm for 5 minutes at
4°C the top, aqueous layer was transferred to a clean eppendorf and 400 pi of 95%
EtOH, 1/10th volume of 3 M NaAc (pH 5.2) and 1 pi glycogen (20 mg/ml) added.
Contents were mixed gently then centrifuged at 14,000 rpm for 5 minutes at 4°C.
The supernatant was removed and the digested DNA pellet washed with 300 pi of
75% EtOH then spun at 14,000 rpm for 2 minutes. The pellet was dried and the
DNA resuspended in 10 pi 1 x TE buffer.
2.9.7.2 Transfecting HEK293 cells with recombinant adenoviral DNA
HEK293 cells were plated in T-25 culture flasks (Costar) 24 h prior to transfection at
a density of 100,000 cells/ml. Each T-25 flask can be transfected with 10 pi ofPad
digested adenoviral DNA. At least 2 h prior to transfection, media was removed and
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5 ml of fresh media added to the cells. In one 5 ml culture tube, the resuspended
PacI digested DNA (10 pi) was diluted in 230 pi Optimem serum free media whilst
in a separate tube 30 pi of Fugene transfection reagent (6 pi per pg DNA) was
diluted in 230 pi Optimem. The DNA/Optimem mix was added to the
Fugene/Optimem mix and the two solutions mixed by gently tapping. After
incubating at room temperature for 15 minutes, 500 pi of the transfection was added
to a T-25 flask and incubated at 37°C until cytopathic effect (CPE, rounding up of
cells and detachment from the plate) was visible.
2.9.7.3 Amplification and preparation of viral stock
Once CPE was visible, a process which may take up to two weeks, amplification was
achieved by manually lysing cells to obtain virus then infecting new cells. Cells
were transferred to a 15 ml tube (Costar) and centrifuged at 1,500 rpm for 5 minutes
at room temperature. The cell pellet was resuspended in 500 pi sterile PBS and
transferred to an eppendorf tube. Cells were lysed by three consecutive freeze-thaw
cycles using dry ice. After the third cycle, cell debris was pelleted by centrifugation
at 5,000 rpm for 1 min and the lysate transferred to an eppendorf tube. A 250 pi
aliquot of lysate was then used to infect a T-25 flask containing HEK293 cells
(100,000/ml) by adding the lysate directly to the medium then incubating as normal,
the remaining lysate can be stored at -20°C. CPE should now become evident within
one week. When >50% of the infected cells have detached from the growing
surface, viral stock was produced by lysing the cells by three consecutive freeze-
thaw cycles as before. This primary amplification stock was stored at -20°C until
required.
2.9.8 Plaque assay to determine adenoviral titer
HEK293 cells were plated in 6-well plates (Costar) 24 h prior to transfection at a
density of 100,000 cells/ml. Using sterile PBS a serial dilution of viral stock was
made (1 x 10"5 to 1 x 10"10). Media was removed from the wells and 250 pi of
diluted virus added to the cells. To control for errors, each viral dilution was added
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to 3 wells and the plates gently tipped to spread the virus evenly over the cells. The
plates were covered and incubated at 37°C for 1 h to allow the virus to infect the
cells, then the virus was removed and 3 ml of 0.5% agarose/PBS solution was added
to each well. When the agarose had set, the plates were returned to the incubator for
7 days. To visualize plaque formation, 1 ml of 0.03% neutral red (Sigma)/PBS
solution was added to each well and plates incubated at 37°C for 3 h. The stain was
then removed and the clear plaques in each well, visible against a pink background,
counted. To calculate the viral titer (plaque forming units [pfu]/ml) the following
formula is used:
pfii/ml = # plaques
(dilution factor) x (volume of diluted virus added to each well)




Regulation of Fanca expression by GnRH
Science never solves a problem without creating ten more - George Bernard Shaw.
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3 Regulation of Fanca expression by GnRH
3.1 Introduction
3.1.1 Background
Fertility, and hence the ability to reproduce, is regulated by the action of the
gonadotropin hormones luteinising hormone (LH) and follicle stimulating hormone
(FSH) on the testes and ovaries. Their biosynthesis and release is controlled by the
signalling of GnRFl through its cognate receptor on the surface of pituitary
gonadotroph cells. As gonadotroph cells only comprise 10-15% of the anterior
pituitary, the development of two transformed gonadotroph cell lines, aT3-l and
LflT2 cells (Windle et al., 1990; Turgeon et al., 1996), has provided an enriched
source of cell-specific material with which to study GnRH regulation of
gonadotropin gene transcription.
Immortalized gonadotroph cell lines were derived from pituitary tumours isolated
from transgenic mice carrying fusion genes of the SV40 T-antigen oncogene linked
to 5' flanking sequence of either the human aGSU or rat Lhfi genes. As aGSU is
expressed in gonadotroph and thyrotroph cells of the anterior pituitary, and LH(3
expression is restricted to terminally differentiated gonadotroph cells (Japon et al.,
1994), the aim was to develop spatially and temporally specific cell lines. Targeted
oncogenesis with the aGSU promoter produced a primitive gonadotroph cell line
(aT3-l), representative ofmouse embryonic day (E) 13.5, that expresses aGsu and
Gnrhr but not Lhfi or Fsh/3 (Windle et al., 1990; Alarid et al., 1996). Targeted
oncogenesis with the Lh/3 subunit promoter produced a more mature gonadotroph
cell line (LPT2), representative of an El6.5 mouse pituitary, that expresses aGsu,
Lh/3, Fsh/3 and Gnrhr (Turgeon et al., 1996; Graham et al., 1999).
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These cell lines have aided dissection of the GnRH receptor activated intracellular
pathways, allowing analysis of the mechanisms involved in gonadotropin synthesis
and secretion and the identification of a role for MAPK signalling cascades in GnRH
regulation of gonadotropin gene transcription (Naor et al., 2000; Yokoi et al., 2000;
Harris et al., 2002; Liu et al., 2002; Bonfil et al., 2004; Coss et al., 2004). To
characterise the mechanisms involved in GnRH regulation of gonadotropin subunit
transcription, the mouse L|3T2 gonadotroph cell line has previously been used as a
model to investigate GnRH regulation of gene expression. Differential display (DD)
RT-PCR was performed on RNA extracted from untreated and GnRH treated L|3T2
cells in order to identify and isolate hormonally regulated transcripts (Chang, 2002).
Differential display involves the linear amplification of partial cDNA sequences
from mRNAs by RT-PCR, thus the complexity of the cDNA population is
representative of the complexity of the mRNA population from which it was derived
(Liang and Pardee, 1992). Unlike other techniques, where success is biased by
relative mRNA abundances, differential display detects both abundant and rare
mRNAs providing the arbitrary primer sequence used matches the target mRNA. To
identify which gonadotroph cell mRNA transcripts were regulated by GnRH, DD-
RT-PCR was performed on RNA harvested from L|3T2 cells that were either left
untreated or treated with one 15 minute pulse of 1 uM GnRH and harvested for RNA
1, 2 or 4 h later (Chang, 2002). Several hormonally regulated transcripts were
identified and one of these showed a rapid increase in expression levels 1 h after
GnRH treatment with expression returning to untreated levels after 4 h. This product
was isolated, amplified by PCR, cloned, sequenced and matched, using bioinformatic
analysis, to exon 43 of Fanconi anaemia complementation group a {Fanca). See
Figure 3.1.
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R5 primer
AGGACCCTGG




ATCTCCTTGATTGCTCTAGTTAGGAAAAGAAATATTAATTATTCATAAAAAAAAAAAAAAAAAAGC 4 51 Obp
CCTTTTTTTTTTTT PolyA+ site
t12vc
Figure 3.1 Alignment of the 74 bp cloned DD-RT-PCR product and
mouse Fanca cDNA nucleotide sequence.
Bioinformatic line-up depicting the region of homology, shown underlined, between
the cloned Fanca DD-RT-PCR product and mouse Fanca cDNA nucleotide
sequence. The likely internal R5 arbitrary primer site is indicated as well as the
location of the R5 and T12VC primers that generated the original 216 bp DD-RT-
PCR product.
FANCA is mutated in >60% of cases of Fanconi anaemia (FA), a rare, autosomal
recessive, chromosomal instability syndrome (OMIM 227650). The disease is
classified as a DNA damage repair disorder since patients have a marked
predisposition to cancer and suffer from progressive bone marrow failure (Buchwald
and Moustacchi, 1998). Murine Fanca shares 74% nucleotide sequence identity with
human FANCA (van de Vrugt et al., 2000; Wong et ah, 2000). At the same time, a
novel penta zinc finger protein (Zfp276) was also identified at the Fanca locus that is
transcribed in an antisense orientation and overlaps with Fanca (Wong et ah, 2000).
Fanca has an ORF of 4503 bp comprised of 43 exons and encoding a protein of-160
kD. The function of FANCA protein is largely unknown and the uniqueness of the
molecule is reflected by the designation of a new protein domain, Fanconia
(PFAM:PF03511), located at the C-terminus of the protein. The discovery, using
DD-RT-PCR, that GnRH regulates Fanca expression demonstrates the non-user bias
of this technique in the identification of genes whose expression has not previously
been associated with hormonal regulation. Microarray technology has also been
used to identify transcripts regulated by GnRH in L|3T2 and aT3-l cells (Wurmbach
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et al, 2001; Yuen et al., 2002). Although Fanca was not included on the arrays used
in these experiments a rapid and transient increase in transcripts known to be
regulated by GnRH, including the transcription factors early growth factor1 (Egrl)
and c-Jun, was detected over a wide range of GnRH concentrations (1 nM up to 1
fxM) indicating that although no novel transcripts were identified using this approach
a detailed profile of transcripts known to be regulated by GnRH was obtained.
3.1.2 Aims of this Chapter
Previous work within the laboratory, using the technique of differential display RT-
PCR (DD-RT-PCR), identified several transcripts, within L|3T2 gonadotroph cells
that were differentially expressed in response to GnRH (Chang, 2002).
Bioinformatic analysis revealed that one of these transcripts, which showed a rapid
and transient up-regulation in response to GnRH, matched sequence from a region of
overlap between two genes, Fanconi anaemia complementation group a {Fanca) and
penta-zinc finger protein 276 (Zfp276), that are transcribed in opposite orientations,
from the same locus, on mouse chromosome 8. This chapter aims to address whether
it is the expression of Fanca or Zfp276 that is altered within L|3T2 gonadotroph cells
in response to addition GnRH.
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3.2 Results
3.2.1 Fanca mRNA is expressed in L/3T2 cells
A transcript, corresponding to exon 43 of Fanconi anaemia complementation group
a gene (Fanca), was identified as being regulated by GnRH in L|3T2 gonadotroph
cells using the technique of differential display (DD) RT-PCR (Chang, 2002).
However, following publication of a manuscript detailing an antisense transcript,
Zinc finger protein 276 (Zfp276), that overlaps with the 3' end of Fanca and could
therefore also be the DD-RT-PCR clone, further experimental analysis of the
expression of both transcripts within L(3T2 cells was required. Figure 3.2 shows a
schematic representation of the Fanca locus indicating the overlap between the two
genes and the location of the DD-RT-PCR clone. To confirm expression of full-
length Fanca mRNA within L|3T2 gonadotroph cells northern blotting analysis was
performed. Total RNA was extracted from L|3T2 cells, fractionated on a
formaldehyde gel, blotted and probed with either 5' or 3' fragments ofmouse Fanca
cDNA as described in Section 2.6.3.2. The 5' Fanca probe used corresponded to 1-
965 bp of cDNA encoding exons 1-11. The 3' probe used corresponded to exon 43
of Fanca cDNA and 1441-1949 bp of Zfp276 cDNA. Analysis of the blots
confirmed that a full-length 4.5 kb transcript, corresponding to Fanca, was detected
with the 5' probe only (See Figure 3.3). As expected, the 3' probe detected two
bands; a large band at 4.5 kb, corresponding to Fanca and a smaller, 3.1 kb,
transcript corresponding to the reported size of full length Zfp276 (Wong et al.,
2000) (See Figure 3.3).
3.2.2 Fanca mRNA is expressed in adult mouse pituitary
In vivo expression of Fanca was determined by RT-PCR analysis of adult mouse
pituitary tissue. RNA was extracted from the tissue; reverse transcribed and cDNA
amplified using gene specific primers corresponding to exons 7 to 18, 14 to 18 or 30
to 32 of mouse Fanca cDNA (See Table 2.1 and Figure 3.4). PCR conditions and
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RNA integrity were confirmed by RT-PCR of Glyceraldehyde 3-phosphate
dehydrogenase (Gapdh). Ethidium bromide staining identified bands at the expected
sizes of 1075, 450 and 211 bp whilst DNA sequencing of the cloned PCR products
established that Fanca is expressed in the pituitary of adult mice (See Figure 3.5).
Fanca gene
1 2 " 40 41 42 43
4— 74 bp DD-RT-PCR Clone
Zfp276 gene
Figure 3.2 Schematic representation of the Fanca locus showing
overlap between Fanca and Zfp276.
Exons 40-43 of Fanca (black boxes) overlap with the 3' untranslated region (UTR) of
Zfp276 (grey box). The location of the cloned 74 bp DD-RT-PCR clone is indicated
with an arrow.
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Figure 3.3 Expression of full-length Fanca and Zfp276 mRNA
transcripts in LfiT2 cells.
Total RNA from L|3T2 cells was fractionated on a formaldehyde gel, northern blotted
and probed with radiolabeled probes corresponding to either exons 1-11 (5' probe)
or exon 43 (3' probe) of mouse Fanca cDNA. The 5' probe detected one band at
4.5 kb corresponding to the size of full-length Fanca transcript. The 3' probe
detected two bands, a Fanca transcript at 4.5 kb and a 3.1 kb transcript
corresponding to Zfp276. The blot was then stripped and re-probed with an 18s
probe as a control.
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Figure 3.5 Fanca in vivo expression analysis.
RT-PCR analysis of RNA extracted from adult mouse pituitary was performed using
primers that amplified exons 7-18, 14-18 or 30-32 of mouse Fanca. A negative
control containing no cDNA was included (-ve). The integrity of pituitary RNA was
confirmed by amplification of Gapdh (+ve). Ethidium bromide staining identified
PCR products of the expected size, which were confirmed as Fanca by DNA
sequencing.
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3.2.3 Fanca mRNA is not expressed in immature pituitary gonadotrophs
Having confirmed expression of Fanca in adult pituitaries and mature gonadotroph
cells, further analysis was carried out to determine if Fanca was expressed in aT3-l
cells, an immature gonadotroph cell line. Fanca expression was also analysed in a
rat somatotroph cell line (GH3 cells); a mouse fibroblast-like cell line (L-cells) and a
human cervical cancer cell line (HeLa cells). RNA was extracted from cultured
cells; reverse transcribed and cDNA amplified using gene specific primers
corresponding to exons 14 to 18 of mouse Fanca cDNA (See Table 2.1 and Figure
3.4). PCR conditions and RNA integrity were confirmed by RT-PCR of Zfp276
using primers designed to Zfp276 mouse cDNA sequence. As expected, ethidium
bromide staining identified DNA bands at the predicted size of 450 bp in L|3T2 cells.
Fanca mRNA expression was also detected in GH3, HeLa and L-cells (Figure 3.6).
DNA sequencing of cloned RT-PCR products confirmed amplification of Fanca
from these cell lines. Interestingly no Fanca expression was detectable when
amplifying aT3-l cDNA although Zfp276 was determined to be present (Figure 3.6).
To analyse the lack ofFanca expression in aT3-l cells further, exons 7-18 ofmouse
Fanca cDNA were amplified from L-cell and aT3-l cDNA, blotted onto Hybond-N+
and hybridised with a radiolabeled probe corresponding to exons 1-11 of mouse
Fanca (as described in Section 2.3.10.1). Exposure of the hybridised blot to x-ray
film revealed that a Fanca specific band of 1075 bp was amplified from L-cell
cDNA only. No Fanca expression was detected by Southern blot analysis of aT3-l
amplified cDNA. (See Figure 3.7)
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Figure 3.6 Fanca in vitro expression analysis.
RNA was extracted from Lf5T2, aT3-1, GH3, HeLa and L-cells, reverse transcribed
and first strand cDNA analysed for expression of mouse Fanca using primers
corresponding to exons 14-18. Ethidium bromide staining identified an expected
DNA band of 450 bp in L|3T2, GH3, HeLa and L-cells. No Fanca expression was
detectable when amplifying aT3-1 cDNA. The integrity of the RNA samples was
confirmed by amplification of Zfp276 using primers matching mouse cDNA
sequence. A specific 1238 bp PCR product, corresponding to Zfp276, was
amplified from LpT2, aT3-1, GH3 and L-cell cDNA.
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Fanca Zfp276
1 L-cell aT3-1 ' 'aT3-11
■Fanca
Figure 3.7 Southern blotting analysis of Fanca expression in aT3-1
cells.
RT-PCR analysis of RNA extracted from aT3-1 and L-cell was performed using
primers that amplified exons 7-18 of mouse Fanca. Ethidium bromide staining
identified an expected DNA band of 1075 bp from L-cell cDNA. No Fanca
expression was detectable when amplifying aT3-1 cDNA but the integrity of aT3-1
RNA was confirmed by amplification of mouse Zfp276. Southern blotting analysis of
the agarose gel with a 5' Fanca probe, corresponding to exons 1-11 of mouse
Fanca cDNA, confirmed that the Fanca PCR product was specific.
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3.2.4 Zfp276 mRNA is not regulated by GnRH
Although it appears highly unlikely that the Zfp276 transcript at the same locus as
Fanca was the transcript identified by DD-RT-PCR RT-PCR was performed to
determine if Zfp276 mRNA expression levels changed in response to GnRH. RNA
was extracted from cultured LpT2 cells that had been left untreated (0 h) or treated
with GnRH for 1, 2 or 4 hours. This was reverse transcribed and cDNA amplified
using gene specific primers corresponding to full-length mouse Zfp276. Ethidium
bromide staining identified a DNA band at the expected size of 1238 bp at all time
points suggesting no difference in expression levels of Zfp276 mRNA in untreated
and treated cells (Figure 3.8).
3.2.5 An alternative Zfp276 transcript is expressed in L/3T2 cells
The 1238 bp PCR products amplified from LPT2 and L-cell cDNA were cloned into
TOPO-pCRII and sequenced to confirm amplification of Zfp276. Analysis of the
sequence data identified the presence of two amplified Zfp276 PCR clones (Clone A
and Clone B) from both L-cell and LPT2 cDNA. Sequence from Clone A was
identical to mouse Zfp276 nucleotide sequence (Accession N° AF178935). Clone B
was also identical to mouse Zfp276 sequence but contained a 70 bp insertion of
genomic sequence 849 bp downstream of the start codon (See Figure 3.9). Analysis
of the predicted protein products of these transcripts revealed that the 70 bp insertion
introduces several in-frame premature STOP codons into the predicted Zfp276 amino
acid sequence presumably resulting in a truncated Zfp276 protein (See Figure 3.9).
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L|3T2





Figure 3.8 RT-PCR analysis of Zfp276 mRNA expression in LPT2 cells.
LpT2 cells were left untreated (0) or treated with GnRH then harvested 1, 2 or 4 h
later. RNA was extracted, reverse transcribed and first strand cDNA analysed for
expression of mouse Zfp276. Ethidium bromide staining identified an expected
DNA band at 1238 bp in all RNA samples. Zfp276 was also amplified from L-cell
cDNA as a positive control (+ve). The 1238 bp Zfp276 PCR product is indicated
with an arrow.
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Figure 3.9 Alignment of Zfp276 PCR Clone A and Zfp276 PCR Clone B
nucleotide and predicted amino acid sequence.
(i) Bioinformatic line-up of the nucleotide sequence of Zfp276 Clone A and Zfp276
Clone B. The 70 bp insertion of genomic sequence in the Clone B is shown (blue
text). The insertion alters the reading frame and results in the introduction of in-
frame premature STOP codons (red boxes). Nucleotide positions are given relative
to the start codon (ATG). Zfp276 cDNA sequence is taken from sequence available
in the GenBank database (Accession N° AF178935). (ii) Bioinformatic comparison
showing the predicted amino acid sequence of the two Zfp276 PCR clones. The
altered amino acid sequence of the Clone B is shown (green text). STOP codons
are indicated with an X. Clone A encodes a predicted protein of 372 amino acids
(aa), Clone B encodes a predicted protein of 283 aa.
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3.2.6 Fanca mRNA levels are regulated by GnRH
RT-PCR was used to analyse expression of Fanca mRNA in untreated and GnRH
treated L(3T2 cells. RNA was extracted from cultured L|3T2 cells that had been left
untreated (0 h) or treated with 1 pM GnRH for 1, 2 or 4 hours. This was reverse
transcribed and cDNA amplified, for 30 PCR cycles, using gene specific primers
corresponding to exons 7 to 17 of mouse Fanca cDNA (See Table 2.1 and Figure
3.4). Ethidium bromide staining identified a DNA band at the expected size of 979
bp in L|3T2 cells harvested for RNA after 1 h of GnRH treatment (Figure 3.10)
agreeing with DD-RT-PCR results showing that Fanca expression increases 1 h after
treatment with GnRH (Chang, 2002). Specific amplification of a 979 bp Fanca PCR
product was confirmed by subsequent Southern blotting analysis, which also
identified lower levels of expression in untreated LPT2 cells and a rapid reduction in
Fanca mRNA expression 2 and 4 h after GnRH treatment (Figure 3.10).
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L[3T2
GnRH (h) H) 1 2 4^ -ve +ve
Figure 3.10 RT-PCR analysis of Fanca expression in LPT2 cells.
LPT2 cells were left untreated (0) or treated with GnRH then harvested 1, 2 or 4 h
later. RNA was extracted, reverse transcribed and first strand cDNA analysed for
expression of mouse Fanca using primers corresponding to exons 7-17. Ethidium
bromide staining identified one PCR product amplified from mRNA harvested 1 h
after treatment with GnRH. Fanca was amplified from L-cell cDNA as a positive
control (+ve). The 979 bp Fanca PCR product is indicated with an arrow. Southern
blotting analysis of the agarose gel with a 5' Fanca probe corresponding to exons 1-
11 of mouse Fanca cDNA confirmed that the Fanca PCR product was specific and
present at all time points.
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3.2.7 Fanca mRNA levels increase 2-fold in response to GnRH
To accurately quantify the GnRH induced increase in Fanca mRNA, quantitative
RT-PCR was performed on RNA extracted from L|3T2 cells that had been left
untreated or treated with 1 pM GnRH then harvested 1, 2 or 4 h later. RNA was
reverse transcribed and first strand cDNA analysed using a LightCycler quantitative
RT-PCR machine (Roche) and primers corresponding to exons 37-38 of mouse
Fanca and exon 1 ofmouse (3-2-microglobulin (B2m) (See Table 2.1 and Figure 3.4).
Fanca mRNA expression levels were measured and normalized against levels of
B2m mRNA within the same sample. The results were then determined as the fold
increase in Fanca mRNA levels when compared to levels of Fanca mRNA in
untreated L(3T2 cells (See Figure 3.11). Analysis of the results revealed a significant
2-fold increase in Fanca mRNA levels 1 h after treatment with GnRH (ANOVA
one-way analysis of variance, p<0.05). Fanca mRNA expression had returned to un¬
stimulated levels 4 h after treatment with GnRH corroborating the results seen from
the semi-quantitative RT-PCR experiments.
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Figure 3.11 Quantitative RT-PCR analysis of Fanca mRNA levels after
treatment with GnRH.
LpT2 cells were left untreated (0 h) or treated with GnRH then harvested 1, 2 or 4 h
later. RNA was extracted, reverse transcribed and first strand cDNA analysed.
LightCycler quantitative RT-PCR analysis of Fanca mRNA levels detected a
consistent 2-fold increase in Fanca mRNA harvested 1 h after treatment with GnRH,
with expression returning to untreated levels after 4 h of treatment. Results are
shown as arbitrary units (AU) of Fanca mRNA normalized against levels of fi-2-
microglobulin (B2m). Each experiment was performed in duplicate and repeated
three times. Error bars indicate the standard error of the mean. Statistical analysis
was performed using ANOVA one-way analysis of variance (* p<0.05).
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3.2.8 Fanca protein levels increase 2-fold in response to GnRH
The rapid up-regulation of Fanca mRNA may not be mirrored by an increase in
Fanca protein, so western blotting analysis was used to quantify Fanca protein levels
in LPT2 cells in response to hormone. Whole cell protein extracts were made from
untreated LPT2 cells and from LPT2 cells harvested 2, 4 and 6 h after addition of 1
pM GnRH. Equal amounts of protein extract, as determined by Bradford assay,
were then fractionated on a 6% SDS-PAGE gel, blotted and incubated with rabbit
anti-mouse Fanca antisera specific for amino acids 1-276 [kind gift from Dr. Fre
Arwert (Waisfisz et al., 1999)]. A specific protein band at -160 kD, corresponding
to the expected size of Fanca protein, was detected in all samples (See Figure 3.12).
Blots were stripped, and then re-probed with a rabbit anti-mouse P-tubulin antibody
to check for even loading of protein on to the gel (See Figure 3.12). Quantification
of protein levels using ImageQuant software and normalization of Fanca protein
levels against P-tubulin protein levels revealed that a significant 2-fold increase in
Fanca protein levels occurred after addition of GnRH for 2 h (ANOVA one-way
analysis of variance, p<0.001). This 2-fold increase was still evident and highly
significant 4 h after treatment with GnRH (p<0.001), but by 6 h, Fanca protein levels
had begun to return to unstimulated levels. (See Figure 3.12) This shows that the
rapid increase in Fanca mRNA in response to GnRH is followed by a 2-4 h sustained
increase in Fanca protein levels (See Figure 3.13).
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Figure 3.12 Western blotting analysis of Fanca protein levels after
treatment with GnRH.
Western blotting analysis of whole cell L(3T2 protein extracts either left untreated (0)
or harvested 2, 4 or 6 h after treatment with GnRH. Protein was fractionated on an
SDS-PAGE gel, blotted and probed with a rabbit anti-mouse Fanca antibody before
being stripped and re-probed with a rabbit anti-mouse (3-tubulin antibody. Probing
with the Fanca antibody detected a protein band at the expected size of -160 kD.
Probing with a p-tubulin antibody gave a protein band at the expected size of -55
kD. Normalization of Fanca protein levels against p-tubulin levels showed that
Fanca protein increased 2-fold 2 h after treatment with GnRH with expression
beginning to return to unstimulated levels 6 h after treatment with GnRH. Results
shown are the mean of three separate experiments with error bars indicating the
standard error of the mean. ANOVA one-way analysis of variance determined that
the increase in Fanca protein levels following treatment with hormone was
significant when compared against Fanca protein levels in untreated cells: ***,
p<0.001; *, p<0.05.
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GnRH treatment (h)
Figure 3.13 Fanca mRNA and protein levels increase after treatment
with GnRH.
Fanca mRNA levels increase 2-fold 1 h after treatment with GnRH and have
returned to untreated levels 4 h after treatment. Fanca protein levels also increase
after treatment with GnRH, a 2-fold rise is evident 2-4 h after treatment with
hormone. Expression levels begin to return to unstimulated levels 6 h after
treatment with GnRH. Results are the mean of three separate experiments. Error
bars represent the standard error of the mean. ANOVA one-way analysis of
variance determined that the increases in Fanca mRNA and protein levels in
response to hormone were significant: ***, p<0.001, *, p<0.05.
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3.3 Discussion
3.3.1 Fanca mRNA is expressed in mature gonadotrophs
Previously, differential display (DD) RT-PCR identified that within L|3T2
gonadotroph cells, GnRH differentially regulates a transcript corresponding to exon
43 of Fanconi anaemia complementation group a {Fanca) (Chang, 2002). Since an
antisense transcript for penta-zinc finger protein 276 (Zfp276) was recently identified
at the same locus as Fanca (Wong et al., 2000), with 3' untranslated Zfp276
sequence actually overlapping with exons 40-43 of Fanca (See Figure 3.14), it was
conceivable that either Fanca or Zfp276 could be the GnRH regulated transcript
identified by differential display. Northern blotting analysis of total RNA from
L|3T2 cells, using probes designed to either 5' (exons 1-11) or 3' (exon 42-43) Fanca
cDNA sequence, confirmed expression of both full length Fanca (4.5 kb) and Zfp276
(3.1 kb) transcripts in gonadotroph cells (See Figure 3.3). However, detailed
bioinformatic analysis of the likely differential display primer binding sites within
Fanca and Zfp276 sequence revealed that the original 216 bp DD-RT-PCR clone
corresponded with the amplification of Fanca. The mRNA poly A+ sequence of
Zfp276, and therefore likely oligo(dT) anchored priming site, maps a considerable
distance downstream from the R5 internal priming site and a lack of any other
suitable priming site within 216 bp of the R5 arbitrary primer indicated that,
amplification of Zfp276, to produce the 216 bp differential display product, was
highly unlikely (See Figure 3.14).
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^"cctttttttttttt T12VC
Figure 3.14 Schematic representation of the Fanca locus showing the
location of the isolated differential display (DD) RT-PCR clone.
Exons 40-43 of Fanca (black boxes) overlap with the 3' untranslated region (UTR) of
Zfp276 (grey box). The location of the cloned 74 bp DD-RT-PCR clone is indicated
with an arrow. The regions of nucleotide identity between Fanca and Zfp276 mRNA
have been aligned beneath the schematic. Fanca mRNA sequence is shown in
bold type, spliced intronic sequence has been omitted and replaced with a dashed
line. Zfp276 mRNA sequence is in normal typeface. The amplified 74 bp DD-RT-
PCR clone has been boxed with a solid line. The original 216 bp DD-RT-PCR clone
is indicated as an extension of the boxed region with dashed lines. DD-RT-PCR
primers, R5 (arbitrary primers) and T12VC (oligo[dT] anchored primer) are also
shown on the corresponding Fanca sequence. No suitable priming sites for the
T12VC primer were identified by bioinformatic analysis of Zfp276 3'UTR sequence.
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Previously, expression analysis of Fanca using in situ hybridisation showed that the
transcript is specifically expressed between embryonic day (E) 8.5 and E16 within
the developing brain, liver and kidney as well as in the mesenchyme, primarily
within cells that will give rise to the soft tissues of the fore and hind-limbs (Abu-Issa
et al., 1999). Northern analysis revealed that a predominant 4.5 kb band,
corresponding to full length Fanca, is expressed from E7.0 and maintained
throughout embryogenesis (Abu-Issa et al., 1999). There are conflicting reports
detailing the detection ofFanca expression in adult mouse tissue by northern blotting
analysis. One report states that three Fanca transcripts of 4.5, 1.6 and 1.1 kb are
expressed in a wide range of adult mouse tissues (Wong et al., 2000), however,
another report was unable to detect Fanca expression in adult brain, heart, lung or
liver (van de Vrugt et al., 2000). This chapter reports that only full length Fanca
transcript (4.5 kb) is detected in total RNA harvested from LPT2 cells (Figure 3.3).
However, as Fanca mRNA is expressed at very low levels alternative transcripts
may be present and analysis of poly-A+ mRNA from LPT2 gonadotroph cells could
prove more informative. These findings extend the expression profile of Fanca
mRNA to include for the first time, LPT2 gonadotroph cells, a specialised endocrine
cell line.
To establish that Fanca was expressed within the pituitary in vivo, RT-PCR analysis
was performed on RNA extracted from adult mouse pituitary tissue. Gonadotroph
cells only comprise 10-15 % of the adult anterior pituitary, and are not concentrated
within a specific area therefore, analysis of the whole gland allows confirmation of in
vivo expression of Fanca within adult mouse pituitary, rather than determining
Fanca expression within specific cell types of the anterior pituitary. Several small
regions of Fanca cDNA were amplified by PCR and analysed on an agarose gel to
ensure that the 4.5 kb Fanca transcript was represented in full. DNA bands
corresponding to exons 7-18, 14-18 and 30-32 ofmurine Fanca cDNA were detected
by ethidium bromide staining and the specific amplification of Fanca confirmed by
sequencing of the cloned PCR products (See Figure 3.5). Fanca expression was also
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analysed in several mammalian cell lines, including a rat somatotroph cell line
(GH3), a mouse fibroblast-like cell-line (L-cells) and a human cervical cancer cell
line (HeLa cells). This assay failed to detect Fanca mRNA in aT3-l cells by RT-
PCR amplification of cDNA (See Figure 3.6 and 3.7). As discussed earlier, aT3-l
cells are an immature, GnRH-responsive gonadotroph cell line derived from El3.5
pituitaries that express aGsu and Gnrhr, but not Lhft or Fsh/3 subunits (Windle et al.,
1990). As Fanca is expressed in LPT2 gonadotroph cells and adult pituitary, a lack
of detectable Fanca mRNA expression within immature aT3-l cells indicates that
the gene may be important for gonadotroph development and/or mature gonadotroph
cell functions. Western blotting analysis of aT3-l protein extracts could be
performed to confirm the absence of Fanca expression within these immature cells.
Furthermore, whole mount in situ hybridisation analysing the expression of Fanca in
mouse pituitaries during various stages of development, and co-localisation of this
expression with anterior pituitary cell markers (eg. Lh/3, Fsh/3, and Gh) could help
identify which cell types within the anterior pituitary express Fanca as well as
providing insight into the onset ofFanca expression in gonadotroph cells in vivo.
3.3.2 An alternative Zfp276 transcript is expressed within L/3T2 cells
Differential display RT-PCR analysis identified that Fanca mRNA is up-regulated in
response to GnRH. The isolated differential display clone matched sequence from
both Fanca and Zfp276, two genes located, in opposite orientations, at the Fanca
locus. However, as discussed earlier, bioinformatic analysis of the cDNA sequence
surrounding the DD-RT-PCR clone revealed that Fanca, and not Zfp276, was the
transcript identified from the differential display gel (Figure 3.14). RT-PCR analysis
of RNA extracted from untreated and hormone treated L|3T2 cells confirmed that
Zfp276 mRNA was expressed at all time points and indicated its expression did not
appear to be regulated by GnRH (Figure 3.8). Interestingly, when the amplified PCR
products were cloned and sequenced, a previously unreported alternative Zfp276
transcript was identified in both L|3T2 and L-cells.
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Murine Zfp276 cDNA is 3123 bp long with a reported open reading frame of 1118
bp comprising 10 exons and encoding a predicted protein of 372 amino acids (Wong
et al., 2000). Bioinformatic analysis of the amino acid sequence predicts the
presence of five C2H2 zinc finger domains (See Figure 3.15), a nucleic acid binding
domain first identified in the Xenopus transcription factor TFIIIA (Miller et al.,
1985a). These domains are composed of 25-30 amino acid residues including two
cysteine and two histidine residues in a C-X2-C-Xi2-H-X3-FI type motif. One zinc
atom binds to the conserved cysteine and histidine residues to yield a finger-like
projection, which interacts with both RNA and DNA (el-Baradi and Pieler, 1991;
Ladomery and Dellaire, 2002). Using the Simple Modular Architecture Research
Tool (SMART, available at http://www.smart-embl-heidelberg.de), analysis also
predicted the presence of a possible plant homeodomain (PF1D) motif at amino acids
256 to 318 (See Figure 3.15). The function of this C4HC3 zinc finger like motif is
still not known, however PHD fingers are found in several proteins implicated in
chromatin mediated transcriptional regulation including members of the Drosophila
melanogastor Trithorax and Polycomb group genes, known to regulate transcription
of homeotic genes (Gould, 1997). Another characteristic shared by many PHD
finger containing proteins is that they function as part of multi-component
complexes, as in the case ofFANCL (Meetei et al., 2003), raising the possibility that,
like the closely related LIM domain, a zinc finger binding domain present in Lin-1,
Isl-1 and Mec-3 proteins (Schmeichel and Beckerle, 1998), PHD fingers are involved
in protein-protein interactions (Aasland et al., 1995).
The alternative Zfp276 transcript identified by PCR amplification of L|3T2 and L-cell
cDNA contains an insertion of 70 bp of genomic sequence 849 bp from the start
codon (See Figure 3.9i). This small insertion may explain why this alternative
transcript was not detected by northern blotting analysis (Wong et al., 2000).
Searches of expressed sequence tag (EST) databases using BLAST (available at
http://www.ncbi.nlm.nih.gov) revealed that expression of this alternative form of Zfp276
is seen within the developing pituitary and limb, as well as in the adult brain and
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liver. The addition of 70 bp of genomic sequence results in the introduction of an in-
frame premature STOP codon (TGA) and, presumably, the production of a 285
amino acid truncated protein product without the last two C2H2 zinc-finger domains
and a disrupted, putative, PHD domain (See Figure 3.15). Western blotting analysis
could be used to determine if this alternative Zfp276 transcript is translated and if
both Zfp276 proteins (expected sizes 41 and 32 kD) are expressed within the same
tissues. Alternatively, in vitro translation would identify if the clones encode full-
length and/or truncated proteins.
The genomic organisation of Fanca and Zfp276, and their co-expression within the
same tissues, suggests that the transcripts from these genes could potentially form
dsRNA. A recent paper suggested that around 8% of the estimated 40,000 human
genes have an antisense partner (Yelin et al., 2003). Although the effects of
antisense RNAs on the corresponding sense RNAs has not been clearly established,
there is evidence to show that they may exert control at various levels of gene
expression including transcription, splicing, stability, transport and translation (Knee
and Murphy, 1997; Hastings et ah, 2000; Li and Murphy, 2000). The recent
discovery that dsRNA can trigger post-transcriptional gene silencing through the
phenomenon of RNA interference (RNAi) lends further evidence to a role for
antisense transcripts in gene regulation (Elbashir et ah, 2001). However, detailed
experimental analysis would need to be performed to determine if this process was
occurring at the Fanca locus.
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Figure 3.15 Addition of 70 bp of genomic sequence disrupts the protein
domain structure of Zfp276.
(i) Schematic to show the domains present within Zfp276 full-length and truncated
proteins. Zfp276 contains five C2H2 zinc finger domains (yellow boxes). Zfp276
Truncated contains three C2H2 zinc finger domains. The last two domains are lost
due to the insert of a premature STOP codon (TAA). (ii) Alignment of amino acid
sequence of Zfp276 and Zfp276 Truncated. The 5 C2H2 zinc finger domains present
within Zfp276 sequence are highlighted yellow. The C4HC3 PHD domain is
indicated by a blue box. Insertion of 70 bp of genomic sequence introduces a
premature STOP codon at amino acid 285 removing the last 2 C2H2 zinc finger
domains and disrupting the PHD domain.
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3.3.3 Fanca mRNA is regulated by GnRH
GnRH up-regulation ofFanca mRNA was first identified by differential display RT-
PCR of LPT2 cells that had been treated with one 15 minute pulse of 1 p,M GnRH
and harvested for RNA after 1, 2 or 4 h (Chang, 2002). This relatively high
concentration of hormone, compared to physiological levels, was chosen because it
has been previously shown to stimulate high levels of gonadotropin sub-unit
transcription, with a similar response being seen with either 10, 100 or 1000 nM
GnRH [P.Brown, personal communication; (Bonfil et al., 2004)]. Southern blotting
analysis of RT-PCR products amplified from RNA extracted from untreated and
hormone treated LPT2 cells suggested that Fanca mRNA levels rose 1 h after
treatment with GnRH and returned to unstimulated levels 4 h after treatment (See
Figure 3.10). As RT-PCR analysis not quantitative, in order to measure the increase
in Fanca mRNA levels seen in response to GnRH, quantitative RT-PCR (Q-RT-
PCR) was performed on RNA extracted from untreated and GnRH treated LPT2
cells. Q-RT-PCR is an extremely sensitive technique, permitting analysis of gene
expression from very small amounts of RNA (Wang et al., 1989). To quantify the
changes in Fanca mRNA expression in response to GnRH, levels of Fanca mRNA
were compared against levels of /3-2-microglobulin (B2m) in LPT2 cells that were
either untreated, or had been harvested for RNA after 1, 2 or 4 h of GnRH treatment.
B2m was chosen as it is detectable in a broad range of tissues and is relatively stably
expressed (Bishop et al., 1974). Whilst B2m mRNA levels did not vary significantly
in response to hormone, Fanca mRNA levels increased 2-fold 1 h after treatment
with GnRH (See Figure 3.11). Two hours after hormone treatment Fanca mRNA
levels began to fall and had returned to unstimulated levels by 4 h (See Figure 3.11).
This rapid and transient increase suggests that levels of Fanca mRNA are tightly
controlled, indicating a role for GnRH in regulating Fanca gene transcription.
Bioinformatic analysis of the FANCA promoter revealed several putative consensus
binding sites for various transcription factors including trans-acting transcription
factor 1 (Spl), early growth response factor 1 (Egrl), adaptor protein complex 2
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(AP2) and nuclear factor 1 (NF1) (Ianzano et al., 1997). Both Spl and Egrl are
known to regulate LH/3 promoter activity in response to GnRH (Kaiser et al., 1998;
Tremblay and Drouin, 1999). Furthermore, Egrl transcription has been shown to be
up-regulated in response to GnRH (Duan et al., 2002) suggesting that this may be a
possible mechanism by which GnRH up-regulates Fanca expression. Functional
analysis of the Fanca promoter, using reporter gene assays, would help determine
whether GnRH and Egrl are involved in its regulation.
Alternatively, the increase in Fanca mRNA levels observed after addition of GnRH
may be due to an increase in the stability of Fanca mRNA. Interestingly, several
hormones, including GnRH, LH and FSH, have been shown to influence mRNA
stability of both pituitary and non-pituitary genes regulating their expression at
transcriptional, posttranscriptional and posttranslational levels (Staton et al., 2000).
The stability of gonadotropin subunit mRNA has also been shown to be regulated by
hormones, with aGSUmRNA stability increasing 6.7-fold in the presence of GnRH
(Chedrese et al., 1994). Similarly GnRH, in concert with progesterone and
oestrogen, stabilises LH/3 mRNA (Park et al., 1996) whilst testosterone has been
shown to regulate FSH(3 mRNA stability (Paul et al., 1990). Not surprisingly several
hormones influence the stability of their own receptor mRNA via a feedback
regulation mechanism. Research has shown that LH acts to destabilise its own
receptor mRNA (Lu et al., 1993) whilst, conversely, FSH stabilises its receptor
mRNA (Tilly et al., 1992). Transcriptional inhibitors could be used to determine if
the increase seen in Fanca mRNA after treatment with GnRH is due to an increase in
Fanca mRNA stability or an increase in transcription. Actinomycin D is widely used
to block DNA dependent RNA synthesis and calculate mRNA half-life (Ross, 1995).
Cells could be cultured with actinomycin D then harvested at various time points to
measure the rate at which Fanca mRNA disappears and if this rate changes in
response to GnRH. However, as Fanca mRNA is expressed at very low levels, and
relatively difficult to detect, experiments to measure its degradation to even lower
levels could prove difficult.
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3.3.4 Fanca protein is regulated by GnRH
In order to determine if the increase in Fanca mRNA levels was mirrored by an
increase in Fanca protein levels, western blotting analysis was performed on
untreated and GnRH treated L|3T2 cells. As Fanca mRNA levels were maximally
increased 1 h after treatment with GnRH, longer hormone treatments were given to
cells harvested for protein extracts to allow sufficient time for translation of Fanca
mRNA. Results showed that the rapid, transient increase in Fanca mRNA levels
measured in response to GnRH was followed by a similar, but sustained, increase in
Fanca protein levels. Measurements of Fanca protein expression at 2 and 4 h after
treatment with GnRH showed a highly significant 2-fold increase in expression when
compared to unstimulated levels. This increase was less significant 6 h after
treatment with hormone, with Fanca protein expression beginning to return to
unstimulated levels (See Figure 3.12). Activation of translation in response to
stimuli is a rapid and simple mechanism to increase protein levels within the cell. In
concert with the reported increase in aGSU mRNA stability in response to GnRH
(Chedrese et al., 1994), significant increases in protein synthetic capacity are seen in
aT3-l gonadotroph cells in response to hormone through a general increase in cap-
dependent translation (Sosnowski et ah, 2000). As the increase in Fanca protein
levels in response to GnRH is seen within 2 h of treatment, it seems unlikely that this
rapid and transient increase is due to a general augmentation of protein synthesis in
these cells in response to GnRH but rather due to the specific regulation of Fanca by
GnRH. This process could occur through various mechanisms including, an increase
in Fanca mRNA stability leading to an increase in Fanca protein levels; an increase
in transcription leading to more Fanca mRNA molecules available for translation or;
an increased rate of translation of Fanca protein.
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3.3.5 Possible role of Fanca in gonadotrophs
The rapid differential regulation of both Fanca mRNA and protein by GnRH in L(3T2
gonadotroph cells (Figure 3.13) indicates that Fanca may be a component of a rapid
response mechanism. This possibility is supported by two recent studies suggesting
a potential role for Fanca in signal transduction cascades. Yeast two-hybrid
screening identified that FANCA interacts with the signalling molecule IkB kinase-2
(IKK2) which is involved in cellular response to stress and activation of the
transcription factor NF-kB (Mercurio and Manning, 1999), whilst studies of
lymphoblast cells show that functional FANCA is required for phosphorylation of
INK and activation of the immediate early response gene EGR-1 (Pipaon et al.,
2004). As GnRH regulates gonadotropin subunit transcription via mitogen activated
protein kinase (MAPK) pathways (Naor et al., 2000; Liu et al., 2002), and Fanca
mRNA is expressed in L|3T2 but not aT3-l cells, regulation of its expression by
GnRH could point towards a role for Fanca in GnRH initiated MAPK signalling in
mature gonadotroph cells. However, much more detailed analysis ofGnRH initiated
signalling pathways would need to be performed to confirm this theory.
3.3.6 Fanca, GnRH and cancer
It is now well established that GnRH and its receptor are expressed, not only in the
hypothalamus and pituitary, but also in, both normal and tumorigenic, reproductive
tissues (Limonta et al., 2003). In these tumours, activation of GnRH receptors has
been shown to down regulate cell proliferation suggesting that GnRH may act as an
autocrine negative regulator of tumour growth (Miller et al., 1985b; Limonta et al.,
1992; Dondi et al., 1994). The discovery that GnRH up-regulates expression of
Fanca, a DNA damage repair gene, is exciting as it lends credibility to a link
between GnRH, Fanca and cancer. Especially given the fact that FA family
members have been implicated in ovarian tumorigenesis (Houghtaling et al., 2003;
Taniguchi et al., 2003) and the prevalence of endocrinopathies in FA patients (Alter,
2003). Taken together with reports that FA patients have progressive bone marrow
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failure due to the loss of haematopoietic stem cells (Alter, 1998); and that GnRH has
been shown to suppress haematopoietic stem cell maturation in female mice (Rao et
al., 1995); a role for Fanca, and other FA family members, in endocrine signalling
seems likely and requires further investigation.
3.3.7 Conclusions
This chapter has fully characterised the regulation of Fanca expression in L|3T2
gonadotroph cells. Quantitative RT-PCR and western blotting analysis have
demonstrated that addition ofGnRH results in a rapid and transient increase in both
Fanca mRNA and protein expression. RT-PCR analysis revealed that whilst Fanca
mRNA expression is observed in L|3T2 cells and adult mouse pituitary, no
expression is observed in aT3-l cells, an immature gonadotroph cell line, suggesting
a role for Fanca in gonadotroph development and maturation, possibly in the
regulation of gonadotropin gene expression. Lastly, analysis of the expression of
Zfp276, the antisense transcript located at the same locus as Fanca, revealed for the
first time that whilst this gene does not appear to be regulated by GnRH, an
alternatively spliced transcript is expressed within L|3T2 and L-cells however, further
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The important thing in science is not so much to obtain new facts as to discover new
ways of thinking about them - Sir William Bragg.
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4 Localization of Fanca protein in LpT2 cells
4.1 Introduction
4.1.1 Background
Eukaryotic cells differ from prokaryotic cells by the presence of intracellular,
membrane bound compartments such as the nucleus. Specific mechanisms have
evolved to transport proteins translated in the cytoplasm into the nucleus, where
genetic information is regulated. This is of particular importance for signal
transduction pathways where an extra-cellular signal must be transduced across the
plasma membrane and nuclear envelope in order to propagate the signal from the
cytosol to the nucleus. Functional molecules communicate continuously between the
nucleus and the cytoplasm by transport through the nuclear pore complex (NPC)
(Feldherr et al., 1984). Disruption of the nuclear localization of proteins can have
serious cellular consequences, such as the initiation and progression of cancer as
reported for transformation related protein 53 (p53), adenomatosis polyposis coli
(APC) and breast cancer susceptibility 1 (BRCA1) tumour suppressor proteins (Moll
et al., 1992; Chen et al., 1995; Zhang et al., 2000).
Small molecules (<50 kD) can diffuse freely in and out of the nucleus through
nuclear pores, whereas larger proteins must be actively transported. This process is
mediated by specific amino acid sequences, present within the protein to be
transported, and referred to as nuclear localization signals (NLS's) and nuclear
export signals (NES's). The classical NLS is comprised of a few basic amino acid
residues, usually lysines (K) or arginines (R). These occur either in the form of a
monopartite NLS with the consensus sequence (K/R)4-6 or as two smaller clusters
separated by approximately a dozen amino acids residues (K/R)2-Xio-i2-(K/R)3
(Dingwall and Laskey, 1991). These NLS sequences are recognised by an NLS
receptor comprised of importin a and p, located at the nuclear pore, which regulates
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the translocation of cytoplasmic NLS containing proteins into the nucleus (Komeili
and O'Shea, 2000). Conversely, NES's are rich in hydrophobic amino acids such as
leucines (L) or isoleucines (I). The NES consensus sequence, LX1.3LX2-4LXL, is
recognised and bound by the export receptor protein CRM1, the human homolog of
yeast chromosome region maintenance protein 1, to direct movement of the NES
containing protein to the cytoplasm (Fornerod et al., 1997; Fukuda et al., 1997;
Flenderson and Eleftheriou, 2000).
FANCA is a relatively large protein (~ 160 kD) that contains a bipartite NLS
sequence at amino acids 19-34 (RK-X10-KKQK). Research has shown that the NLS
sequence found within FANCA is required, not only for the nuclear localization of
FANCA protein (Naf et al., 1998), but also for the direct interaction of FANCA with
FANCG (Kruyt et al., 1999; Garcia-Higuera et al., 2000). Interestingly, the C-
terminus of FANCA is also required for localization to the nucleus (Lightfoot et al.,
1999) and may be required for binding of the NLS motif to importin a/|3. Correct
localization of FANCA is crucial for nuclear accumulation of the FA complex,
comprised of FANCA, FANCC, FANCG, FANCE and FANCF (Joenje and Patel,
2001). Along with the recently identified FANCL protein, this nuclear complex is
thought to be required for mono-ubiquitination of FANCD2 which targets the
FANCD2 molecule to DNA repair foci containing the DNA damage repair proteins
BRCA1 and FANCD1/BRCA2 (See Figure 1.14). This complex appears to be
constitutively present and no signals have been identified that lead directly to its
assembly, however, bi-allelic mutations in FANCA block complex formation. To
date more than 100 different mutations, spread along the length of the FANCA gene,
have been reported (Lo Ten Foe et al., 1996; Levran et al., 1997; Morgan et al.,
1999; Wijker et al., 1999). Most of these involve small insertions or deletions,
presumably resulting in null mutations, but >30 mutations are predicted to produce
altered proteins with a single amino acid substitution or a small in-frame deletion. A
sub-set of these have been studied in vitro with particular reference to their cellular
localization and ability to reconstitute the FA pathway (Adachi et al., 2002). It is
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thought that the variability in phenotypes seen in FA patients is due to variable
activation of the FA pathway by these mutations, indicating that nuclear-cytoplasmic
transport is a critical component of the FA pathway, however, the transport
mechanisms and signals that regulate this process have not been characterized.
4.1.2 Aims of this chapter
Chapter three established that the expression of Fanca is rapidly and transiently up-
regulated in LpT2 cells in response to GnRFf. This chapter analyses the expression
of Fanca protein within gonadotroph cells and, in a bid to identify a mode of Fanca
action in these cells, asks whether addition of GnRFl promotes a redistribution of
Fanca protein within L|3T2 cells and what specific mechanisms may be involved in
this 'shuttling' process. Lastly, the cellular distribution ofmutant FANCA proteins
within LPT2 cells is also investigated to determine whether the introduction of
specific point mutations into the Fanca protein can alter the localization pattern of
Fanca protein within gonadotroph cells.
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4.2 Results
4.2.1 Sub-cellular localization of Fanca protein in L(3T2 cells
The localization of endogenous Fanca protein within L(3T2 cells was investigated by
indirect immunofluorescence using rabbit anti-mouse Fanca antisera. L|3T2 cells,
grown on 2-well glass chamber slides, were either left untreated, or treated with 1
pM GnRH for 2 h before being incubated overnight with rabbit-anti-mouse Fanca
antisera specific for amino acids 1-276 [kind gift from Dr. Fre Arwert (Waisfisz et
al., 1999)]. The following day, Fanca protein was visualized by incubating with a
goat anti-rabbit secondary antibody conjugated to biotin followed by a fluorescent
probe conjugated to streptavidin (See Section 2.7.10). Nuclei were then
counterstained with a fluorescent dye (Topro-3) and slides mounted to allow
detection of fluorescence signal by confocal microscopy. Fluorescence,
corresponding to Fanca protein expression, was detected in both the cytoplasm and
nucleus of L(3T2 cells where it co-localized with Topro-3 staining (See Figure 4.1 a,
b and c). Analysis of fluorescence levels measured by Z-stack sectioning through the
middle of a L|3T2 cell showed that Fanca protein expression was relatively evenly
distributed through the cell (See Figure 4.1g). Addition of GnRH had no dramatic
detectable effect on Fanca protein localization within L|3T2 cell, but, visual
examination of Fanca expression in these cells suggested that addition of GnRH
increased expression of Fanca, particularly within the cytoplasm (See Figure 4.1 d, e
and f). However, Z-stack analysis of the fluorescence levels from a single L(3T2 cell
revealed that Fanca expression is still detectable in both cellular compartments, as in
the case of untreated L|3T2 cells (See Figure 4.1h).
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Figure 4.1 Detection of sub-cellular localization of Fanca protein in
LpT2 cells using indirect immunofluorescence.
Localization of Fanca protein within L(3T2 cells was determined using rabbit anti-
mouse Fanca antisera and indirect immunofluorescence. Fanca protein is localized
to the cytoplasm and nucleus of LJ3T2 cells (a). Addition of GnRH does not alter
Fanca localization (d). Cell nuclei were identified by staining with Topro-3, a DNA-
specific dye (b, e). Fanca protein expression (green) is seen within the cytoplasm
and co-localizes with Topro-3 staining (blue) within L|3T2 cell nuclei (c, f). Levels of
fluorescent signal determined by Z-stack sectioning through a single, untreated
LPT2 cell (c, red line) and a GnRH treated cell (f, red line) are represented
graphically (g [untreated] and h [GnRH treated]). Negative control, no primary
antibody (i).
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4.2.2 Western blotting analysis of Fanca sub-cellular localization in L/3T2
cells
Having demonstrated that Fanca protein is expressed in both sub-cellular
compartments of LPT2 cells, the effects of GnRH on Fanca protein expression
within these compartments was investigate using western blotting analysis.
Cytoplasmic and nuclear extracts were prepared from untreated LPT2 cells and from
LPT2 cells harvested 2 h after addition of GnRH (See Section 2.7.2.2). Equal
amounts of protein extracts, as determined by Bradford assay, were fractionated on a
6% SDS-PAGE gel, blotted and incubated with rabbit anti-mouse Fanca antisera. A
specific protein band was detected at -160 kD, corresponding to the expected size of
Fanca, in extracts from both cytoplasmic and nuclear compartments (See Figure
4.2i). The veracity of the protein extracts was confirmed by stripping the blots and
re-probing with either a rabbit anti-mouse p-tubulin antibody, to confirm
cytoplasmic extracts, or a rabbit anti-mouse Sp-1 antibody, to confirm nuclear
extracts. Quantification of protein levels using ImageQuant software revealed that a
significant 2-fold increase in Fanca protein levels occurred in both the cytoplasmic
and nuclear compartments of LPT2 cells after addition of 1 pM GnRH for 2 h
(ANOVA one-way analysis of variance, p<0.001). See Figure 4.2ii.
4.2.3 Nuclear-cytoplasmic shuttling of Fanca protein in Lf3T2 cells
The observed GnRH induced increase in Fanca protein within LPT2 gonadotroph
cells could be due to de novo translation with no re-distribution of Fanca protein
within the cell. Alternatively, the increase in response to GnRH could be explained
by an increase in Fanca protein levels and a further re-distribution of protein between
cellular compartments. To investigate these possibilities LPT2 cells were treated
with inhibitors of translation, nuclear import and export and western blotting analysis
performed on nuclear and cytoplasmic protein extracts. Cells were treated for 30
minutes with cycloheximide (CHX), to block translation; actinomycin D (AMD), to
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block nuclear import; or leptomycin B (LMB), to block nuclear export, followed by
addition of 1 qM GnRH for 2 h. Protein extracts were then prepared from both
cytoplasmic and nuclear compartments as described in section 2.7.2.2. Equal
amounts of protein extract, as determined by Bradford assay, were then fractionated
on a 6% SDS-PAGE gel, blotted and incubated with rabbit anti-mouse Fanca
antisera. A specific protein band at -160 kD, corresponding to the expected size of
Fanca, was detected in all samples and quantification of Fanca protein levels was
performed using ImageQuant software. An approximate 2-fold increase in Fanca
protein levels was observed in both cellular compartments after addition of GnRH
for 2 h (ANOVA one-way analysis of variance, p<0.001, see Figures 4.3 and 4.4).
Treatment of cells with CHX prior to addition ofGnRH blocked the 2-fold hormone
induced increase in Fanca protein levels in both compartments (Figures 4.3 and 4.4).
A significant decrease in Fanca protein levels was observed in L(3T2 cytoplasmic
extracts made from L|3T2 cells after treatment with CHX in conjunction with either
AMD or LMB, prior to addition of GnRH, when compared to cytoplasmic Fanca
levels seen after addition of hormone alone (ANOVA one-way analysis of variance,
p<0.01, see Figure 4.3). The usual 2-fold increase in Fanca protein levels after
treatment with GnRH was not detectable in nuclear extracts from cells incubated
with CHX and AMD prior to treatment with GnRH. In contrast, Fanca protein levels
in nuclear extracts made from L|3T2 cells incubated with CHX and LMB prior to
GnRH were increased 1.5-fold when compared to Fanca protein levels in untreated
cells (ANOVA one-way analysis of variance, p<0.01, see Figure 4.4), and were not
significantly different from nuclear Fanca protein levels measured in L|3T2 cells
treated with GnRH alone. These experiments demonstrate that the GnRH induced
increase in Fanca protein is due to de novo translation, and importantly they also
indicate that Fanca protein is actively transported from the nucleus of L|3T2
gonadotroph cells via a CRM1 dependent mechanism.
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Figure 4.2 Detection of sub-cellular localization of Fanca protein in
L^T2 cells using western blotting analysis.
(i) Western blotting of cytoplasmic and nuclear protein extracts from LPT2 cells
either left untreated (-GnRH) or harvested 2 h after treatment with GnRH (+GnRH).
Protein was fractionated on an SDS-PAGE gel, blotted and probed with rabbit anti-
mouse Fanca antisera. A protein band, corresponding to Fanca, was detected at
the expected size of -160 kD in both cytoplasmic (Cyt) and nuclear (Nuc)
compartments. Cytoplasmic extracts were confirmed by stripping the blot and re-
probing with a p-tubulin antibody. Nuclear extracts were confirmed by stripping the
blot and re-probing with an Sp-1 antibody, (ii) Addition of GnRH resulted in a 2-fold
increase in Fanca protein levels in both compartments. Results shown are the
mean of three separate experiments with error bars indicating the standard error of
the mean. ANOVA one-way analysis of variance determined that the increase in
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Figure 4.3 Western blotting analysis of cytoplasmic Fanca protein
levels after treatment with inhibitors and GnRH.
Western blotting analysis of LpT2 cytoplasmic extracts either left untreated (no
GnRH) or harvested after incubation with cycloheximide (CHX), actinomycin D
(AMB) or leptomycin B (LMB) prior to treatment with GnRH. Protein was
fractionated on a 6% SDS-PAGE gel, blotted and probed with a rabbit anti-mouse
Fanca antibody. This detected a protein band at the expected size of -160 kD as
shown on a representative blot. ImageQuant analysis of protein levels showed, as
expected, that Fanca protein levels increased 2-fold 2 h after treatment with GnRH
(ANOVA one-way analysis of variance ***, p<0.001). Addition of CHX, CHX and
AMD or CHX and LMB prior to hormone treatment resulted in no GnRH induced
increase in Fanca protein levels within the cytoplasm. Results shown are the mean
of three separate experiments with error bars indicating the standard error of the
mean. ANOVA one-way analysis of variance determined that addition of inhibitors
prior to GnRH significantly repressed the expected 2-fold increase in Fanca protein
levels: ***, p<0.001; **, p<0.01).
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Fanca 160 kD
Figure 4.4 Western blotting analysis of nuclear Fanca protein levels
after treatment with inhibitors and GnRH.
Western blotting analysis of L|3T2 nuclear extracts either left untreated (no GnRH) or
harvested after incubation with cycloheximide (CHX), actinomycin D (AMB) or
leptomycin B (LMB) prior to treatment with GnRH. Protein was fractionated on a 6%
SDS-PAGE gel, blotted and probed with a rabbit anti-mouse Fanca antibody. This
detected a protein band at the expected size of -160 kD as shown on a
representative blot. ImageQuant analysis of protein levels showed, as expected,
that Fanca protein levels increased 2-fold 2 h after treatment with GnRH (ANOVA
one-way analysis of variance ***, p<0.001). Addition of CHX or CHX and AMD prior
to hormone treatment resulted in no GnRH induced increase in Fanca protein levels
within the nucleus, however Fanca protein levels in nuclear extracts from cells
incubated with CHX and LMB prior to hormone treatment increased 1.5-fold when
compared against untreated levels (ANOVA one-way analysis of variance **,
p<0.01). Results shown are the mean of three separate experiments with error bars
indicating the standard error of the mean. ANOVA one-way analysis of variance
determined that addition of inhibitors prior to GnRH significantly repressed the
expected 2-fold increase in Fanca protein levels: ***, p<0.001; **, p<0.01.
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4.2.4 Generation of GFP-tagged mutant FANCA clones
Having determined that Fanca protein is expressed in both the cytoplasm and nucleus
of LPT2 cells, the localization of point-mutated forms of FANCA was analysed to
determine if a single base change could disrupt the distribution of FANCA protein
within LPT2 cells. Site-directed mutagenesis was used to engineer two specific
mutations, H1110P and Q1128E (Adachi et ah, 2002), into a GFP tagged human
FANCA clone (kind gift from Manuel Buchwald) as described in Section 2.3.11.
Sequencing analysis verified the production of FANCA clones with a single specific
mutated base (See Figure 4.5).
i)
H1110^ Q1128E
NLS 3H2 SH3 SH3 SH2 Leucine
ziDDer
1 18 34 496 597 1069 1090 1500 Amino acids
ii)
H1110P Q1128E
Figure 4.5 Confirmation of site-directed mutagenesis of GFP-FANCA.
Two separate mutations were engineered into GFP-FANCA by site-directed
mutagenesis, (i) Position of introduced mutations relative to other FANCA protein
features, (ii) Sequencing was performed along the entire length of each clone to
ensure that only the specific mutation (H1110P or Q1128E) had been introduced.
Electropherograms show the region of GFP-FANCA containing the two introduced
mutations and indicate the base-pair change.
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4.2.5 Western blotting analysis of GFP-tagged mutant FANCA constructs in
L/3T2 cells
Since altering the amino acid sequence of a protein can often result in mis-folding
and consequently direct the recombinant protein into a lysosomal degradation
pathway within the cell, it was important to verify that the engineered wildtype and
mutated proteins were expressed in L|3T2 cells as fusion proteins and at similar
levels. L|3T2 cells were transiently transfected for 48 h with pEGFP-FANCA-
wildtype, pEGFP-FANCA-Hl 110P or pEGFP-FANCA-Ql 128E plasmid and whole
cell protein extracts made. Equal amounts of protein extract, as determined by
Bradford assay, were fractionated on a 6% SDS-PAGE gel, blotted and incubated
with a goat anti-GFP antibody. A specific protein band at -187 kD, corresponding to
the expected size of GFP tagged full length FANCA, was detected in extracts from
cells transfected with GFP plasmids (See Figure 4.6). No band was detected in mock
transfected cells (Fugene only). Blots were stripped, and then re-probed with a
rabbit anti-mouse (1-tubulin antibody as a control (See Figure 4.6).
4.2.6 Expression analysis of GFP-tagged mutant FANCA constructs
Having determined that the GFP-FANCA fusion proteins were intact and expressed
in equivalent amounts, confocal microscopy was used to study the location of GFP-
tagged wildtype and mutant FANCA proteins in L|3T2 and HeLa cells. Cells, grown
on 2-well glass chamber slides, were transiently transfected with either GFP-tagged
wildtype FANCA or GFP-tagged mutant FANCA (H1110P or Q1128E) plasmid.
After 48 h, cells were fixed, counterstained with a DNA-specific dye and confocal
microscopy performed to visualize fluorescence levels. Analysis determined that
GFP-tagged FANCA-wildtype was expressed in both the cytoplasm and nucleus of
HeLa and L|3T2 cells (Figures 4.7 and 4.8, panels b and j). Further examination of z-
stack scans taken through the middle of a representative cell revealed a
predominantly nuclear expression pattern of FANCA in both cell types (Figures 4.7
and 4.8, panels j and n). Replacement of a histidine residue at position 1110 with a
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proline (H1110P) resulted in complete restriction of FANCA expression to the
cytoplasm of both HeLa and LPT2 cells (Figures 4.7 and 4.8, panels c and k).
Replacement of a glutamine residue at position 1128 with a glutamic acid residue
(Q1128E) did not alter FANCA expression within HeLa cells (Figure 4.7, panels d
and 1). Close examination of the z-stack profile of a representative GFP-FANCA-
Q1128E transfected HeLa cell (Figure 4.7p) clearly showed a predominantly nuclear
staining pattern indistinguishable from GFP-FANCA-wildtype expression (Figure
4.7n) but different from the cytoplasmic and nuclear expression pattern seen with
GFP alone (Figure 4.7m). In contrast, analysis of z-stack scans through an LPT2 cell
transfected with GFP-FANCA-Q1128E revealed that FANCA protein was highly
expressed within both the cytoplasm and nucleus (Figure 4.81) resembling the
expression pattern observed when LPT2 cells were transfected with un-coupled GFP
(Figure 4.8m) rather than the expression pattern seen for GFP-FANCA-wildtype
(Figure 4.8n).
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Figure 4.6 Expression analysis of GFP FANCA constructs in LfJT2 cells
Western blotting analysis of whole cell protein extracts from LPT2 cells transiently
transfected with GFP-FANCA-WT, GFP-FANCA-H1110P or GFP-FANCA-Q1128E
plasmid. Protein was fractionated on a 6% SDS-PAGE gel, blotted and probed with
a goat anti-GFP antibody before being stripped and re-probed with a rabbit anti-
mouse p-tubulin antibody. Probing with a GFP antibody detected a protein band at
the expected size of -187 kD in extracts from cells transfected with GFP plasmid.
No band was detected in cells transfected with Fugene alone. Probing with a p-
tubulin antibody detected a protein band at the expected size of -55 kD in all
samples.
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Figure 4.7 Expression analysis of GFP-tagged wildtype and mutant
FANCA protein in HeLa cells.
Wildtype and mutant GFP-tagged FANCA clones were transfected into HeLa cells
and localization of fluorescence analysed by confocal microscopy. Cell nuclei were
identified by staining with Topro-3, a DNA specific dye (e-h). GFP (a,m) and GFP-
FANCA (b,j) are expressed in both the cytoplasm and nucleus of HeLa cells with
GFP-FANCA expression being predominantly nuclear (b,j). GFP-FANCA-H1110P
expression is restricted to the cytoplasm of HeLa cells (c,k). Mutating position 1128
of FANCA (GFP-FANCA-Q1128E) localized protein expression to the nucleus (d,l).
Levels of fluorescent signal determined by Z-stack sectioning through the middle of
a single cell (red line) are represented graphically for each GFP clone (m-p). Co-
localization of GFP expression (green) with nuclear Topro-3 stain (blue) is seen for
GFP-FANCA (j,n) and GFP-FANCA-Q1128E (d,p) but not GFP-FANCA-H1110P
(c,o).
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Figure 4.8 Expression analysis of GFP-tagged wildtype and mutant
FANCA protein in L0T2 cells.
Wildtype and mutant GFP-tagged FANCA clones were transfected into L|3T2 cells
and localization of fluorescence analysed by confocal microscopy. Cell nuclei were
identified by staining with Topro-3, a DNA specific dye (e-h). GFP (a,i) and GFP-
FANCA (b,j) are expressed in both the cytoplasm and nucleus of l_pT2 cells with
GFP-FANCA expression appearing to be predominantly nuclear (b,j). Mutant GFP-
FANCA-H1110P expression is restricted to the cytoplasm of L|3T2 cells (c,k).
Mutating position 1128 of FANCA (GFP-FANCA-Q1128E) localized protein
expression to the nucleus (d,l). Levels of fluorescent signal determined by Z-stack
sectioning through the middle of a single cell (red line) are represented graphically
for each GFP clone. Co-localization of GFP expression (green) with nuclear Topro-
3 stain (blue) is seen for GFP-FANCA (j,n) and GFP-FANCA-Q1128E (l,p) but not
GFP-FANCA-H1110P (k,o).
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4.3 Discussion
4.3.1 Fanca protein is expressed in both the cytoplasm and nucleus of L/3T2
cells
There has been much controversy regarding the cellular localization of FANCA
protein. Initial reports using a C-terminus GFP tagged FANCA protein stated that
FANCA localized to the cytoplasm of HEK293 cells (Kruyt et al., 1997). Further
reports analysing the expression of endogenous FANCA protein in HeLa cells, using
an antibody to FANCA, demonstrated that the protein is located in both cellular
compartments (Kruyt and Youssoufian, 1998). However, more recent analysis of
FANCA protein expression in Cos-7, HeLa and NIH-3T3 cells, using an N-terminus
GFP tagged FANCA construct, has concluded that FANCA protein is located in both
cellular compartments, but is predominantly expressed within the nucleus (Kupfer et
al., 1999; Lightfoot et al., 1999; Adachi et al., 2002). With these conflicting reports,
and the discovery that Fanca is expressed within gonadotroph cells, it was important
to establish where Fanca protein localizes to in LPT2 cells. Using an antibody to the
N-terminus of Fanca and indirect immunofluorescence, expression of endogenous
Fanca protein within untreated and GnRH treated gonadotroph cells was localized to
both cellular compartments (Figure 4.1), agreeing with reports detailing endogenous
FANCA expression in HeLa cells (Kruyt and Youssoufian, 1998). Western blotting
analysis of cytoplasmic and nuclear extracts prepared from untreated and GnRH
treated cells confirmed that expression of Fanca protein was observed in both the
cytoplasm and nucleus of LPT2 cells and revealed that addition of GnRH generated a
significant 2-fold increase in Fanca protein levels within both cellular compartments
(Figure 4.2).
Interestingly, analysis of the expression pattern of GFP-tagged FANCA protein
revealed that whilst expression of FANCA is observed within both cellular
compartments, GFP-tagged FANCA appears to be localized predominantly to the
148
Chapter 4 Localization of Fanca protein in LBT2 ceils
nucleus of both HeLa and L(3T2 cells (Figure 4.8n). This data agrees with several
other reports detailing the expression of GFP-tagged FANCA protein within other
cell types (Kupfer et al., 1999; Lightfoot et al., 1999; Adachi et al., 2002) but
contrasts with the expression pattern of endogenous Fanca protein within
gonadotroph cells (Figure 4.1). This difference may be due to the fact that one
method is detecting endogenous protein where as the other is looking at FANCA
protein translated from DNA that has been transfected into the cell. As FA proteins
are thought to be involved in homologous DNA repair (Thompson et al., 2005), it is
conceivable that the process of transfection may trigger DNA damage repair
pathways, leading to the nuclear accumulation of FANCA protein. Analysis of
endogenous Fanca expression in gonadotroph cells that have been transfected with a
LacZ reporter construct would help to determine whether transfecting the cells
affects the localization of Fanca protein.
4.3.2 Fanca protein shuttles between the nucleus and cytoplasm of L/3T2
cells
Proteins synthesised within the cytoplasm that contain an NLS, such as FANCA, are
transported across the nuclear envelope, via pores, to perform their required function
within the nucleus. To analyse the rapid and transient increase in Fanca protein
levels in response to GnRH (See Chapter 3) and the movement of Fanca protein
across the nuclear membrane in L|3T2 gonadotroph cells, inhibitors of protein
translation, nuclear import and nuclear export were added to L|3T2 cells in culture
and the location of Fanca protein analysed. Three inhibitors were used:
cycloheximide, actinomycin D and leptomycin B.
Cycloheximide (CHX) is an antifungal antibiotic that inhibits protein synthesis in
eukaryotes (Obrig et al., 1971). Treating L|3T2 cells with CFIX prior to addition of
GnRH blocked the 2-fold increase in Fanca protein levels usually seen after addition
of hormone, in both cytoplasmic (See Figure 4.3) and nuclear (See Figure 4.4)
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compartments. This indicates that the rapid increase in Fanca protein levels seen
after addition of GnRH is a result of de novo translation.
The addition of Actinomycin D (AMD), which is an antibiotic that inhibits DNA
dependent RNA synthesis and nuclear import (Pinol-Roma and Dreyfuss, 1992;
Kalland et al., 1994) in conjunction with CHX ensured that any observed changes in
protein levels within either cellular compartment would be due to the re-distribution
of Fanca protein rather than an increase in transcription or translation. Fanca protein
levels in both cellular compartments of LPT2 cells treated with CHX and AMD prior
to GnRH were not significantly different from levels of Fanca protein in untreated
cells but were significantly different from Fanca protein levels in cells treated with
GnRH alone (ANOVA one-way analysis of variance, p<0.01, see Figures 4.3 and
4.4). Thus, addition of AMD did not block the nuclear import of Fanca protein in
LPT2 cells or an increase in cytoplasmic levels of Fanca protein would have been
observed as reported for SRY-box containing gene 9 (Sox9), HIV Type 1 Rev
protein and heterogeneous nuclear ribonucleoprotein (hnRNP Al) (Pinol-Roma and
Dreyfuss, 1992; Kalland et al., 1994; Gasca et al., 2002). However, mutation of the
NLS sequence within FANCA does block nuclear entry (Naf et al., 1998) suggesting
that the protein is actively imported. Interestingly, C-terminus amino acids have also
been shown to be required for FANCA nuclear localization, as mutation of amino
acids at the C-terminus prevents normal nuclear localization, even in the presence of
an intact NLS (Lightfoot et al., 1999). Perhaps specific inhibition of the NLS
receptor proteins, importin a and P, rather than using a broad spectrum inhibitor such
as AMD, would prove informative in determining whether Fanca protein is actively
transported into the nucleus of LPT2 cells.
In contrast to AMD, Leptomycin B (LMB) is an antibiotic that inhibits export of
certain proteins from the nucleus by disrupting the function of a specific nuclear
export pathway controlled by CRM1, a nuclear protein that binds to specific leucine
rich nuclear export signal (NES) motifs. Proteins that bind to CRM1 are then
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actively exported into the cytoplasm via nuclear pores. LMB disrupts nuclear export
of proteins by binding CRM1 and thus inhibiting its interaction with NES containing
proteins (Kudo et al., 1997). As before, CHX was added in parallel with LMB to
ensure that any observed changes in protein levels within cytoplasmic or nuclear
extracts were due to the re-distribution of Fanca protein rather than the presence of
newly translated protein. Levels of cytoplasmic Fanca protein in L|3T2 cells
incubated with CFIX and LMB prior to treatment with GnRH were significantly
decreased when compared to cells treated with GnRFI only (p<0.001, see Figure 4.3).
They were also significantly decreased when compared with cytoplasmic Fanca
protein levels in untreated cells (p<0.05, see Figure 4.3), indicating that the
cytoplasmic pool of Fanca protein had been depleted. Examination of nuclear Fanca
protein levels after pre-treatment with CHX and LMB and after addition of GnRH
revealed a 1.5-fold increase in Fanca protein levels. This increase in nuclear Fanca
protein was not significantly different from the 2-fold increase usually seen in
nuclear Fanca levels in response to GnRH (See Figure 4.4), but was significantly
different from levels of nuclear Fanca protein measured in untreated cells (p<0.01,
see Figure 4.4). Taken together, these results indicate that Fanca protein is exported
from the nucleus of L|3T2 cells via a specific, CRM1 dependent mechanism since
blocking CRM1 mediated nuclear export results in a depletion of cytoplasmic, and
an accumulation of nuclear, Fanca protein.
CRM1 dependent protein export from the nucleus requires a leucine/isoleucine rich
NES with the consensus sequence (L/I)-Xi_3-(L/I)-X2-4-(L/I)-X-(L/I). Analysis of
mouse Fanca protein sequence reveals the presence of a CRM1 dependent NES motif
at amino acids 1113-1125 (LSRLQEIALDL) that is also relatively well conserved in
the human protein (1018ISRLQEMVADLEL1030). Interestingly, a recent report
investigated export of FANCA protein from the nucleus of fibroblast cells and
hypothesised that this particular sequence was involved (Ferrer, 2003). However,
mutational analysis of the putative NES sequence would need to be performed to
prove that this motif is required for the export of FANCA protein. Bioinformatic
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analysis reveals that the putative NES sequence is located at exons 31 and 32 of
human FANCA and whilst there are no reports of patients with specific point
mutations within this 46 bp region, deletions that include exon 31 have been detected
in -19% of patients assigned to complementation group A (Morgan et al., 1999).
With the discovery that both Fanca mRNA and protein levels are differentially
regulated in response to GnRH (Chang, 2002; Larder et al., 2004), it is conceivable
that GnRH may also be involved in the transport of FANCA protein between the
cytoplasm and nucleus of L[3T2 cells. Whilst the experiments described in this
chapter have shown that Fanca is actively transported from the nucleus of L|3T2 cells
they have not established whether GnRH is playing an active role in this process.
However, this issue could be addressed if further western blotting analysis was
performed on cytoplasmic and nuclear protein extracts from L|3T2 cells treated with
LMB and a GnRH antagonist.
4.3.3 Specific mutations affect FANCA sub-cellular localization
FANCA point mutations are classified into three groups, group I mutants behave like
wild-type FANCA, group II mutants are mildly impaired in their ability to localize to
the nucleus whilst the ability of group III mutants to localize to the nucleus and
interact with other FANC proteins is severely compromised. Two mutations were
chosen from these groups (HI HOP and Q1128E) and generated by site-directed
mutagenesis. H1110P is classified as a group III mutant as replacement of a
histidine with a proline at position 1110 results in restriction of FANCA expression
to the cytoplasm and a complete inability to activate the FA pathway. In contrast,
Q1128E exhibits normal protein localization and FA pathway activation and as such
is classified as a group I mutant. However, patients with this single base change
have Fanconi Anaemia indicating other, as yet undefined roles for FANCA within
the cell that must be disrupted by this mutation, which was why this particular
mutation was chosen for analysis in this study.
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Localization of these mutant proteins within HeLa and L(3T2 cells was confirmed by
tagging FANCA with the green fluorescent protein (GFP), from Aequorea victoria.
This widely used reporter gene is utilized to track the expression, location and
activity of specific proteins of interest within a host cell and is detected after
excitation with light at a wavelength of 488 nm (Chalfie et al., 1994). Confocal
microscopy analysis of the expression pattern of uncoupled GFP demonstrated
localization of GFP within both the cytoplasm and nucleus ofHeLa and L(3T2 cells
(See Figures 4.7 and 4.8, panels a and m). This pattern of protein distribution
reflects the small size of GFP (-27 kD), which is capable of passively diffusing
across the nuclear envelope after synthesis in the cytoplasm. FANCA protein tagged
with GFP had a different expression pattern with the majority of GFP expression,
and therefore localization of FANCA, being located within the nucleus, although
there was some cytoplasmic expression in both HeLa and L|3T2 cells (See Figures
4.6 and 4.7, panels b and j). These findings agree with the expression pattern of
GFP-FANCA previously reported after transfection into HeLa, Cos-7 and NIH-3T3
cells (Lightfoot et ah, 1999). Expression of a GFP-tagged FANCA construct
containing a proline rather than a histidine residue at position 1110 (HI 110P) results
in no co-localization of GFP and Topro-3 signal within the nucleus, as FANCA-
H1110P was completely restricted to the cytoplasm of both HeLa and L|3T2 cells
(See Figure 4.7 and 4.8, panels c and k). Expression of a GFP-tagged FANCA
construct containing a glutamic acid rather than a glutamine at position 1128
(Q1128E) generated a different expression pattern profile within HeLa and L(3T2
cells. In HeLa cells this mutant clearly localizes to the nucleus (Figure 4.7 1 and p)
and gives a similar localization profile to wild-type FANCA (See Figure 4.7, panels j
and n). However, in L|3T2 cells an even distribution of GFP expression was
observed across the cell (Figure 4.8 1 and p) as in the case of uncoupled-GFP (Figure
4.8, panels i and m). This cell specific difference indicates that the function of
FANCA may differ, or that different FANCA-interacting proteins, are expressed in
these cells.
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Why a single base change from a histidine to a proline at position 1110 should result
in the restriction of FANCA protein expression to the cytoplasm has yet to be
determined. This mutation is located outside the putative NLS and NES signal
sequences however, it is known that FANCA protein with this single base change
fails to interact with FANCC or be phosphorylated, processes that may be required
for transport of the FANCA into the nucleus (Kupfer et ah, 1999; Adachi et ah,
2002). The Q1128E mutation was also studied because this point mutation does not
affect the interaction of the mutant FANCA protein with FANCC, FANCG or
FANCF (Adachi et ah, 2002). Whether this FANCA mutant can still interact with
FANCE and FANCL has not been reported but since FANCD2 ubiquitination is
restored when FANCA-Q1128E is transfected into FANCA null cells, it seems likely
that interactions with other FA proteins are not disrupted (Adachi et ah, 2002).
FANCA-Q1128E is similar to 4 other reported mutations in this respect; all seem to
activate the FA pathway yet patients are reported to have Fanconi Anaemia. The
specific phenotype of the patient carrying the Q1128E mutation has not been
reported, nor the identification of the FANCA mutation present in the second allele.
As FA patients have a wide variety of clinical phenotypes, which are likely to be
associated not only with genotype but also genetic background and environmental
factors (Alter, 1993; Yamashita and Nakahata, 2001), determination of the
relationships between specific mutations and clinical phenotypes would help in the
understanding of the molecular basis of genotype-phenotype correlations associated
with FA. Further analysis of mRNAs and proteins from patient cells carrying the
specific Q1128E mutation may help to determine why this specific, single base
change results in Fanconi Anaemia, whilst interactions ofQ1128E with other FA and
non-FA family members may help determine the pathogenicity of this mutation and
the aetiology of Fanconi Anaemia.
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4.3.4 Conclusions
This chapter is the first report detailing the localization of Fanca protein within L|3T2
gonadotroph cells. Western blotting, indirect immunofluorescence and GFP tagging
has been used to study, for the first time, the localization of Fanca protein within
L|3T2 gonadotroph cells. Studies using indirect immunofluorescence and western
blotting analysis show that Fanca protein is localized to both the cytoplasm and
nucleus of gonadotroph cells whereas analysis of GFP-tagged FANCA protein
indicates that the protein is localized predominantly to the nucleus (See Figures 4.1,
4.2 and 4.8). Preliminary experiments designed to address transport of Fanca
between the cytoplasm and nucleus of LPT2 cells have identified that active export
of Fanca, via a CRM-1 dependent mechanism, occurs in LPT2 gonadotroph cells.
However, as discussed earlier, whether GnRH is involved in shuttling of Fanca
protein between sub-cellular compartments requires further investigation. Lastly, a
specific, patient-derived, point mutation at amino acid 1110 (FANCA-H1110P) is
sufficient to restrict Fanca protein expression to the cytoplasm of HeLa and LPT2
cells (See Figures 4.7 and 4.8, panels k and o). Interestingly, another mutation,
FANCA-Q1128E, had a different expression pattern between cell types (See Figures
4.7 and 4.8, panels 1 and p). Within HeLa cells, a predominantly nuclear expression
pattern was observed, as for wildtype FANCA. However, in LPT2 cells, localization
of FANCA-Q1128E protein was not predominantly nuclear, since similar levels of
protein expression were seen within the cytoplasm, giving a distribution pattern
analogous to uncoupled GFP. These results indicate that other factors, specific to
gonadotroph cells, may be involved in the correct localization and function of intact
FANCA protein within these highly specialised cells.
155
Chapter 5
Fanca and gonadotropin gene expression
Knowledge is of no value unless you put it into practise - Anton Chekov.
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5 Fanca and gonadotropin gene expression
5.1 Introduction
5.1.1 Background
LH and FSH are heterodimeric glycoproteins comprised of a common a.-subunit
(aGSU) and a unique beta subunit (LH|3 or FSH|3). As each subunit is encoded by a
single gene, their transcriptional regulation is complicated especially given that both
LH and FSH are produced in, and released from, the same gonadotroph cells (Childs
et al., 1987; Liu et al., 1988; Lloyd and Childs, 1988), but with very different
patterns of synthesis and secretion, indicating that discrete cellular mechanisms must
be in place to control their differential transcription. Regulation of gonadotropin
subunit transcription occurs at two levels: basal and GnRH induced. Basal gene
expression is switched on during development, whilst activation of the GnRH pulse
generator at puberty results in the increased, pulsatile release of GnRH, which
stimulates an increase in gonadotropin subunit expression. This process is
demonstrated in hpg mice, which have basal levels of gonadotropin subunit gene
expression, and have functional gonadotrophs, but require injections of GnRH to
increase basal levels of subunit expression (Cattanach et al., 1977; Iddon et al.,
1980). GnRH induced levels of gonadotropin gene transcription can be decreased to
basal levels if GnRH action is blocked, indicating that the regulation of basal and
GnRH induced transcription occurs via different mechanisms (McNeilly et al.,
1991). The processes by which GnRH regulates gonadotropin gene transcription are
not fully characterised, but it is known that variation in GnRH pulsatility is directly
involved in the control of subunit specific gene transcription, as demonstrated in
L(3T2 gonadotroph cells where administration of pulsatile doses of GnRH results in
secretion of LH but not FSH (Turgeon et al., 1996). Activation of the GnRH
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receptor and coupling to second messenger signalling pathways also contributes to
the differential regulation of gonadotropin gene transcription. Analysis of MAPK
signalling cascades in gonadotroph cells reveals that signalling through ERK and
activation of the MAPK-responsive transcription factor, Elkl (Roberson et al., 1995),
controls aGsu transcription in response to GnRH. Control of GnRH induced LH/3
subunit transcription has been shown to be regulated by signalling through both ERK
and JNK (Harris et al., 2002) and the up-regulation of Egrl (Dorn et al., 1999;
Tremblay and Drouin, 1999; Wolfe and Call, 1999). Recently, ERK and JNK have
also been implicated in GnRH signalling to the FSH/3 promoter via AP-1 sites
(Bonfil et al., 2004; Coss et al., 2004). Table 5.1 and Figure 5.1 show some of the
transcription factors that have been identified to be important for basal and GnRH
induced gonadotropin subunit gene expression, but research is still ongoing to fully
characterise how GnRH, steroids and gonadal peptides activate disparate intracellular
signalling pathways to transduce specific transcriptional activation of gonadotropin
subunit gene expression.
Basal GnRH regulated
aGsu Lhx2/3(Schoderbek et al., 1992;
Roberson et al., 1994; Tremblay et al.,
1998)
Elkl (Roberson et al., 1995)
Sfl(Barnhart and Mellon, 1994)
Gata(Dasen et al., 1999)
Pitxl(Tremblay et al., 1998)
USF(Jackson et al., 1993; Jackson et al.,
1995)
LHP Sfl(Keri andNilson, 1996) Spl(Kaiseret al., 1998)
Pitxl(Tremblay et al., 1998; Quirk et al.,
2001)
Egrl (Tremblay and Drouin, 1999)
FSLip Lhx3(West et al., 2004) AP-l(Strahl et al., 1998; Coss et al.,
2004)Pitxl(Zakaria et al., 2002)
Table 5.1 Transcription factors shown to be involved in basal and/or
GnRH regulation of gonadotropin subunit transcription.
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Differential display RT-PCR (DD-RT-PCR) has been used to identify and isolate
transcripts regulated by GnRH in gonadotroph cells, which may play a role in the
differential regulation of gonadotropin gene transcription in response to GnRH. This
approach revealed that Fanconi Anaemia complementation group a {Fanca) mRNA
is differentially expressed in L|3T2 gonadotroph cells in response to hormone
(Chang, 2002). Data presented in this thesis has illustrated that GnRH tightly
regulates the expression of both Fanca mRNA and protein in mature gonadotroph
cells (See Chapter 3) and that Fanca protein is localized predominantly to the nucleus
of L(3T2 cells (See Chapter 4). FANCA is mutated in >60% of patients with Fanconi
Anaemia (FA), an autosomal recessive disorder characterised by progressive bone
marrow failure and a marked pre-disposition to cancer. A wide range of other
symptoms are associated with the disorder including microcephaly, short stature and
infertility (Young and Alter, 1994). Transgenic mice with targeted disruption of
Fanca (Cheng et al., 2000; Wong et al., 2003), Fancc (Chen et al., 1996; Whitney et
ah, 1996) or Fancg (Yang et ah, 2001) were generated to understand more about the
aetiology of the disease, unfortunately neither single or double Fanca"/Fanccgene
disrupted mice (Noll et ah, 2002) recapitulated the phenotype seen in human
patients. Instead, the most striking phenotype in these knockout mice was a dramatic
decrease in fertility. As discussed in Section 1.8, studies of post-pubertal FA patients
reveal that both males and females are sub-fertile and have hypogonadism (Bargman
et ah, 1977; Alter et ah, 1991; Liu et ah, 1991). Gonadotropin serum levels have
been measured in a limited number of FA patients and all had abnormal levels of
both LH and FSH (Berkovitz et ah, 1984; Schoof et ah, 2000; Massa et ah, 2002).
However, abnormal gonadotropin levels may also be explained by disruption of the
HPG-axis since the gonadal phenotype in Fanca and Fancc disrupted mice indicates
that the genes are involved in germ cell development and proliferation (Cheng et ah,
2000; Nadler and Braun, 2000). Nevertheless, the novel discovery that Fanca
expression is regulated by GnRH in gonadotroph cells, together with its nuclear
localization, suggests that Fanca may be involved, either directly or indirectly, in
gonadotropin gene transcription.
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5.1.2 Aims of this chapter
As previous data presented within this thesis has shown that Fanca is expressed
within gonadotroph cells and that GnRH regulates the expression of both Fanca
mRNA and protein, this chapter addresses whether expression of Fanca is required
for the activation of aGsu, LH/3 and FSH/3 promoters in response to GnRH. This
chapter also seeks to determine if other members of the FA complex are expressed
within gonadotroph cells and if the innovative technique of RNA interference
(RNAi) can be used to knockdown expression ofFanca in gonadotroph cells.
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5.2 Results
5.2.1 Mutating FANCA has no effect on LHj3 promoter activity
To assess whether FANCA affects basal or GnRH induced LH/3 transcription, -692
bp of the ovine LFffi gene promoter linked to a luciferase reporter gene (-692LH(3-
pA3Luc) was co-transfected with vectors expressing either wildtype (pEGFP-
FANCA) or mutant FANCA (pEGFP-Hl 110P-FANCA and pEGFP-Ql 128E-
FANCA). Cells were left untreated, or treated with 1 pM GnRH 48 h after
transfection and harvested 6 h post GnRH treatment, then luciferase activity was
assayed as described in Section 2.5.3. As expected, GnRH significantly up-regulated
the activity of the LH/3 promoter in L|3T2 cells (ANOVA one-way analysis of
variance, p<0.01, see Figure 5.2). Co-transfection with either wildtype FANCA,
FANCA-H1110P or FANCA-Q1128E had no affect on either the basal or GnRH
induced activity of the promoter (p<0.05, p<0.001, see Figure 5.2).
5.2.2 Mutating FANCA increases FSH/3 basal promoter activity
The study the effect of FANCA on basal and GnRH induced FSH/3 transcription
-4741 bp of the ovine FSHfi gene promoter linked to a luciferase reporter gene
(-4741FSH|3-pXP2, kind gift from W.Miller) was co-transfected with vectors
expressing either wildtype (pEGFP-FANCA) or mutant FANCA (pEGFP-Hll 10P-
FANCA and pEGFP-Ql 128E-FANCA). Cells were left untreated, or treated with 1
pM GnRH 48 h after transfection and harvested 6 h post GnRH treatment. Co-
transfection with wildtype FANCA had no effect on the basal activity of the
promoter. However, co-transfection with either FANCA-H1110P or FANCA-
Q1128E significantly increased the basal activity of the promoter cells when
compared to cells co-transfected with wildtype FANCA (p<0.05, see Figure 5.3). As
expected, GnRH significantly up-regulated the activity of the FSH/3 promoter in
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L|3T2 cells (ANOVA one-way analysis of variance, p<0.001, see Figure 5.3) and co-
transfection with either wildtype FANCA, FANCA-H1110P or FANCA-Q1128E
had no affect on the GnRH induced activity of the promoter (p<0.001, see Figure
5.3). These results indicate that nuclear localization of a fully functional FANCA
protein may be crucial for basal regulation ofFSH/3 promoter activity.
5.2.3 Mutating FANCA obliterates GnRH induced aGsu promoter activity
To determine whether Fanca effects basal and GnRFl induced aGsu transcription,
-480 bp of the aGsu gene promoter linked to a luciferase reporter gene (-480alpha-
pA3Luc) was co-transfected with vectors expressing either wildtype (pEGFP-
FANCA) or mutant FANCA (pEGFP-Hl 110P-FANCA and pEGFP-Ql 128E-
FANCA). This promoter fragment is known to target aGsu expression to the
gonadotroph cells of transgenic mice (Horn et al., 1992) and contains both basal and
GnRH responsive regions (Schoderbek et ah, 1992). Cells were left untreated, or
treated with 1 pM GnRH 48 h after transfection and harvested 6 h post GnRH
treatment. As expected, GnRH significantly up-regulated the activity of the aGsu
promoter in L(3T2 cells (ANOVA one-way analysis of variance, p<0.01, see Figure
5.4). Co-transfection with wildtype FANCA had no affect on the GnRH induced
activity of the promoter (p<0.001, see Figure 5.4). However, the GnRH induced
activity of the promoter after co-transfection with either FANCA-H1110P or
FANCA-Q1128E was significantly reduced when compared to the response after co-
transfection with wildtype FANCA (p<0.05, see Figure 5.4). These results indicate
that nuclear localization of a fully functional FANCA protein is required for up-
regulation of aGsu promoter activity by GnRH.
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Figure 5.2 Effects of mutating FANCA on GnRH induced LH0 promoter
activity in L.pT2 cells.
A -692bp LH/3 promoter construct linked to a luciferase reporter gene, and a control
(3-galactosidase reporter gene were transfected into L|3T2 cells. Where indicated
(+), cells were co-transfected with either wildtype (FANCA WT) or mutated FANCA
(FANCA-H1110P or FANCA-Q1128E) expression vectors. After 48 h, cells were
either left untreated (-) or treated with GnRH (+) before harvesting. The results are
expressed as the fold induction of promoter activity and are corrected for
transfection efficiency as determined by (3-galactosidase expression. Basal promoter
activity was not affected by addition of FANCA constructs. Addition of GnRH
resulted in a significant 3-fold increase in promoter activity that was not affected
when cells were co-transfected with FANCA WT, FANCA-H1110P or FANCA-
Q1128E. Results shown are the mean of three separate experiments with error
bars indicating the standard error of the mean. Statistical analysis was performed
using ANOVA one-way analysis of variance: **, p<0.01; *, p<0.05.
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Figure 5.3 Effects of mutating FANCA on GnRH induced FSH|3
promoter activity in Lj3T2 cells.
A -4741 bp FSHjS promoter construct linked to a luciferase reporter gene, and a
control |3-galactosidase reporter gene were transfected into L(3T2 cells. Where
indicated (+), cells were co-transfected with either wildtype (FANCA WT) or mutated
FANCA (FANCA-H1110P or FANCA-Q1128E) expression vectors. After 48 h, cells
were either left untreated (-) or treated with GnRH (+) before harvesting. The results
are expressed as the fold induction of promoter activity and are corrected for
transfection efficiency as determined by (3-galactosidase expression. Co-
transfection with FANCA-H1110P or FANCA-Q1128E significantly increased basal
activity of the FSH(3 promoter. Addition of GnRH resulted in a significant 2.5-foid
increase in promoter activity that was still observed when cells were co-transfected
with FANCA WT, FANCA-H1110P or FANCA-Q1128E. Results shown are the
mean of three separate experiments with error bars indicating the standard error of
the mean. Statistical analysis was performed using ANOVA one-way analysis of
variance: ***, p<0.001; **, p<0.01 p<0.05.
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Figure 5.4 Effects of mutating FANCA on GnRH induced aGsu
promoter activity in LPT2 cells.
A -480bp aGsu promoter construct linked to a luciferase reporter gene, and a
control p-galactosidase reporter gene were transfected into LPT2 cells. Where
indicated (+), cells were co-transfected with either wildtype (FANCA WT) or mutated
FANCA (FANCA-H1110P or FANCA-Q1128E) expression vectors. After 48 h, cells
were either left untreated (-) or treated with GnRH (-) before harvesting. The results
are expressed as the fold induction of promoter activity and are corrected for
transfection efficiency as determined by p-galactosidase expression. Basal
promoter activity was not affected by addition of FANCA constructs. Addition of
GnRH resulted in a significant 1.6-fold increase in promoter activity that was not
affected when cells were co-transfected with FANCA WT. Co-transfection with
FANCA-H1110P or FANCA-Q1128E resulted in a significant decrease in GnRH
induced increase in promoter activity seen with FANCA WT. Results shown are the
mean of three separate experiments with error bars indicating the standard error of
the mean. Statistical analysis was performed using ANOVA one-way analysis of
variance: **, p<0.01; *, p<0.05.
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5.2.4 Design of siRNAs against Fanca
Co-transfection of dominant negative forms of FANCA results in ablation of the
GnRH induced response of the aGsu promoter (See Figure 5.4) and increases basal
activity of the FSH/3 promoter (See Figure 5.3) indicating that FANCA is involved in
gonadotropin subunit transcription. In order to analyse this in more detail, Fanca
expression in L|3T2 cells was knocked down using the technique of RNA
interference (RNAi). Two short interfering RNAs (siRNAs) were designed, specific
for murine Fanca, as described in Section 2.8 (Fanca-siRNA-A and Fanca-siRNA-
B). As a negative control, a scrambled siRNA was also designed that BLAST
analysis revealed did not match any known transcripts. Figure 5.5 details the
sequence of the designed siRNAs and their target sequence within the Fanca gene.
5.2.5 RT-PCR analysis of Fanca mRNA expression in L/3T2 cells treated
with siRNAs
To ensure that the selected siRNAs specifically knocked down Fanca mRNA
expression, RT-PCR was performed. LPT2 cells were transfected with 400 nM
siRNA (Fanca-siRNA-A, Fanca-siRNA-B or scrambled siRNA), cultured for a
further 24 h and RNA extracted. Reverse transcription was performed using an oligo
dT primer, as described in Section 2.1.3, and cDNA was amplified using gene
specific primers for Fanca (exons 14-18), Zfp276 and Gapdh (See Table 2.1).
Ethidium bromide staining identified bands at the expected sizes in all samples (See
Figure 5.6). However, transfection with specific Fanca siRNAs resulted in a highly
visible decrease in Fanca expression levels when compared against Fanca levels in
untreated cells or cells treated with a scrambled siRNA. Transfection with specific
Fanca siRNAs may have had a modest effect on expression levels of Zfp276 but had
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Figure 5.6 RT-PCR analysis of Fanca expression in LPT2 cells after
transfection with siRNAs.
LPT2 cells were mock transfected (no siRNA) or transfected with an siRNA against
Fanca (Fanca-siRNA-A or Fanca-siRNA-B) or a scrambled siRNA. After 24 h, RNA
was extracted, reverse transcribed and first strand cDNA analysed for expression of
Fanca, Zfp276 and Gapdh. Ethidium bromide staining identified that all three genes
were expressed in all samples tested. Transfection with siRNAs did not alter
expression levels of Gapdh however, a highly visible decrease in Fanca mRNA
expression and a modest decrease in Zfp276 expression could be seen after
transfection with Fanca specific siRNAs. A negative control containing no cDNA
was included (-ve).
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5.2.6 Indirect immunofluorescence of Fanca protein expression in L/3T2
cells treated with siRNAs
To ensure that the selected siRNAs specifically knocked down Fanca protein
expression, indirect immunofluorescence using rabbit anti-mouse Fanca antisera was
performed on cells transfected with siRNAs. LPT2 cells, grown on 2-well glass
chamber slides, were either left un-transfected, or transfected with 400 nM siRNA.
After culturing for a further 48 h, cells were incubated overnight with rabbit-anti-
mouse Fanca antisera specific for amino acids 1-276. The following day, Fanca
protein was visualized by incubating with a goat anti-rabbit secondary antibody
conjugated to biotin followed by a fluorescent probe conjugated to streptavidin (as
described in Section 2.7.10). Nuclei were then counterstained with a fluorescent dye
(Topro-3) and slides mounted before detection of fluorescence signal by confocal
microscopy. LPT2 cells transfected with a non-specific, scrambled siRNA (Figure
5.6, panels j, 1) showed similar levels of Fanca protein expression to that seen in un-
transfected cells (Figure 5.6, panels a, c). In contrast, cells transfected with Fanca
specific siRNAs had visibly decreased levels ofFanca protein expression (See Figure
5.6, panels d, f, g, i).
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Figure 5.7 siRNA knockdown of Fanca protein expression in L0T2
cells.
Expression of Fanca protein within untreated and siRNA transfected L(3T2 cells was
determined using rabbit anti-mouse Fanca antisera and indirect
immunofluorescence. Cell nuclei were identified by staining with Topro-3, a DNA
specific dye (b,e,h,k). Expression of Fanca protein (green) is seen in un-transfected
cells (a,c) and cells transfected with a non-specific, scrambled siRNA (j, I). Cells
transfected with siRNAs specific to Fanca (Fanca-siRNA-A or B), have decreased
levels of Fanca protein expression (d, f, g, i).
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5.2.7 Western blotting analysis of Fanca protein expression in L/3T2 cells
after treatment with siRNAs
The 'knockdown' of endogenous Fanca protein within L|3T2 cells was quantified by
western blotting analysis. L|3T2 cells were transfected with either 200 nM or 400
nM siRNA, cultured for a further 24 h then whole cell protein extracts prepared.
Equal amounts of protein extract, as determined by Bradford assay, were then
fractionated on a 6% SDS-PAGE gel, blotted and incubated with a rabbit anti-mouse
Fanca antisera specific for amino acids 1-276. A specific protein band at -160 kD,
corresponding to the expected size of Fanca protein, was detected in all samples (See
Figure 5.8). Blots were stripped, and then re-probed with a rabbit anti-mouse [3-
tubulin antibody to control for even loading of protein on to the gel (See Figure 5.8).
Analysis revealed that Fanca protein levels were only significantly decreased after
addition of siRNAs specific to Fanca and increasing the concentration of siRNA
resulted in a greater decrease in protein expression. Quantification of protein levels
using ImageQuant software and normalization of Fanca protein levels against |3-
tubulin protein levels revealed that Fanca protein expression in L|3T2 cells was
decreased 19% after treatment with 200nM Fanca-siRNA-A, 15% after treatment
with 200 nM Fanca-siRNA-B, 33% after treatment with 400 nM Fanca-siRNA-A
and 41% after treatment with 400 nM Fanca-siRNA-B, when compared to levels of
expression in untreated L|3T2 cells (See Figure 5.8, ANOVA one-way analysis of
variance; p<0.05, p<0.001). Transfection of 400 nM of a scrambled siRNA did not
significantly alter Fanca protein levels indicating that no non-specific knockdown of
Fanca protein had occurred.
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Figure 5.8 Western blotting analysis of siRNA knockdown of Fanca
protein expression in L0T2 cells.
Western blotting analysis of whole cell L|3T2 protein extracts transfected with
siRNAs. Protein was fractionated on an SDS-PAGE gel, blotted and probed with
anti-rabbit mouse Fanca antisera before being stripped and re-probed with a rabbit
anti-mouse (3-tubulin antibody. Probing with the Fanca antibody detected a protein
band at the expected size of ~ 160 kD. Probing with a (3-tubulin antibody gave a
protein band at the expected size of ~ 55 kD. Normalization of Fanca protein levels
against (3-tubulin levels showed that Fanca protein expression was decreased after
transfection with siRNAs specific to mouse Fanca (Fanca-siRNA-A or B).
Transfection of a scrambled siRNA did not alter Fanca protein levels. Results show
the mean of at least three separate experiments with error bars indicating the
standard error of the mean. ANOVA one-way analysis of variance determined
treatment with Fanca specific siRNAs significantly decreased Fanca protein levels:
*, p<0.05; ***, p<0.001.
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5.2.8 Generation of adenoviral vectors expressing wildtype and mutant
FANCA
To investigate a link between Fanca protein expression and GnRH induced
expression of aGsu, it was necessary to develop a system that would target all
gonadotroph cells. As aGsu is expressed in >50% of gonadotroph cells (Liu et al.,
2002) and LPT2 cells have a low transfection efficiency (P.Brown, personal
communication), it is unlikely that transfection of dominant negative forms of
FANCA or Fanca siRNAs would have a detectable impact on aGsu protein
expression. However, adenoviral infection of cellular monolayers is extremely
efficient, with infection rates of >90% reported (Imperiale and Kochanek, 2004).
Thus, to study the effects of over expression of dominant negative forms of FANCA
(FANCA-H1110P and FANCA-Q1128E) within gonadotroph cells in more detail,
adenoviral expression constructs expressing these proteins were generated as
described in Section 2.9. The BD-Adeno-X Expression System 2 with BD Creator
Technology (Clontech) was used to clone both wildtype and mutant FANCA inserts
into an adenoviral vector using Cre-loxP site-specific recombination. The gene of
interest is first cloned into a donor vector (pDNR-CMV), then using Cre
Recombinase the insert is cloned into an adenoviral vector (pLP-Adeno-X) and the
resulting virus propagated in HEK293 cells. Target cells (LPT2 cells) are then
infected with this virus to achieve efficient transfer of the gene of interest and
produce high levels of protein expression under standard laboratory conditions.
Vectormaps for the three constructs, pLP-Adeno-X-FANCA, pLP-Adeno-X-
FANCA-H1110P and pLP-Adeno-X-FANCA-Ql 128E are shown in Figure 5.9.
Unfortunately, time constraints have meant that virus production has not yet begun
but Section 5.3.3 discusses the future experiments that could be performed using this
expression system.
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Figure 5.9 Vector maps of EGFP-FANCA adenoviral constructs.
EGFP tagged wildtype and mutant FANCA inserts were cloned into pDNR-CMV
Donor vector via NhellXbal compatible sites. This was then transferred to the
adenoviral acceptor vector (pLP-AdenoX) by Cre-/oxP site specific recombination.
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5.2.9 Expression analysis of Fanconi Anaemia complex members
FA proteins form a nuclear complex to regulate the cellular response to DNA
damage (See Figure 1.14) (Garcia-Higuera et al, 2001), and defects in any one of the
genes involved in the pathway results in an inability to process DNA damage repair
effectively (DAndrea and Grompe, 2003). With the recent discovery that Fanca is
expressed within L(3T2 gonadotroph cells (Chang, 2002; Larder et al., 2004), RT-
PCR analysis was performed to determine if other FA complex members (Fancc,
Fancd2, Fance, Fancf, Fancg and Fancl) are also expressed in LPT2 cells. As a
comparison, RNA was also extracted from an immature gonadotroph cell line (aT3-
1), a rat somatotroph cell line (GH3) and human (HeLa) and mouse cell lines (L-
cell). RNA was extracted, reverse transcribed and cDNA amplified using gene
specific primers (See Table 2.1). Ethidium bromide staining was used to identify the
presence of amplified DNA at the appropriate sizes for each PCR reaction and DNA
sequencing of the cloned PCR products established the correct products had been
amplified. Fancd2 expression was detected in all cell lines tested. Fanca and Fancc
expression was detected in all cell lines tested with the exception of aT3-l cells.
Fancg and Fancl expression was detected in all cell lines tested with the exception of
a rat somatotroph cell line (GH3). Fance expression was detected in all cell lines
tested with the exception of HeLa cells. Fancf expression was detected in LPT2,
aT3-l and L-cells, but did not amplify from GH3 and HeLa cell cDNA. (See Figure
5.10).
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Figure 5.10 In vitro expression analysis of FA complex members.
RT-PCR analysis to show the expression profile of various FA family members.
RNA was extracted from L(3T2, aT3-1, GH3, HeLa and L-cells, reverse transcribed
and first strand cDNA analysed for expression of Fanca, Fancc, Fancd2, Fance,
Fancf, Fancg and Fancl using gene specific primers. A negative control containing
no cDNA was included (-ve). Ethidium bromide staining identified PCR products of
the expected size. Amplification of specific FA family members was confirmed by
DNA sequencing.
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5.2.10 Expression of Fanca and Fancc in aT3-1 cells augments the GnRH
induced response of the aGsu promoter
Expression of dominant negative forms of FANCA has shown that the presence of a
fully functional FANCA protein is required for GnRH induction of the aGsu
promoter. As RT-PCR analysis has shown that aT3-l cells, an immature
gonadotroph cell line that expresses aGsu and Gnrhr, express all known FA complex
members other than Fanca and Fancc (See Figure 5.10), experiments were
performed to determine if constitutive expression of these proteins within aT3-l
cells would have any affect on GnRH induced activity of the aGsu promoter. Fanca
and/or Fancc expression vectors were co-transfected with —480 bp of the aGsu gene
promoter linked to a luciferase reporter gene (-480alpha-pA3Fuc). Cells were left
untreated, or treated with 1 uM GnRH 48 h after transfection and harvested 6 h post
GnRH treatment to allow luciferase activity to be assayed. Addition of GnRH
resulted in a significant 3.5-fold increase in aGsu promoter activity (See Figure 5.11,
ANOVA one-way analysis of variance, p<0.001). This increase was also observed if
cells were co-transfected with either Fanca or Fancc (See Figure 5.11). However,
co-transfection of both Fanca and Fancc with the aGsu promoter resulted in
augmentation of the GnRH response resulting in a 6.7-fold increase in aGsu
promoter activity, a significant increase when compared to the promoter activity in
cells treated with GnRH alone or co-transfected with either Fanca or Fancc (See
Figure 5.11, ANOVA one-way analysis of variance, p<0.01).
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**
GnRH + + + +
Fanca — — + — +
Fancc — — — + +
Figure 5.11 Effects of Fanca and Fancc on GnRH induced aGsu
promoter activity in aT3-1 cells.
A -480bp aGsu promoter construct linked to a luciferase reported gene, and a
control p-galactosidase reporter gene were transfected into aT3-1 cells. Where
indicated (+), cells were co-transfected with either Fanca or Fancc. After 48 h, cells
were either left untreated (-) or treated with GnRH (+) before harvesting. The results
are expressed as the fold induction of promoter activity after addition of GnRH and
are corrected for transfection efficiency as determined by p-galactosidase
expression. Addition of GnRH resulted in a significant 3.5-fold increase in promoter
activity. A similar increase was seen when cells were co-transfected with Fanca
(3.8-fold) or Fancc (2.7-fold) then treated with GnRH. Co-transfection with both
Fanca and Fancc resulted in a 6.7-fold increase in promoter activity upon addition of
GnRH. Results shown are the mean of three separate experiments with error bars
indicating +/- standard error of the mean. Statistical analysis was performed using
ANOVA one-way analysis of variance: ***, p<0.001; **, p<0.01.
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5.3 Discussion
5.3.1 FANCA is required for gonadotropin subunit gene transcription
Whilst the basal activity of the LH/3 and aGsu promoters were not significantly
altered by co-transfection with point-mutated forms of FANCA (See Figures 5.2 and
5.4), a small, but significant, increase in the basal activity of the FSH/3 promoter was
seen after co-transfection with either FANCA-H1110P or FANCA-Q1128E (See
Figure 5.3). This suggests that FANCA may act as a specific signalling molecule to
regulate basal levels of the FSH/3 gene. Co-transfection of wildtype and mutant
FANCA proteins with FSFf/3 promoter resections could be performed in order to
localise the region of the promoter regulated by wildtype FANCA. Treatment with
GnRH showed that all three promoters were hormone responsive and co-transfection
with wildtype FANCA had no affect on either the basal or GnRH induced activity of
the promoters (See Figures 5.2, 5.3 and 5.4). However, whilst the GnRH induced
activity of the LH/3 and FSH\Q promoters were not significantly affected by co-
transfection with point-mutated forms of FANCA, the significant 1.6-fold increase in
aGsu promoter activity usually observed upon addition of GnRH was no longer
measured if mutated forms of FANCA were co-expressed (See Figure 5.4),
suggesting that FANCA may act as a specific signalling molecule to differentially
regulate GnRH induced gonadotropin gene transcription.
Co-transfection with FANCA-H1110P blocked GnRH induced activity of the -480
bp aGsu promoter and increased basal activity of the FSIIfi promoter. Expression of
this mutant form of the protein is restricted to the cytoplasm of L|3T2 gonadotroph
cells (Chapter 4) and other cellular models (Kupfer et al., 1999; Adachi et al., 2002).
However, as Fanca protein is normally localized to both the cytoplasm, and nucleus,
of L(3T2 cells (Chapter 4), these results, taken alone, suggest that localization of
FANCA protein to the nucleus of L(3T2 cells is required for control of aGsu and
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FSH/3 promoter activity. Wildtype FANCA may be having a direct effect on aGsu
and FSH/3 transcription within the nucleus, or could be acting as a carrier molecule
to transport a protein required for regulation of gonadotropin promoter activity, into
the nucleus. Alternatively, wildtype FANCA may be signalling from its location
within the cytoplasm of gonadotroph cells to control gonadotropin gene transcription
within the nucleus and mutation of an amino acid at position 1110 disrupts this
function. Support for the latter theory was obtained by co-transfecting the
gonadotropin promoters with FANCA-Q1128E, which does not have an altered
expression pattern as it still localizes to the nucleus of gonadotroph cells. This
mutant FANCA protein also compromised GnRH induced activity of the aGsu
promoter and increased basal expression of the FSH/3 promoter suggesting that it
may not be the ability of FANCA to localize to the nucleus that is crucial for control
of aGsu and FSH/3 promoter activity but that it is its capacity to function correctly
within the cytoplasm that is important. As with the HI 11 OP mutation, the Q1128E
mutation could be altering the ability of FANCA to function as a signalling molecule
and as both mutations are at the C-terminus of the protein this suggests that this
region of the protein may be important for this process. Recently, yeast two-hybrid
studies have shown that FANCA can interact with G-protein beta 2 subunit, a protein
involved in signalling via the Ras/Raf pathway (Reuter et al., 2003). This pathway is
activated by binding of GnRH to its receptor on the surface of gonadotroph cells and
signals downstream to control transcription of the gonadotropin promoters (Benard et
al., 2001; Harris et al., 2002; Bonfil et al., 2004). Confirmation of an interaction
between Fanca and proteins involved in activation of the Ras/Raf pathway in
gonadotroph cells may help determine whether Fanca is acting as a signalling
molecule in response to GnRH.
As expression of Fanca protein is localized to the nucleus and recent studies have
shown that the FA complex associates with chromatin (Qiao et al., 2001; Mi and
Kupfer, 2004; Montes De Oca et al., 2004; Wang et al., 2004), chromatin
immunoprecipitation (ChIP) assays could be performed to determine if FANCA is
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functioning within the nucleus to control gonadotropin promoter activity by binding
directly to the gonadotropin promoters. Yeast two-hybrid analysis also identified
that FANCA can interact with several non-FA proteins (Reuter et al., 2003), some of
which are involved in transcriptional regulation, suggesting that it may indirectly be
involved in gonadotropin promoter regulation via interaction with other proteins,
possible as part of a complex.
The evidence that FANCA is involved in both GnRH induced activity of the aGsu
promoter and basal activity of the FSH/3 promoter is very interesting. Analysis of
transcription factors known to regulate gonadotropin gene transcription reveals that
the LIM homeodomain (LIM-HD) proteins, Lhx2, Lhx3 and Lhx4, are involved in
aGsu and FSH/3, but not LH/3, transcription (Roberson et al., 1994; Howard and
Maurer, 2001; Sloop et al., 2001b; West et al., 2004). LIM-HD proteins have been
shown to bind the pituitary glycoprotein hormone basal element (PGBE) of the aGsu
promoter (Roberson et al., 1994; Bach et al., 1995; Howard and Maurer, 2001; Sloop
et al., 2001a). However, evidence now suggests that within L|3T2 cells, Lhx2 is not
as essential for basal activation of the aGsu promoter as Pitxl and Sfl are, but is
involved in activation of the promoter in response to GnRH (P.Brown, personal
communication). The role of LIM-HD proteins in FSH/3 promoter activity has only
recently been established with the identification of six LHX3 binding sites within the
human FSH/3 promoter that are required for its basal transcription (West et al., 2004).
Whilst it is known that the response of the FSH/3 promoter to activin does not require
induction of the LHX3 gene, studies of the role of LHX3 in GnRH regulation of the
promoter have not been analysed. As LIM-HD proteins are not involved in LH/3
transcription (West et al., 2004), and mutation of FANCA only affects aGsu and
FSH/3 promoter activity, it is possible that the LIM-HD proteins and FANCA
cooperate to regulate expression of these specific subunits. Yeast two-hybrid
analysis of a pituitary cell library using FANCA as bait may help to identify specific
proteins, such as the LIM-HD proteins, that interact with FANCA in gonadotroph
cells, to activate gonadotropin promoter activity.
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5.3.2 Role of other FA complex members in activation of aGsu and FSH/3
promoter transcription
To determine whether Fanca may be interacting with other FA complex members to
activate gonadotropin promoter activity it was important to first establish whether
L|3T2 cells express other FA genes. Fanconi Anaemia is a genetically heterogeneous
disease with bi-allelic mutations in any one of eight identified genes (FANCA,
FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG and FANCL) resulting in
the syndrome. With the relatively recent identification ofFancd2, Fance, Fancfand
Fancl, little information is available regarding their expression profiles. Flowever,
northern blotting and in situ hybridisation analysis have described the expression
patterns of Fancc (Wevrick et al., 1993; Krasnoshtein and Buchwald, 1996), Fancg
(van de Vrugt et al., 2002), Fancdl/Brca2 (Rajan et al., 1997) and Fanca (Abu-Issa
et al., 1999; van de Vrugt et al., 2000; Wong et al., 2000) in both embryonic and
adult mouse tissues.
An RT-PCR screen for FA complex members was undertaken using L|3T2 cell RNA
(See Figure 5.10). As a comparison, the immature gonadotroph aT3-l cell-line was
also included along with somatotroph GFI3 RNA and both human (HeLa) and mouse
(L-cell) cell lines. Results revealed that only L|3T2 cells expressed the full
complement of all the currently identified FA complex members (See Figure 5.10).
The lack of detectable Fancf, Fancg and Fancl expression in GH3 cells and Fance
and Fancf expression in HeLa cells probably reflects mis-priming since the PCR
primers were optimised for amplification of mouse sequence (See Table 2.1) and
may not be ideal for amplifying rat or human cDNA. Western blotting analysis
using antibodies against the Fane proteins could identify if FA proteins are also
expressed within gonadotroph cells.
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RT-PCR analysis also demonstrated that unlike the other Fane genes, expression of
Fanca and Fancc is not detectable in aT3-l cells, an immature, mouse gonadotroph
cell line, indicating a possible role for these genes in mature gonadotroph function.
To address this further, transient transfection assays were performed in aT3-l cells
to determine if constitutively expressed Fanca and Fancc would have any affect on
GnRH induced activity of the aGsu promoter, which is endogenously expressed in
aT3-l cells. Addition of GnRH resulted in a 3.5-fold increase in the activity of the
promoter and this increase was unaffected by co-transfection of either Fanca or
Fancc (See Figure 5.11). However, co-transfection with both Fanca and Fancc
augmented the GnRH response giving a 6.7-fold increase in aGsu promoter activity
(See Figure 5.11). This suggests that Fanca and Fancc can cooperate, possibly with
other FA family members, to control GnRH induced activity of the aGsu promoter.
This contrasts with the lack of effect ofwildtype FANCA on aGsu promoter activity
in L(3T2 cells (See Figure 5.4), which endogenously express both Fanca and Fancc
(See Figure 5.10). Over expression of both Fanca and Fancc has not been performed
in L(1T2 cells so it has not been established whether augmentation of the GnRH
induced aGsu promoter, as seen in aT3-l cells, would also be observed in mature
gonadotroph cells. It is possible that both these proteins are required to transport in
an additional, potentially regulatory, molecule into the nucleus of gonadotroph cells
to activate the aGsu promoter in response to GnRH. Conversely, the complex could
be involved in the recruitment and deactivation of a protein that would otherwise
repress GnRH induced activation of the aGsu promoter and these hypotheses are
discussed in more detail in Chapter Six. The transient transfection of point mutated
forms ofFANCA with Fancc could confirm co-operation between these genes in the
control of aGsu expression in aT3-l cells and could identify whether Fanca or
Fancc is the crucial factor involved in augmentation of the GnRH induced response
in aGsu promoter activity seen in these cells.
184
Chapter 5 Fanca and gonadotropin gene expression
5.3.3 Analysis of gonadotropin levels in FA patients
Whilst FA patients have been reported with hypergonadotrophic as well as
hypogonadotrophic hypogonadism (Cowdell et al., 1955; Stubbe and Prindull, 1975;
Aynsley-Green et al., 1978), analysis of gonadotropin levels has only been reported
in a few cases of FA (Berkovitz et al., 1984; Schoof et al., 2000; Massa et al., 2002).
Although studies of gonadotropin levels in children with FA were not informative,
probably due to GnRH stimulation tests being unreliable in children who are pre¬
pubertal (Kelch et al., 1980), analysis of adult FA patients reveals abnormal levels of
LH and FSH in both sexes, with males also having reduced levels of testosterone
(See Table 5.1).
Sex LH FSH T Mutation Reference
1 M Normal * sk Not (Massa et al.,
increased decreased known 2002)
2 F "b T N/A Not (Berkovitz et al.,
increased increased known 1984)
3 M t * vk Not (Berkovitz et al.,
increased increased decreased known 1984)
4 M sk sk sk FancD2 (Schoof et al.,
decreased decreased decreased 2000)
Table 5.2 Analysis of LH, FSH and testosterone levels in four cases of
FA.
M: male; F: female; LH: luteinising hormone; FSH: follicle stimulating hormone; T:
testosterone.
As negative feedback mechanisms control gonadotropin levels (See Figure 1.2 and
1.3), it is difficult to determine whether the hypogonadism seen in FA patients and
Fanca/_, Fanccand Fancg'~ knockout mice is due to a primary defect involving the
pituitary or the gonads as both a diminished amount of functioning gonadal tissue, as
a result of defective DNA damage repair, or the abnormal regulation of gonadotropin
gene transcription within the pituitary could result in gonadal dysgenesis. Data
presented within this chapter has revealed for the first time that the hypogonadism
seen in FA patients may be due to abnormal gonadotropin gene transcription within
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the pituitary resulting in disruption to the HPG axis. With information concerning
gonadotropin levels in FA patients, as well as knowledge concerning the specific
mutations in these patients, a picture of the effects of loss of specific FA genes on the
regulation of gonadotropin gene transcription could be established.
5.3.4 Fanca expression can be 'knocked down' in L/3T2 cells using siRNAs
Flaving established that co-transfection of dominant negative FANCA molecules had
a profound effect on basal FSHfi activity and GnRH induced activity of the aGsu
promoter in L|3T2 cells, an additional approach, such as the new technique of RNA
interference (RNAi), was required to confirm the role of Fanca in aGsu gene
expression in gonadotroph cells. RNAi is the name of the process by which dsRNA
silences gene expression by inducing the sequence specific degradation of
complementary mRNA (Flannon, 2002). Figure 5.12 illustrates how RNAi-mediated
gene silencing is thought to occur in mammals. Long dsRNAs are processed by
Dicer, an evolutionarily conserved enzyme, into short interfering RNAs (siRNAs) of
21-23 nucleotides (nt) with 2-3nt overhangs at the 3' ends and 5' phosphate groups
(Bernstein et al., 2001; Elbashir et ah, 2001). These siRNAs associate with cellular
proteins to form an RNA-induced silencing complex (RISC). This complex contains
a helicase to unwind the duplexed siRNA (Nykanen et al., 2001) so the antisense
strand of the siRNA can direct the cleavage of a corresponding sense RNA target or
the sense strand of an siRNA can direct cleavage of an antisense target (Elbashir et
al., 2001; Martinez et al., 2002). (See Figure 5.12). This process has been
manipulated in C.Elegans to knockdown expression of specific genes (Sharp, 1999),
however, introduction of dsRNA molecules longer than 30 bp into mammalian cells
provokes the antiviral/interferon response pathway resulting in the global shutdown
of protein synthesis (McManus and Sharp, 2002). To bypass this, chemically
synthesized short dsRNA molecules of 21-22 nt, matching the target transcript can
be transfected into cells to decrease expression of the gene of interest.
186









Degraded mRNA WVWWVN VVWWVVN polyA
Figure 5.12 RNAi-mediated gene silencing.
Long dsRNAs are cleaved by Dicer to produce short interfering RNAs (siRNAs).
These siRNAs then associate with cellular proteins to form an RNA-induced
silencing complex (RISC) which unwinds the duplexed siRNA and guides it to the
target mRNA for cleavage.
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Two siRNAs were designed to knockdown expression of Fanca in LPT2
gonadotroph cells and due to the considerations outlined above, a series of
experiments were undertaken to verify the siRNAs were specific for Fanca. Semi¬
quantitative RT-PCR was used to analyse Fanca mRNA levels in Fanca siRNA
treated or scrambled siRNA treated cells. Fanca mRNA expression was only
reduced in cells that had been treated with Fanca specific siRNAs (See Figure 5.6).
Although Zfp276 mRNA expression levels appeared to show a modest decrease in
LPT2 cells with knocked down expression of Fanca (See Figure 5.6), quantitative
RT-PCR analysis would need to be performed to fully analyse the effects of Fanca
knockdown on Zfp276 expression. For a complete picture of the effects a specific
siRNA has on expression of the gene of interest protein levels must also be analysed
in siRNA transfected cells thus, Fanca protein expression in siRNA treated cells was
analysed using an antibody to the N-terminus of Fanca and indirect
immunofluorescence. In cells treated with either of the Fanca specific siRNAs,
Fanca protein expression was almost undetectable (See Figure 5.7, panels d, f, g, i).
Whilst mock transfected cells, and cells transfected with a non-specific scrambled
siRNA, showed normal levels of Fanca expression (See Figure 5.7, panels a, c, j, 1).
To quantify the decrease in Fanca protein expression after transfection with a siRNA,
Fanca protein levels were normalized against levels of P-tubulin protein using
western blotting analysis. LPT2 cells were transfected with either 200 nM or 400
nM of each siRNA, harvested for protein extracts after 24 h then Fanca and P-tubulin
protein expression were measured. Increasing the concentration of Fanca-siRNA
decreased Fanca protein expression with the highest concentration giving the greatest
reduction (41% for Fanca-siRNA-B, See Figure 5.8). Levels of P-tubulin protein
expression remained constant (See Figure 5.8) and no significant knockdown of
either P-tubulin or Fanca protein expression was seen after transfection with 400 nM
of a scrambled siRNA (See Figure 5.8) indicating that specific knockdown of Fanca
had been achieved.
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Since siRNAs have been defined as successful when a >90% reduction in protein
levels is achieved (Schwarz et al., 2002), the 33% and 41% reduction in Fanca
protein expression observed by western blotting analysis after transfection with
Fanca specific siRNAs (See Figure 5.8) would suggest inefficient knockdown of
Fanca protein expression. However, this may be due to two reasons, firstly, Fanca
protein may be relatively stably expressed therefore analysis of Fanca protein levels
after a longer time period (>24 h) may reveal a greater knockdown in Fanca protein
expression. Additionally, as protein extracts for western blotting analysis are made
from all the cells in the flask, and not all cells would be transfected with siRNA, it is
conceivable that Fanca expression is unaffected in a considerable proportion of cells,
which would still be detectable by western blotting analysis. Adenoviral vectors can
achieve efficient gene delivery into hard to transfect cell lines by viral infection and
could be utilised to achieve better transfection of L|3T2 cells with siRNAs. siRNA
plasmid expression vectors with selectable markers can enrich for stably transfected
cells but repeated passaging of L(3T2 cells tends to affect their GnRH responsiveness
(P.Brown, personal communication), so this method of siRNA expression would be
unsuitable in this cell type. With a specific siRNA (Fanca-siRNA-A or
Fanca-siRNA-A) ablating Fanca expression in a large sample of cells, the
requirement of Fanca for GnRH induced aGsu transcription in LPT2 cells, as shown
in transient transfection assays, could be confirmed.
5.3.5 Further studies using FANCA expressing adenoviral vectors
To investigate the effects of FANCA on gonadotropin gene expression, adenoviral
vectors expressing wildtype and mutant forms of FANCA were constructed (See
Figure 5.9). Infectious adenovirus is produced by transfecting PacI digested
recombinant adenoviral vectors into HEK293 cells. Packaged adenovirus can then
be used to infect target cells, such as LPT2 cells, with wildtype and mutant FANCA
proteins. This technique gives a high rate of transfection efficiency (-90%) and will
prove useful in the study of LPT2 cells. GnRH induced levels of aGsu mRNA, in
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cells infected with dominant negative FANCA adenovirus, could be studied to assess
whether wildtype and mutant FANCA do indeed have a role in gonadotropin gene
expression. Furthermore, the adenoviral constructs express GFP-tagged FANCA and
can be used to study the sub-cellular localization of FANCA in response to GnRH.
5.3.6 Conclusions
This chapter has shown that FANCA may act as a specific signalling molecule to
differentially regulate basal and GnRH induced gonadotropin gene transcription.
Transient transfection assays have shown that FANCA regulates basal activity of the
FSHfi promoter and GnRH induced activity of the aGsu promoter. Expression of
Fanca and Fancc in immature gonadotroph cells, that do not express these members
of the FA complex, results in amplification of the normal GnRH induced response of
the aGsu promoter suggesting that Fanca cooperates with Fancc, and possibly with
other FA members, in order to control GnRH induced activity of the aGsu promoter.
Data presented in this chapter clearly shows that FANCA is crucial for GnRH
regulation of aGsu promoter activity and the control of basal levels of FSHfi and
may explain the molecular basis of the infertility phenotype seen in many FA
patients. Whether this phenotype is solely due to the expression of gonadotropin
subunits or is also associated with a role for the FA genes in a DNA damage repair
pathway requires further investigation. With the development of adenoviral vectors
expressing wildtype and mutant FANCA proteins and the characterisation of siRNAs
that will specifically knockdown Fanca expression the novel role of Fanca in
gonadotroph cells can be studied in more detail.
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General Discussion and Conclusions
Science is what you know. Philosophy is what you don't know - Bertrand Russell.
Chapter 6 General Discussion
6 General Discussion
6.1 Introduction
Previously, differential display RT-PCR (DD-RT-PCR) identified that a transcript
corresponding to Fanconi Anaemia complementation group a (Fanca), a gene
involved in DNA damage repair, was expressed in gonadotroph cells and regulated
by GnRH (Chang, 2002). This thesis presents data that further characterises the
effects of GnRH on Fanca mRNA and protein expression within gonadotroph cells
and has investigated the impact of Fanca on gonadotropin subunit gene transcription.
This chapter summarises the findings presented in this thesis, discusses the possible
roles of this gene in the control of fertility, and the wider implications of these
findings in the aetiology of Fanconi Anaemia.
6.1.1 Regulation of Fanca expression by GnRH
Detailed investigations of the GnRH regulation of Fanca mRNA and protein
expression has demonstrated that, within LPT2 gonadotroph cells, both are rapidly
and transiently increased in response to GnRH. Fanca mRNA increases 2-fold 1 h
after addition of GnRH with expression returning to unstimulated levels 4 h after
treatment. This increase is mirrored by an increase in Fanca protein expression with
Fanca protein levels increasing 2-fold 2 h after treatment with hormone with
expression returning to unstimulated levels by 6 h (Larder et al., 2004).
Mutations in FANCA account for >60% of cases of Fanconi Anaemia (FA)
(Auerbach et al., 1998). Patients have a mean survival age of 20 years and are
affected by a wide range of symptoms other than anaemia, such as short stature,
microcephaly and pigmentation abnormalities. In patients that progress through
puberty, infertility is a common clinical feature of the disease. FA is genetically
heterogeneous with mutations in any one of eight identified genes resulting in FA
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(Joenje et al., 1997). These structurally unrelated Fane proteins interact to form a
complex to ensure efficient DNA damage repair and checkpoint control of mitosis
within the cell nucleus (D'Andrea and Grompe, 2003). RT-PCR expression analysis
of L|3T2 cells reveals that all identified members of the FA complex (Fanca, Fancc,
Fancd2, Fance, Fancf, Fancg and FancT) are expressed in mature gonadotroph cells,
although so far only Fanca has been shown to be regulated by GnRFl. Further
experiments are required to determine if GnRH also regulates the other members of
the complex especially given that a recent paper identified that Fancc expression in
L[3T2 cells is down regulated 1 h after treatment with GnRH (Kakar et al., 2003).
6.1.2 Effects of knocking out Fanca expression in mice
Two transgenic mouse lines have been generated with targeted disruption of the
Fanca gene (Cheng et al., 2000; Wong et al., 2003). In both cases these mice did not
recapitulate the severity of the phenotype seen in human FA patients, however, like
human FA patients, homozygous offspring from both these transgenic lines had
severely reduced fertility. Both lines were hypogonadal with few or no follicles in
the ovaries and Leydig cell hypoplasia in the testes. However, the second model did
display a broader range of FA-like phenotypes, possibly due to a different genetic
background, which included tumour formation, growth retardation, microcephaly,
craniofacial malformations and severely reduced fertility (Wong et al., 2003).
Furthermore, in this model, female mice developed ovarian cysts, a phenotype
associated with elevated LH plasma levels in humans, and a clinical feature seen in
some FA patients (Berkovitz et al., 1984; Massa et al., 2002). In the first FA
knockout model, whilst aGsu expression was not analysed, immunohistochemical
studies of Lh/3 and Fsh/3 expression within the pituitary gland revealed no difference
in expression between wildtype and knockout mice (Cheng et al., 2000), and
unfortunately, were not investigated in the second model. Since analysis of
gonadotropin levels proved inconclusive, pituitaries should be examined further to
determine if gonadotroph cell numbers, expression of aGsu, Lh/3 or Fshfi and levels
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of LH and FSH are altered as a consequence of ablating Fanca expression. Data
presented in this thesis has shown that wildtype FANCA is required for GnRH
induced aGsu transcription, suggesting that aGsu levels within knockout mouse
pituitaries may be decreased, which would also cause hypogonadism. Transient
transfection assays have shown that FANCA also regulates basal levels of FSH/3
transcription. Mutation of FANCA results in a small, but significant increase in
FSH/3 expression. As high concentrations of basal levels of FSH can lead to
desensitisation of gonadal cells to the actions of FSH (O'Shaughnessy and Brown,
1978; Gnanaprakasam et al., 1979), a rise in FSHfi levels, as a result ofmutations in
FANCA, could contribute to the hypogonadism seen in FA patients and knockout
mice. Lastly, as a proportion of FA patients present with short stature due to reduced
levels of growth hormone (Nordan et al., 1979; Young and Alter, 1994; Massa et al.,
2002), and since the second knockout mouse model displayed growth retardation, it
would also be interesting to study the development of somatotroph cells and analyse
growth hormone levels in these FancaA mice to see if Fanca is required for the
regulation of other pituitary hormones.
6.1.3 Fanca, GnRH and cancer
Patients with FA have a marked pre-disposition to cancer with a median age of
tumour development at 16 years of age, which contrasts with 68 years of age for the
general population (Alter, 2003). The most frequent types of cancer seen in FA
patients are aerodigestive (>40%) or reproductive (>15%) (Alter, 2003). The
expression of GnRH types I and II, and GnRH receptor type I, has been reported in
both normal and cancerous tissues of the reproductive tract (Grundker et al., 2002)
and in non-endocrine tumours such as glioblastomas and melanomas (van
Groeninghen et al., 1998; Moretti et al., 2002). The activation of GnRH receptors in
these tumours down-regulates cell proliferation and reduces the metastatic and
invasive capabilities of cancerous cells (Miller et al., 1985; Limonta et al., 1992;
Dondi et al., 1994; Moretti et al., 2002; Limonta et al., 2003). Recently it was
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demonstrated that the apoptotic effect of GnRH in prostate cancer cells is mediated
by JNK signalling (Kraus et al., 2004), and interestingly, GnRH is used as a
therapeutic in prostate cancer (Conn and Crowley, 1994) and has been trialled as a
second line therapy for advanced ovarian cancer (Balbi et al., 2004). Further
investigations could determine if the regulation of Fanca expression by GnRH within
gonadotroph cells also occurs within other GnRH receptor expressing tissues.
Perhaps the anti-proliferative and anti-metastatic actions of GnRH on cancerous
tissues are achieved through an up-regulation in Fanca expression? (See Figure 6.1).
Analysis of the levels of Fanca expression in response to GnRH in normal and
cancerous tissues could determine whether signalling by GnRH to Fanca contributes
to the marked pre-disposition to cancer seen in FA patients with bi-allelic loss of
FANCA mutations.
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Figure 6.1 Hypothetical role of GnRH and FANCA in the control of
tumour development.
Activation of GnRHR in cancer cells decreases the proliferation rate and metastatic
capabilities of tumour cells. This process may occur via the up-regulation of FANCA
expression in response to GnRH and could be a factor in the marked pre-disposition
to cancer seen in FA patients, in addition to the role of FANCA in DNA damage
repair.
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6.1.4 Fanca protein expression in gonadotroph cells
This thesis presents the first report detailing the localization of Fanca protein within
L|3T2 gonadotroph cells. Western blotting analysis and indirect immunofluorescence
localized expression of endogenous Fanca protein to both cellular compartments and
addition of GnRH generated a significant 2-fold increase in Fanca protein levels in
both the cytoplasm and nucleus. Interestingly, analysis of the expression pattern of
FANCA protein tagged with GFP revealed that whilst expression of FANCA is
observed within both cellular compartments, GFP-tagged FANCA appears to be
localized predominantly to the nucleus of L|3T2 cells. However, this difference in
localization may be an artefact of the process of transfection resulting in an
accumulation of FANCA protein within the nucleus therefore further analysis is
required to determine why exogenous and endogenous Fanca protein localizes to
different areas of the cell. Treatment of gonadotroph cells with inhibitors of nuclear
import and export, and subsequent western blotting analysis of protein extracts from
these cells, has shown that Fanca protein shuttles between the nucleus and cytoplasm
of L|3T2 gonadotroph cells via a CRM-1 dependent mechanism. Bioinformatic
analysis of Fanca protein sequence predicted the presence of a putative nuclear
export signal (NES) consensus sequence, at the C-terminus of the protein, which has
been implicated in the binding of proteins to CRM-1 and their subsequent export to
the cytoplasm. This is the first report to describe that Fanca protein shuttles between
the nucleus and cytoplasm of cells via a specific mechanism. The ability ofFANCA
protein to translocate to the nucleus has been documented (Naf et al., 1998; Lightfoot
et al., 1999) in contrast, movement of FANCA protein from the nucleus to the
cytoplasm has not be studied. Mutational analysis of the putative NES sequence
identified within Fanca would help determine the importance of this region in
nuclear export of Fanca and could elucidate whether export of Fanca is crucial for its
role in DNA damage and whether this shuttling is also associated with another role
of the protein.
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6.1.4.1 Does Fanca act as a molecular scaffold?
The localization of key signalling components is highly regulated during signal
transduction with many signalling responses rapidly affecting the nuclear
localization of various proteins, transcription factors and kinases (Lenormand et al.,
1993; Beals et al., 1997; DiDonato et al., 1997; Khokhlatchev et al., 1998). In yeast
a molecular scaffold protein, Ste5, is known to shuttle between the nucleus and
cytoplasm in response to pheromone (Elion, 2001). Scaffold proteins physically
connect various signal transduction components such as receptors, kinases and
elements of the cytoskeleton into stable complexes (Pawson and Scott, 1997). In the
absence of the yeast mating pheromone factor, Ste5 is localized to the nucleus of the
cell. However, in the presence of pheromone, it is translocated to the plasma
membrane where it activates a G-protein coupled receptor (GPCR). The receptor
then activates the MAPK proteins bound to Ste5 and initiates the signalling
mechanisms required to induce morphogenesis. The ability of Fanca to bind other
proteins is well documented, and bioinformatic analysis of Fanca amino acid
sequence has identified putative SH2 and SH3 domains, motifs known to be
important for the function of scaffold proteins (Pawson, 2004). Taken together, with
evidence presented in this thesis that Fanca protein shuttles between the nucleus and
cytoplasm of gonadotroph cells, and a recent report demonstrating that FANCA
interacts with a protein involved in signalling via the Ras/Raf pathway (Reuter et al.,
2003), it is conceivable that Fanca may be acting as a molecular scaffold protein to
elicit the regulation of gonadotropin gene transcription in response to GnRH (See
Figure 6.2). However, further experiments are required to determine if GnRH is
directly involved in the movement of Fanca between cellular compartments.
Screening a yeast two-hybrid gonadotroph cell library using Fanca as bait could help
identify new binding partners for Fanca and determine whether this hypothesis is
true.
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Figure 6.2 Hypothetical role of GnRH in the shuttling of Fanca protein.
In the absence of GnRH, Fanca protein is localised predominantly to the nucleus of
LPT2 cells. Binding of GnRH to its receptor on the surface of gonadotroph cells
increases Fanca mRNA levels within LPT2 cells, either by increasing Fanca
transcription or stabilising Fanca mRNA (black lines). Transient transfection assays
have shown that Fanca is required for GnRH induced aGsu transcription. As in
yeast, where pheromone regulates the shuttling of the molecular scaffold protein
Ste5, from the nucleus to the cytoplasm, signalling through the GnRH receptor
(black line) may regulate shuttling of Fanca between the nucleus and cytoplasm of
LpT2 cells (dotted lines). This then allows various signal transduction components
(X, Y and Z) to be bought together into a stable complex to regulate aGsu
transcription in response to GnRH.
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6.1.4.2 Is Fanca involved in GnRH receptor desensitization?
The carboxy-terminal domain of G-protein coupled receptors (GPCRs) has an
important role in regulating receptor activity including desensitization of G-protein
mediated signalling, recruitment of G-protein independent signalling molecules,
receptor internalization, recycling and degradation (Willars et al., 1999; Ferguson,
2001). It is known that binding of (3-arrestin to the carboxy-terminal tail of a GPCR
leads to the rapid desensitization and internalization of the agonist stimulated
receptor. After internalization, receptors can either be sorted into endosomes for
recycling back to the cell surface or alternatively may undergo degradation within
lysosomes (Koenig and Edwardson, 1997). Non-mammalian type I GnRH receptors,
which possess a C-terminal tail, undergo rapid desensitization and internalization
(Heding et al., 1998; Pawson et al., 1998; Hislop et al., 2001). Consistent with the
requirement of the carboxy-terminal tail for enhanced receptor desensitization and
internalization, mammalian type I GnRH receptors, which uniquely lack a C-terminal
tail, are desensitized and internalized slowly (Pawson et al., 1998; Willars et al.,
1999). Whilst this process does not occur through (3-arrestin, there is evidence to
suggest that it is mediated via a clathrin dependent mechanism (Vrecl et al., 1998).
A large family of cytoplasmic and membrane associated proteins called Sorting
Nexins, are known to be involved in GPCR receptor recycling via clathrin coated pits
(Worby and Dixon, 2002) and may be involved in the clathrin-dependent
internalization ofmammalian type I GnRH receptors. Interestingly, yeast two-hybrid
analysis has shown that FANCA protein interacts with a member of this family,
Sorting nexin 5 (SNX5), although the significance of this has yet to be determined
(Otsuki et al., 1999; Reuter et al., 2003). Perhaps FANCA and SNX5 are both
involved in rapid recycling of GnRHR to the cell membrane? Or maybe binding of
FANCA to SNX5 blocks the internalization and recycling of the receptor resulting in
continued signalling by GnRH? (See Figure 6.3). Expression of dominant negative
forms of SNX5 and FANCA, and subsequent analysis of GnRHR internalization,
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would be required to determine if this process is dependent on either of these
proteins.
Figure 6.3 Hypothetical role of FANCA and SNX5 in recycling of
GnRHR.
Mammalian GnRH receptor (GnRHR) desensitization and internalization occurs via
a clathrin dependent pathway. Sorting nexin proteins may also be involved in this
pathway. Yeast two-hybrid analysis has shown that FANCA protein interacts with
Sorting nexin 5 (SNX5). This interaction may serve to assist (i) or prevent (ii)
GnRHR internalization and thus affect gonadotropin subunit gene transcription.
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6.1.5 Fanca and gonadotropin subunit transcription
The regulation of Fanca expression by GnRH, taken together with results showing
that Fanca protein is expressed in both the cytoplasm and nucleus of gonadotroph
cells, suggests that Fanca might be involved in the regulation of gonadotropin gene
expression. Analysis of the effects of both wildtype and mutant forms of FANCA on
gonadotropin subunit promoter activity reveals that whilst mutating FANCA had no
effect on LH{5 promoter activity, the expression of wildtype FANCA was required
for GnRH induced activation of the aGsu promoter and basal regulation of the FSH/3
promoter in L(3T2 cells.
This is the first report to show that FANCA is implicated in the transcription of
genes involved in fertility. However, how FANCA regulates these promoters
remains to be determined. Analysis of the data presented in this thesis produces
several hypotheses to suggest a potential role of Fanca in gonadotroph cells. This
chapter has already discussed the potential role of Fanca as a molecular scaffold and
it is possible that Fanca may be functioning within the cytoplasm of gonadotroph
cells to control signalling, from the GnRHR, to the nucleus in order to activate
gonadotropin subunit transcription (See Section 6.1.4.1) and that the C-terminus of
the protein is crucial in this process. Alternatively, Fanca may be active within the
nucleus of LPT2 cells perhaps by binding directly to the gonadotropin promoters in
order to regulate their activity. Alternatively, expression of wildtype Fanca within
the nucleus may be required for binding of another protein involved in gonadotropin
transcription. This hypothetical protein could either be involved in the activation of
GnRH induced aGsu promoter activity in the presence ofFANCA or alternatively be
prevented from repressing GnRH regulated promoter activity if bound to FANCA
(See Figure 6.4). A similar situation could be occurring for the basal regulation of
FSH/3 promoter activity. Wildtype FANCA could activate a protein that is
subsequently required for repression of basal transcription or conversely prevent an
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activator from binding the promoter, thus keeping basal levels of expression low
(See Figure 6.5).
To date, no FA genes have been directly implicated in transcriptional regulation
however, interactions between FANCA and other proteins, such as the transcriptional
repressors Inhibitor of NFkB (IkBy) and Fas death domain associated protein
(DAXX) are well documented (Reuter et al., 2003). This suggests that it may be the
interaction of FANCA with other proteins that controls the activity of the
gonadotropin promoters. The two mutant FANCA proteins studied here indicate that
specific mutations affecting the C-terminus of the protein severely compromise the
activity of the aGsu promoter in response to GnRH as well as basal regulation of the
FSH/3 promoter. Perhaps this region of FANCA is required for binding of another
protein involved in activation of these promoters? It would be informative to study
the effects of other FANCA mutations on aGsu promoter activity to establish if a
specific region of FANCA is required for activation of these promoters. Yeast two-
hybrid analysis of a gonadotroph cell library using full length FANCA as bait could
help identify gonadotroph specific proteins that interact with FANCA and may be
involved in aGsu and/or FSH/3 transcription in L(3T2 cells.
RT-PCR analysis reveals that aT3-l cells do not express Fanca or Fancc, however;
transient transfection of both these molecules into aT3-l cells augments the GnRH
response of the aGsu promoter. This suggests that Fanca and Fancc are cooperating
to produce an increase in promoter activity, in response to GnRH, in these cells and
this cooperation may also be occurring within LPT2 cells, which endogenously
express Fanca and Fancc. Co-transfection of mutant FANCA and FANCC
molecules into both cell types would establish whether expression of both proteins is
required for regulation of the aGsu promoter by GnRH.
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Figure 6.4 Hypothetical role of FANCA in GnRH induced aGSU
promoter activity in L|3T2 cells.
Wildtype FANCA is required for GnRH induced activity of the aGSU promoter.
FANCA may be interacting directly with the promoter to regulate GnRH induced
activity or alternatively, interaction of FANCA with either an activator (A) or
repressor protein (R) may control promoter activity (i and iii). If FANCA is mutated
then this may affect interaction with an activator protein (ii) and prevent GnRH
induced activation of the aGSU promoter. Alternatively, mutation may prevent
interaction with a repressor protein (iv) allowing the protein to bind the promoter and
prevent GnRH induced activation by other factors.
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Figure 6.5 Hypothetical role of FANCA in basal FSHjS promoter
transcription in LpT2 cells.
Wildtype FANCA is required for basal activity of the FSH/3 promoter. FANCA may
be interacting directly with the promoter to regulate its activity or alternatively,
interaction of FANCA with either an activator (A) or repressor protein (R) may
control promoter activity (i and iii). If FANCA is mutated then this may affect
interaction with an activator protein (ii) and disrupt correct basal regulation of the
FSH/3 promoter. Alternatively, mutation may prevent interaction with a repressor
protein (iv) that is controlling basal transcription of the FSF//3 promoter leading to an
up-regulation in basal FSH/3 expression.
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6.1.6 Role of the FA complex in transcriptional regulation via ubiquitination
Studies to try and elucidate the DNA damage phenotype seen in FA patients have
identified that a nuclear, multi-protein complex of five FA proteins (FANCA, C, E, F
and G) is required for the mono-ubiquitination of FANCD2 by FANCL, which
promotes activated FANCD2 to interact with the DNA damage repair proteins
BRCA1 and BRCA2/FANCD1 (D'Andrea and Grompe, 2003; Grompe, 2003). RT-
PCR analysis has shown that all the identified Fane genes, including the ubiquitin
ligase enzyme Fancl, are expressed within L|3T2 cells. Ubiquitin is a seventy-six
amino acid polypeptide that can be covalently attached to proteins through the
hierarchical action of three enzymes termed, ubiquitin-activating enzyme (El),
ubiquitin-conjugation enzyme (E2) and ubiquitin-protein ligase (E3) (Pickart, 2001).
The best defined role of ubiquitin is its ability to label a protein with multiple
ubiquitins (poly-ubiquitination) and thus target proteins for degradation via the
proteasome (Pickart, 2001). Ubiquitin also has another major role in the endocytosis
and subsequent trafficking of plasma membrane proteins and this is thought to occur
via mono-ubiquitination of the target protein (Raiborg et al., 2003), as in the case of
FANCD2 (Garcia-Fliguera et ah, 2001; Taniguchi et ah, 2002). Ubiquitin is also a
regulator of transcriptional activation of LIM-HD proteins, ubiquitination regulates
binding of Lhx3 to a repressing co-factor rather than an activating one (Ostendorff et
ah, 2002) and interestingly, Lhx3 has been shown to regulate both aGsu and FSlIfi
gene expression (Roberson et ah, 1994; Howard and Maurer, 2001; West et ah,
2004). Recent studies have shown that some GPCRs can undergo regulated
ubiquitination in response to activation by ligand (Chaturvedi et ah, 2001; Petaja-
Repo et ah, 2001; Cook et ah, 2003) although there are no studies analysing agonist-
regulated ubiquitination of the GnRH receptor. However, the role of ubiquitin in the
regulation of proteins downstream of GnRHR has been analysed in aT3-l cells. The
continued stimulation of the GnRHR results in a dramatic increase in Inositol 1,4,5-
triphosphate [Ins(l,4,5)P3] receptor poly-ubiquitination, leading to the suppression of
Ca2+ mobilization and consequently, suppression of LH and FSH secretion (McArdle
et ah, 2002; Wojcikiewicz et ah, 2003).
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This thesis has shown that, within LPT2 cells, GnRH up-regulates expression of
Fanca, one of the FA complex members required for ubiquitination of FANCD2 by
FANCL (Garcia-Higuera et al., 2001; Meetei et al., 2004) and that Fanca is involved
in gonadotropin subunit transcription. Taken together with the diverse roles of
ubiquitin in the regulation of receptor signalling and transcriptional activation it is
conceivable that the effects of Fanca on gonadotropin subunit transcription may be
mediated through the FA complex and its role in ubiquitination of proteins. Perhaps
the FA complex is involved in the ubiquitination and consequent degradation of
transcription factors involved in basal FSHfi transcription, a process that is disrupted
by mutation of FANCA resulting in an increase in FSH/5 transcription. Conversely,
the FA complex could be involved in the ubiquitination of repressor co-factors of
transcription factors required for GnRH induced aGsu transcription. Alternatively,
the FA complex may be involved in the ubiquitination of signalling protein pathways
initiated in response to GnRHR activation that control gonadotropin subunit
transcription. (See Figure 6.6). However, as FANCL was only recently identified as
the ligase thought to be responsible for FANCD2 ubiquitination, further studies into
the role of this ligase in ubiquitination are required before the role of the FA complex
in ubiquitination of proteins involved in GnRH signalling can be determined.
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Figure 6.6 Hypothetical role of the FA complex in control of
gonadotropin gene transcription.
FANCA (A) forms a complex in the nucleus of cells with other FA proteins (C, G ,E
,F and L) to ubiquitinate FANCD2. This complex may also regulate gonadotropin
transcription via ubiquitination (Ub). Control of FSH/3 transcription may occur via
targeting of an activator protein (Ac) for degradation such that a repressor co-factor
(R) can bind transcription factor X thus regulating activation of the promoter (i).
Control of GnRH induced activation of aGSU promoter may occur at several levels.
Firstly, the FA complex may be involved in ubiquitination of the receptor itself.
Secondly it may control signalling from the receptor by ubiquitination of downstream
proteins. Lastly it may ubiquitinate a repressor co-factor bound to protein X such
that the repressor protein is targeted for degradation and an activating co-factor can
bind and regulate promoter activity (ii).
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6.1.7 FA genotypes and phenotypes
Data presented within this thesis reveals, for the first time, that FANCA is required
for processes other than DNA damage repair, namely gonadotropin gene
transcription. This discovery may partly explain the reduced fertility seen in the
majority of FA patients. Further analysis using mutated forms of other FA complex
members would help to determine whether FANCA is acting independently, or as
part of the FA complex, to control gonadotropin gene transcription. Whilst there are
reports that some FA patients are fertile (Alter et al., 1991), the specific gene
mutations present in these individuals are not known. However, with the huge
variability in FA phenotypes, and considering that 30% of FA patients have no
abnormalities, it is highly likely that specific FA genes are involved in processes
other than DNA damage repair (Tischkowitz and Hodgson, 2003). Therefore, it
would be informative to determine which complementation groups these
reproductively viable patients were assigned to. If FANCA was mutated in any of
these patients, analysis of the specific mutations might help to determine which
regions of the gene are crucial for aGSU and FSHfi transcription and which are not.
The realization that BRCA2 and FANCD1 are actually the same gene may unravel
some of the molecular mechanisms involved in FA. The inheritance of germline
mutations that affect one allele of either BRCA1 or BRCA2 results in an increased
risk of developing breast and ovarian cancer (Ford et al., 1998; Antoniou et al.,
2003). Cancers arise in germline mutation carriers that have lost the function of the
second BRCA1 or BRCA2 allele, due to a further somatic mutation occurring within
the breast or ovarian tissue, resulting in tumour development (Collins et al., 1995;
Cornells et al., 1995). However, germline mutations affecting both alleles of BRCA2
results in Fanconi Anaemia (Howlett et al., 2002) indicating that germline
inheritance of mono-allelic or bi-allelic BRCA2 mutations can generate two very
different phenotypes. Perhaps this effect is also seen with mono-allelic or bi-allelic
mutation of other FA genes? Given that BRCA2/FANCD1 confers a pre-disposition
to specific cancers when one mutant allele is inherited, and mutations in BRCA
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genes account for only 40% of familial breast cancer cases (Ford et al., 1998), it is
feasible that carriers of other FA gene mutations may also be pre-disposed to
developing specific types of cancer. With the evidence presented in this thesis
indicating a molecular basis for FANCA in fertility, it is conceivable that mono-














Figure 6.7 Hypothetical consequences of mono-allelic loss of FANCA.
BRCA2 and FANCD1 are identical. Germline mutation affecting one allele of
BRCA2 results in a predisposition to developing breast and/or ovarian cancer.
Germline mutations affecting both BRCA2 alleles results in Fanconi Anaemia. Bi-
allelic loss of FANCA also results in Fanconi Anaemia. As wildtype FANCA is
required for GnRH induced aGsu transcription perhaps mono-allelic loss of FANCA
results in reduced fertility in carriers of FANCA mutations.
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6.1.8 Understanding the genetic and molecular basis of FA
The past few years have witnessed a considerable expansion in our understanding of
the FA pathway however, much more remains to be elucidated. Unfortunately, the
genetic heterogeneity of the disease hinders investigation of its molecular basis. For
instance, in other autosomal recessive disorders, such as Cystic Fibrosis (CF), the
first stage after diagnosis is to genotype the patient using multiplex PCR techniques
(Bradley et al., 1998) and has been ofmajor benefit to both patients and researchers.
For the patients this gives a definitive genetic explanation for their illness, allows
screening of family members and pre-implantation diagnosis of any future
pregnancies. For researchers, it constructs a picture of possible genotype/phenotype
correlations and an example of the efficacy of this approach is demonstrated with the
discovery that the R117H mutation causes congenital bilateral absence of vas
deferens (CBVAD) in CF patients (Bienvenu et al., 1993). Whilst FA patients may
be assigned to a complementation group, identification of a specific mutation is
rarely performed and unfortunately, ancestral mutations, equivalent to AF508 in the
CFTR (Cystic fibrosis transmembrane conductance regulator) gene, have not been
identified in any of the FA genes, instead, >100 different mutations have been found
in FANCA alone (Savino et al., 1997; Tachibana et al., 1999; Wijker et al., 1999).
This suggests that, unlike CF, the disease alleles have not evolved by conferring a
preferential advantage in the hemizygous state, instead, the FANCA locus appears to
be a mutational hotspot. Some links between complementation groups and clinical
phenotypes have been made. A relatively early onset of anaemia is seen in FANCG
patients compared with those in groups A and C and FANCA null patients have a
more severe haematological disease than non-null patients (Faivre et al., 2000). The
only report of a specific genotype/phenotype correlation shows that patients with a
frameshift mutation in FANCC (322delG in exon 1) do not have any of the major
skeletal abnormalities usually seen in FA patients, indicating that mutations at the N~
terminus of FANCC do not alter its role in skeletal development (Yamashita et al.,
1996). It would therefore be extremely useful to collect data on the specific
mutations and clinical phenotypes of a large cohort of FA patients in order to analyse
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phenotype-genotype correlations thereby acquiring more information on the genetic
and molecular basis of FA.
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6.2 Summary
This thesis presents data characterising the function of Fanca in gonadotroph cells
and provides the first molecular evidence of a role for Fanca in the control of
gonadotroph function.
Chapter three analyses in detail the regulation of Fanca mRNA and protein
expression by GnRH. Semi-quantitative and quantitative RT-PCR techniques reveal,
for the first time, that there is a rapid and transient increase in Fanca mRNA levels in
response to GnRH and western blotting analysis shows that this increase is mirrored
by a transient rise in protein levels after treatment with GnRH (Larder et ah, 2004).
Chapter four describes Fanca protein expression within L|3T2 gonadotroph cells.
Using western blotting analysis, indirect immunofluorescence and tagging of
FANCA with a fluorescent protein (GFP) Fanca protein expression was localized to
both the cytoplasm and nucleus of LPT2 cells. Treatment of LPT2 cells with an
inhibitor of CRM-1 dependent nuclear export prevented the export of Fanca protein
to the cytoplasm, showing for the first time that Fanca protein shuttles between the
nucleus and cytoplasm of LPT2 cells. This chapter also characterises the localization
of two point-mutated forms of FANCA in LPT2 cells. Substitution of a histidine for
a proline at position 1110 (H1110P) restricts FANCA protein expression to the
cytoplasm of LPT2 cells whilst substitution of a glycine with a glutamic acid at
position 1128 (Q1128E) distributes protein expression across both cellular
compartments.
Chapter five analyses the affects of these mutant proteins on gonadotropin subunit
transcription using transient transfection assays. Co-transfection ofmutant FANCA
proteins with aGsu, LHf> and FSH(5 promoters reveals wildtype FANCA is required
for GnRH induction of aGsu promoter activity and also regulates basal levels of the
FSFf/3 promoter suggesting that FANCA is involved in the differential control of
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gonadotropin subunit transcription. Future work to further elucidate the role of
Fanca in gonadotroph cells is also discussed in this chapter. The construction of
adenoviral vectors expressing wildtype and mutant FANCA proteins and the
characterisation of siRNAs that can be used to knockdown expression of Fanca in
L(3T2 cells to confirm a role for Fanca in gonadotropin gene transcription are also
described.
This thesis provides the first molecular evidence of a role for Fanca in the regulation
of gonadotroph function and may help in the understanding of both the infertility and
cancer development phenotype seen in FA patients. Analysis of the transcriptional
regulatory function of Fanca may help identify the specific molecular mechanisms
that this gene is required for and may help progress the understanding and treatment
of other clinical features of the disease.
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This appendix contains vector maps detailing some of the vectors used during the


















Figure A1.1 Vector map of pCRII-TOPO plasmid.
Features of pCRII-TOPO cloning vector used for cloning of PCR products.
Restriction sites are labelled. KanR, Kanamycin resistance; AmpR, Ampicillin
resistance; LacZ, p-galactosidase; M13For, M13 Forward primer binding site;
M13Rev, M13 Reverse primer binding site.
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Figure A1.2 Vector map of pBluescript plasmid.
Features of pBluescript-SK+ cloning vector. Restriction sites are labelled. AmpR,





















Figure A1.3 Vector map of pBluescript-FANCA-EcoRV.
A 1803 bp fragment was cloned out of pEGFP-FANCA by EcoRV digestion. This
was ligated into pBluscript plasmid that had also been digested with EcoRV
restriction endonuclease. This plasmid was then used as a template in site-directed
mutagenesis PCR reactions in order to introduce the point mutations H1110P and
Q1128E (See Section 2.3.11).
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Figure A1.4 Vector map of pCEP4-Fanca.
To obtain a 965 bp probe for hybridization to a northern blot, pCEP4-Fanca was
disgetsed with Hindlll and Asp700 restriction endonucleases. AmpR, Ampicillin



















Figure A1.5 Vector map of pEGFP-C1 -FANCA(H1110P/Q1128E).
Position of the point mutations (H1110P or Q1128E) introduced by site directed
mutagenesis are indicated. Restriction sites are labelled. KanR, Kanamycin
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ABSTRACT
Gonadal function is critically dependant on regulated secre¬
tion of the gonadotropin hormones from anterior pituitary go¬
nadotroph cells. Gonadotropin biosynthesis and release is trig¬
gered by the binding of hypothalamic GnRH to GnRH receptor
expressed on the gonadotroph cell surface. The repertoire of
regulatory molecules involved in this process are still being de¬
fined. We used the mouse LPT2 gonadotroph cell line, which
expresses both gonadotropin hormones, as a model to investi¬
gate GnRH regulation of gene expression and differential display
reverse transcription-polymerase chain reaction (RT-PCR) to
identify and isolate hormonally induced changes. This approach
identified Fanconi anemia a (Fanca), a gene implicated in DNA
damage repair, as a differentially expressed transcript. Mutations
in Fanca account for the majority of cases of Fanconi anemia
(FA), a recessively inherited disease identified by congenital de¬
fects, bone marrow failure, infertility, and cancer susceptibility.
We confirmed expression and hormonal regulation of Fanca
mRNA by quantitative RT-PCR, which showed that GnRH in¬
duced a rapid, transient increase in Fanca mRNA. Fanca protein
was also acutely upregulated after GnRH treatment of LpT2
cells. In addition, Fanca gene expression was confined to mature
pituitary gonadotrophs and adult mouse pituitary and was not
expressed in the immature aT3-1 gonadotroph cell line. Thus,
this study extends the expression profile of Fanca into a highly
specialized endocrine cell and demonstrates hormonal regula¬
tion of expression of the Fanca locus. We suggest that this reg¬
ulatory mechanism may have a crucial role in the GnRH-re-
sponse mechanism of mature gonadotrophs and perhaps the eti¬
ology of FA.
anterior pituitary, gene regulation, gonadotropin-releasing hor¬
mone, mechanisms of hormone action, pituitary
INTRODUCTION
Reproduction requires regulated pulsatile release of the
gonadotropin hormones, LH and FSH, from the gonado¬
troph cells of the anterior pituitary to stimulate gonadal
function. The gonadotropin hormones are heterodimeric
proteins, comprised of a common a subunit (aGSU) and a
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hormone-specific (3 subunit. Their biosynthesis and release
is triggered by the binding of decapeptide GnRH to its cog¬
nate receptor (GnRHr), this stimulates second messenger
signaling pathways, which, coupled with GnRHr number
and turnover, combine to differentially regulate hormone
biosynthesis [1-3]. Indeed, the pattern of GnRH adminis¬
tration is crucial for upregulating the mRNA levels of the
constituent aGSU and (3 subunits that comprise LH and
FSH, both in vivo [4, 5] and in vitro [6, 7].
Gonadotroph cell lines recapitulate the embryonic ante¬
rior pituitary temporal expression profile of gonadotropin
genes [8-10], Furthermore, because gonadotroph cells only
comprise 10-15% of the cells in the anterior pituitary, cell
lines afford greater manipulation of treatment conditions
and provide a source of enriched cell-specific material. In
this study, we used L(3T2 cells, an immortalized gonado¬
troph cell line that is GnRH responsive, expresses GnRHr
and all three gonadotropin subunits [9, 11, 12]. In addition,
the second messenger signaling pathways required to trans¬
duce the GnRH signal are starting to be elucidated in these
cells [13-16], Thus, because L(3T2 cells express all the fea¬
tures associated with mature pituitary gonadotrophs, they
are a suitable cell model for investigating regulation of gene
expression by GnRH.
To identify and isolate new and novel mRNAs that are
differentially regulated by GnRH in gonadotrophs, which
may be important for gonadotropin hormone biosynthesis,
differential display (DD) reverse transcription-polymerase
chain reaction (RT-PCR) [17] was performed on RNA ex¬
tracted from untreated and GnRH-treated L(3T2 cells. This
approach identified that, among others, expression of Fan¬
coni anemia a (Fanca) mRNA, was altered in response to
GnRH treatment. Fanca is a member of a protein complex
required for genome homeostasis [18, 19] and mutations in
Fanca account for >60% of cases of Fanconi anemia (FA),
an autosomal recessive inherited disorder. However, the
pleiotropic phenotype of FA patients indicates that other
cellular functions may also depend on the FA complex [20],
Therefore, we decided to investigate the expression pro¬
file of Fanca mRNA in detail and report that GnRH acutely
upregulates the expression of both Fanca mRNA and pro¬
tein. This suggests that Fanca may have a regulatory role
in gonadotroph cells, and this is the first report of distinct
hormonal regulation of this gene.
MATERIALS AND METHODS
Cell Culture
L(3T2 and aT3-l cells (obtained from P. Mellon, San Diego, CA) were
cultured in DMEM (Sigma, Dorset, UK) supplemented with 10% FCS
(Sigma) and 1% penicillin/streptomycin (Sigma). All gonadotroph cell cul¬
ture plasticware was coated with a 1:30 dilution of Matrigel (Becton Dick-
828
GnRH REGULATES FANCONI ANEMIA A 829





A1 5' - ACAGAGCACA-3'
A2 5' - ACGTATCCAG - 3'
MAX1 5' -GAGCATATCC-3'
MAX2 5' - CACAGCTTGC - 3'
MAX3 5' -CCACAGAGTA-3'
R21 5' - AGTCAGCCAC - 3'
R5 5' -AGGACCCTGG-3'
inson Labware, Oxford, UK) in PBS (Sigma). Cells were treated with 1
|J.M of native GnRH (Peninsula, St. Helens, UK) for 15 min. This con¬
centration is known to stimulate high levels of LH and FSH p subunit
gene expression [21, 22], with an interpulse interval of 75 min, for either
3 or 6 pulses; fresh media was added and the cells harvested or cells were
treated with one 15-min pulse and harvested 1, 2, or 4 h post-GnRH
treatment into RNAzol B (AMS Biotechnology, Abingdon, UK) and stored
at -70°C. Mouse L-cells and HeLa cells (ECACC, CAMR, Porton Down,
UK) were passaged in growth media as described above, and all cells were
grown in a humidified 5% C02 atmosphere at 37°C.
Differential Display RT-PCR
RNA was extracted as per the manufacturer's protocol and differential
display was performed as described [17], with further modifications [23].
Briefly, cDNA was generated using a First Strand cDNA synthesis kit
(Amersham Pharmacia Biotech, Little Chalfont, UK) and degenerate oli-
go(dT) primers (primers have 12 thymidine bases and a combination of
two random bases TTTTTTTTTTTTVN where V and N = A, G, or C).
The oligo(dT) primers were pooled into 3 X 24 jxM mixes; T12VA, T12VC,
and T12VG were used to prime first-strand cDNA subpopulations. DD-
RT-PCR was performed using oligo(dT) and random 10-mer primers (Sig-
ma-Genosys, Pampisford, UK), which are listed in Table 1. The 20-|xl
reaction mix contained 5 p,l of cDNA (pipetted from a 1:131-^1 dilution
of the first-strand reaction), 0.5 fxM random primer, 3 mM MgCl2, 2.4 |xM
T12VC, 2 p,M dNTP's (Amersham Pharmacia Biotech), 1 |xl 35S-dATP
(1000 Ci/mmol, Amersham Pharmacia Biotech), 0.3 pi AGS Gold Taq
polymerase, 2 pi each reaction buffer and enhancer (Hybaid, Ashford,
UK), and 1.2 pi H20. The PCR reaction conditions were as described
[23]. A 4-pl aliquot was loaded on a 6% acrylamide gel (HR-1000; Beck-
man Coulter UK Ltd, High Wycombe, UK) and electrophoresed on a
GenomyxLR DNA analyzer (Beckman Coulter) at 2700 V for 2 h 15 min
at 50°C. The gel was transferred to 3MM paper (Whatman, Fisher Sci¬
entific, Loughborough, UK) dried, and bands were visualized using
BiomaxMR autoradiographic film (Amersham Pharmacia Biotech), ex¬
cised and rehydrated in 150 pi low TE (10 mM Tris HCI, 0.1 mM EDTA,
pH 7.4). The DNA was eluted at 100°C, ethanol precipitated, and resus-
pended in 10 pi of low TE. To facilitate subcloning, this was combined
with a 40-pl reaction mix (3 mM MgCl2, 0.3 pi AGS Gold, 4 pi buffer,
4 pi Enhancer, 0.8 mM dNTP, 1.25 pM T12VN, 1.25 pM random primer,
and 11 pi H20) and amplified by PCR before splitting into four 10-pl
aliquots and reamplified. The Fanca fragment was cloned into pT7-Blue
(Novagen, CN Biosciences Ltd., Beeston, UK) using the Perfectly Blunt
cloning kit (Novagen) and sequenced.
Northern blotting, Semiquantitative and Quantitative
RT-PCR
Total RNA (40 pg) was fractionated, Northern blotted, and probed,
then quantified as described [24]. Radiolabeled probes used corresponded
to either the 5' region (exons 1-11) or the 3' region (exons 42-43) of
Fanca cDNA.
RT-PCR was performed by reverse transcribing 1 pg RNA using First
Strand cDNA synthesis kit (Amersham Pharmacia Biotech) and 1 pi was
added to a 25-pl reaction containing 2 pM upstream and downstream
primers and 10 pi Extensor High Fidelity Master Mix Buffer 2 (AB Gene,
Epsom, UK). Standard PCR conditions were used and were identical for
Fanca and penta zinc-finger protein 276 (Zfp276). For details of primers
and PCR fragments, see Table 2. PCR products were verified by sequenc¬
ing individual clones after ligation into TA-cloning vectors (Invitrogen,
UK) using ABI big dye terminator reagents (ABI, Warrington, UK). DNA
fragments were visualized on an ethidium bromide-stained agarose gel,
which for Fanca was Southern blotted and probed with a radiolabeled
probe (exons 7-17) before exposing to x-ray film.
Quantitative RT-PCR was performed for Fanca mRNA using a
LightCycler Instrument (Roche Diagnostics, Lewes, East Sussex, UK),
FastStart DNA Master SYBR Green I (Roche Diagnostics), and mouse
beta-2-microglobulin (B2m) as an internal control. Specific primers are
shown in Table 2. Each LightCycler reaction consisted of 5.8 pi dH20,
1.2 pi MgCl2 (4 mM), 1 pi Primer Pair Mix (25 pM each), 1 pi
LightCycler DNA Master SYBR Green I (Roche Diagnostics), and 1 pi
cDNA. The LightCycler program used for Fanca and B2m real-time PCR
was as follows: one cycle of 95°C for 10 min, 60 cycles of 95°C for 5
sec, 57°C for 5 sec, and 72°C for 15 sec, and a melting curve program
(57-95°C). A standard curve of Fanca and B2m expression was deter¬
mined using serially diluted cDNA made from mouse L-cell RNA. Results
are expressed as arbitrary units of Fanca mRNA expression normalized
against B2m mRNA expression levels and are a mean of three separate
experiments performed in duplicate.
Western Blotting Analysis
L[JT2 cells were left untreated or were treated with GnRH and har¬
vested 2, 4, or 6 h later. Whole-cell extracts were prepared by washing
the cell monolayer in ice-cold PBS with Complete (Roche Diagnostics)
protease inhibitors, before scraping into a 1.5-ml centrifuge tube, which
was frozen on dry ice. Total cellular protein was liberated by three rapid
freeze-thaw cycles, and cellular debris was cleared by centrifugation at
4°C for 5 min at 20 000 X g. Protein concentration was determined using
Bio-Rad protein assay reagent (Bio-Rad, Hemel Hempstead, UK), 50 pg
of whole-cell extract was boiled in IX loading buffer (62.5 mM Tris-HCl,
pH 6.8, 2% SDS, 10% glycerol, 0.01% Bromophenol Blue, 1% p-mer-
captoethanol), fractionated on a 6% SDS-PAGE gel, and electroblotted
overnight at 25 V onto Immobilon-P (Millipore, Watford, UK) in IX TGS/
20% methanol (TGS; 25 mM Tris, pH 8.8, 250 mM glycine, 0.1% SDS).
Blots were probed as described [5] with anti-mouse Fanca antisera raised
TABLE 2. Specific primers were used in PCR reactions to amplify first strand Fanca, Zfp276, and B-2-microglobulin cDNA.
PCR product
Specific primers* DNA sequence Location (base pairs)
Fanca s 5' -CTGTGTGAGCAGATAGGC-3' Exon 7 (640 bp) 979
Fanca as 5' -TCACGCTCGGCAATGTCCC-3' Exon 17 (1619 bp)
Fanca s 5' - CAGCATGGTCACTGCGTTCC - 3' Exon 14 (1263 bp) 450
Fanca as 5' -CCTGAATATGCTGGCCTCCA-3' Exon 18 (1713 bp)
Fanca s 5' - GTGGTGGAGACCTGGAAGA-3' Exon 30 (2900 bp) 211
Fanca as 5' -CGGCGTAGAACAGCCATG-3' Exon 32 (3111 bp)
Fanca s 5' -GCACTTTGCGTGGAGAGG-3' Exon 37 (3666 bp) 129
Fanca as 5 '-CAGGTAGGACGAGAGTAGAC-3' Exon 38 (3795 bp)
Zfp276 s 5' - CACTGTCCTCTGAGTACTGC-3' 5' ATG 68 bp 1238
Zfp276 as 5' - CGTCACCTGCTGAGTTCAAG-3' 3' ATG 1170 bp
B2m s 5' -ATGGCTCGCTCGGTGACCCTGGT-3' Exon 1 (ATG) 102
B2m as 5'-TGTTCGGCTTCCCATTCTCC-3' Exon 1 (102 bp)
* Primer annealing sites are expressed relative to the translational start site (ATG) in Fanca, Zfp276, and B-2-microglobulin (B2m). s, Sense; as, antisense;
bp, base pairs.
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FIG. 1. Differential display RT-PCR analysis of GnRH-regulated transcripts isolated from L|3T2 cells. A) Matrigel basement membrane was excluded
as an inducer of gene expression in LPT2 gonadotroph cells while GnRH was shown to upregulate transcripts. Cells were grown without Matrigel (1)
or were cultured on Matrigel (2, 3, and 4) and treated with 3 (3) or 6 (4) 15-min pulses of GnRH with an interpulse interval of 75 min. RNA was
extracted and subjected to differential display (DD) RT-PCR using primers stated. Matrigel did not alter transcript expression (arrows a and b), while
numerous transcripts altered after GnRH treatment (arrows c and d). B) In two separate experiments, LPT2 cells were left untreated (-G) or were treated
with 1 X 15-min pulse of GnRH (+G), RNA was harvested (-G, 1, 2, and 4 h) and subjected to DD-RT-PCR. First-strand cDNA was generated using
the T12VC downstream primer, then amplified by PCR using primers R21, MAX1, or R5. Arrow denotes location of Fanca. The location of DNA size
markers, indicated as bp, are also shown. C) Bioinformatic line-up depicting the region of homology, shown underlined, between the cloned Fanca
DD-RT-PCR product and mouse Fanca cDNA nucleotide sequence, and the likely internal R5 priming site. The location of DD-RT-PCR primers R5 and
T,jVC that generated the original 216-bp DD-RT-PCR product are also indicated.
to amino acids 1-271 (kind gift from Dr. Fre Arwert, VU University Med¬
ical Center, Amsterdam, The Netherlands) at a concentration of 1:1500,
then stripped in 2% SDS, 50 mM Tris, pH 6.8, 0.7% p-mercaptoethanol
at 55°C for 30 min before washing and reprobing with anti-mouse p-
tubulin antisera at a concentration of 1:500 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA).
Bioinformatics and Statistics
All bioinformatic comparisons were made using Wisconsin Package
Version 10.3 (Accelrys Inc., San Diego, CA) housed on the Medical Re¬
search Council's Human Genome Mapping Project server (MRC, HGMP,
Hinxton, UK). Statistical differences were determined using one-way anal¬
ysis of variance (ANOVA), with P < 0.05 deemed significant.
RESULTS
Differential Display RT-PCR Analysis of GnRH-Treated
Lj3T2 Cells
L(3T2 cells were grown in vitro on Matrigel basement
membrane, which contains collagen, other extracellular
basement membrane proteins, growth factors, metallopro-
teinases, and factors that promote cell adherence. These
factors may upregulate gene expression independent of
GnRH, so to test this, two different treatment regimes were
designed. In regime 1, cells were grown on uncoated or
Matrigel-coated flasks, while for regime 2, cells were
grown on Matrigel and left untreated or treated with GnRH.
RNA was isolated and subjected to DD-RT-PCR analysis
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4418 jagaat^tagattaccaatctcctt^ttgctctagttaggaaaagaaatattiaattattcat 4479 Fanca
1731 jfc'TTT'TATCTMTGGTTAGAGGAACTAACGAGAVcAATCCTTVTcVTTATAAJTTAATAAGTA 1670 Zfp276
4— cctttttttttttt T12VC
FIG. 2. Schematic representation of the
Fanca locus showing the location of the
differential display RT-PCR clone. Exons
40-43 of Fanca, shown as black boxes,
overlap with the 3' untranslated region
(UTR) of Zfp276, shown in grey. The loca¬
tion of the cloned 74-bp differential dis¬
play (DD) RT-PCR clone is indicated. Be¬
neath the schematic, the regions of nucle¬
otide identity between Fanca mRNA and
Zfp276 mRNA have been aligned, Fanca
mRNA sequence is shown in bold type,
and spliced intronic sequence has been
omitted and replaced with a dashed line,
with ZIp276 mRNA in normal typeface.
The amplified 74-bp DD-RT-PCR clone has
been boxed with a solid line, and the
original 216-bp DD-RT-PCR clone is indi¬
cated as an extension of the boxed region
with dashed lines. The amplification prim¬
ers R5 and T12VC are also shown on the
corresponding Fanca sequence. No suit¬
able priming sites were identified by
bioinformatic analysis for the Tl2VC-an-
chored primer on the Zfp276 3' UTR se¬
quence.
(Fig. 1A). There was no visible alteration in DD-RT-PCR-
generated transcripts between cells grown on uncoated or
Matrigel-coated flasks, while addition of GnRH clearly af¬
fected transcript levels. This treatment regime has previ¬
ously been used to regulate expression and trigger pulsatile
release of LH from these cells [9], However, we found that
a short 15-min pulse of GnRH induced rapid changes in
gene expression (Fig. IB). The identified 216-base pair (bp)
cDNA was isolated, subjected to a further two rounds of
PCR amplification, cloned, and sequenced. Bioinformatic
analysis of the 74-bp DNA sequence obtained produced an
identical match to exon 43 of Fanca. The difference in size
between the identified 216-bp DD-RT-PCR product and the
amplified 74-bp cDNA clone was due to internal priming
during the second round of PCR amplification, and the two
sets of priming sites are shown in Figure 1C. This was a
common feature (unpublished observation) due to the in¬
herent redundancy of the PCR amplification and may reflect
the poor processivity of some Taq polymerases and pref¬
erential cloning of small DNA fragments. The 216-bp DD-
RT-PCR product visible on the gel was consistent with
priming of Fanca mRNA by a T^VC-anchored primer
(Fig. 1C). Bioinformatics also highlighted that the 74-bp
cDNA clone obtained could possibly correspond to penta-
zinc finger protein 276 (Zfp276) because Zfp276 mRNA is
encoded on the opposite DNA strand from Fanca and over¬
laps the Fanca gene locus at the 3' end [25]. The orienta¬
tion of these genes and region of DNA overlap between
them is indicated in Figure 2. We concluded that Zfp276
was unlikely to be the original DD-RT-PCR clone because
the mRNA polyA+ addition site and likely T12VC priming
site maps a considerable distance downstream and there
was no suitable T12VC annealing site within 200 bp of im¬
mediate flanking DNA sequence. However, because two
transcripts, Fanca and Zfp276, matched the cloned DD-RT-
PCR DNA fragment, additional expression analysis was
needed to confirm that Fanca was differentially expressed.
Fanca mRNA Is Differentially Expressed in L/3T2 Cells
Northern blotting of total RNA extracted from GnRH-
treated L(3T2 cells and probing with 5' and 3' fragments
of mouse Fanca cDNA (Fig. 3A), confirmed that a full-
length 4.5-kilobase (kb) transcript was expressed. The 5'
Fanca probe corresponded to 1-965 bp of the cDNA,
which encodes exons 1-11. The 3' Fanca probe corre¬
sponded to 4231-4500 bp of the mouse cDNA that encodes
exons 42-43 and should cross-hybridize with the Zfp276
transcript that overlaps this coding region. Indeed, a large
4.5-kb Fanca transcript and a small 3.1-kb transcript cor¬
responding to the reported size of Zfp276 mRNA [25] were
detected. The Northern blot was stripped and reprobed with
a ribosomal probe specific for 18s, which was used to con¬
trol for loading (Fig. 3A).
Although nonquantitative, there appeared to be no dif¬
ference in expression levels of Zfp276 mRNA amplified by
RT-PCR in untreated and treated cells (Fig. 3B). Interest¬
ingly, semiquantitative RT-PCR amplification of Fanca
mRNA suggested that Fanca expression increased 1 h after
GnRH treatment. Specific amplification of a 979-bp Fanca
PCR product was confirmed by subsequent Southern blot¬
ting analysis, which also identified lower levels of expres¬
sion in untreated, and a rapid reduction 2 and 4 h after
hormone treatment (Fig. 3C).












Thus, quantitative RT-PCR was used to measure the rap¬
id increase in Fanca mRNA after GnRH treatment. In this
assay, Fanca mRNA clearly increased 2-fold 1 h after
GnRH treatment (P < 0.05) and returned to unstimulated
levels by 4 h (Fig. 3D). Taken together, these results indi¬
cate that Fanca, but not Zfp276, mRNA is acutely regulated
by GnRH in LPT2 cells.
Analysis of Fanca Protein Expression
The rapid upregulation of Fanca mRNA may not be mir¬
rored by an increase in protein, so Western blotting analysis
was used to quantify Fanca protein levels in LPT2 cell
protein extracts. First, protein extracts were made from un¬
treated cells and from cells harvested 2 h after addition of
GnRH, and were fractionated on a 6% SDS-PAGE gel,
blotted onto polyvinylidene fluoride (PVDF) and incubated
with Fanca antisera specific for amino acids 1-271 [26]. A
specific 160-kDa band, corresponding to the expected size
of Fanca protein, was detected in untreated and GnRH-
treated extracts (Fig. 4A). Thus, the increase in levels of
Fanca protein was measured over a longer time period fol¬
lowing GnRH treatment and quantified (Fig. 4B). Again,
Fanca protein levels increased 2-fold after addition of
GnRH for 2 h (P < 0.001). This 2-fold increase was still
evident 4 h after treatment with GnRH (P < 0.001), but by
6 h, Fanca protein levels had begun to fall (P < 0.05). This
shows that a rapid increase in Fanca mRNA (Fig. 3D) is
followed by a 2-4-h sustained increase in Fanca protein.
In Vivo and Temporal Expression Profile of Fanca mRNA
We next determined if Fanca was expressed in the pi¬
tuitary in vivo. Mouse pituitary RNA was extracted, reverse
transcribed, and cDNA amplified using specific primers to
Fanca. DNA bands corresponding to exons 7-18, 14-18,
and 30-32 were identified (Fig. 5A). This analysis con¬
firmed pituitary expression of Fanca in adult mice. Because
LPT2 cells are derived from embryonic Day 16.5 mouse
pituitaries, we also investigated if Fanca mRNA was ex¬
pressed in a different immature gonadotroph cell line (Fig.
5B). As expected, Fanca was expressed in LpT2 cells,
HeLa, and L cells, but no corresponding PCR product was







FIG. 3. Characterization and quantification of Fanca and Zfp276 mRNA
after GnRH treatment. A) Confirmation of expression of full-length 4.5-kb
Fanca and 3.1-kb Zfp276 mRNA transcripts in LPT2 cells. Total RNA from
LPT2 cells was fractionated on a formaldehyde gel, Northern blotted, and
probed with radiolabeled probes corresponding to either the 5' region
(exons 1-11) or 3' region (exons 42-43) of Fanca. The blot was then
stripped and reprobed with an 18s probe. Specific Fanca, Zfp276, and
18s bands are indicated by arrows. B) Semiquantitative RT-PCR analysis
of Zfp276 expression. LPT2 cells were left untreated (0) or treated with 1
X 15-min pulse of GnRH, then harvested 1, 2, and 4 h later, RNA was
extracted, and first-strand cDNA made. PCR was performed to amplify
full-length Zfp276 (1238 bp) and the products were visualized on an eth-
idium bromide-stained agarose gel. One specific 1238-bp PCR product
was visible at all time points. L-cell cDNA was included as a positive
control. An arrow denotes the 1238-bp PCR product, and DNA size mark¬
ers are labeled. C) Semiquantitative RT-PCR analysis was performed for
Fanca expression in LPT2 cells that were left untreated (0) or treated with
1 pulse of GnRH; harvested 1, 2, and 4 h later; RNA extracted, and cDNA
made. Ethidium bromide staining identified one PCR product amplified
from mRNA harvested from the 1-h time point. L-cell cDNA was included
as a positive control. An arrow denotes the 979-bp PCR product, and size
markers are labeled. Southern blotting analysis of the agarose gel with a
5' Fanca probe confirmed that the Fanca PCR product was specific and
present at all time points. D) LightCycler quantitative RT-PCR analysis of
Fanca mRNA extracted from LpT2 cells either left untreated or treated
with GnRH and harvested 1, 2, and 4 h later detected a consistent 2-fold
increase in Fanca mRNA harvested 1 h after treatment. Results are shown
as arbitrary units (AU) of Fanca mRNA normalized against the levels of
internal control B-2-microglobulin (B2m) mRNA. This experiment was
performed in duplicate and repeated three times. *P < 0.05 was deter¬
mined as being significant by ANOVA one-way analysis of variance.























FIG. 4. Western blotting analysis of Fanca protein. A) Western blotting
analysis of protein extracts from untreated, 0, and extracts harvested 2 h
after GnRH treatment identified Fanca protein. Cellular protein was frac¬
tionated, transferred to PVDF, and probed with anti-mouse Fanca antisera
before being stripped and reprobed with anti-mouse p-tubulin. Arrows
indicate the 160-kDa Fanca and 55-kDa (3-tubulin proteins. B) Western
blotting analysis of whole-cell protein extracts from untreated (0) and hor¬
mone-treated cells harvested 2, 4, and 6 h later. Blots were probed as
above in A. ANOVA one-way analysis of variance determined that the
increases in Fanca protein levels after hormone treatment were significant:
***P < 0.001; ***P < 0.001; *P < 0.05.
DISCUSSION
Murine Fanca mRNA has a predicted size of 4503 bp,
which encodes a 160-kDa protein [27, 28]. Fanca mRNA
is relatively highly expressed in lymphoid tissues, testes,
and ovary in adult mice and is activated as early as Em¬
bryonic Day 7, largely in cells of epithelial origin [27, 28].
This is the first report of hormonal regulation of Fanca and
of Fanca expression in a specialized endocrine cell. Al¬
though there have been reports of smaller Fanca mRNA
molecules being expressed in brain [27], none of these were
localized to the pituitary, and they may correspond to the
recently identified Zfp276 gene [25], because in our hands,
neither Northern nor RT-PCR analysis indicated any vari¬
ation in size of Fanca mRNA in L[3T2 cells.
Because DD-RT-PCR amplifies the transcriptome, low-
abundance messages are represented with no preselection
bias from the user [17, 29]. This approach was particularly
suited toward identification and isolation of Fanca cDNA.
FIG. 5. Fanca is expressed in adult mouse pituitary. A) RT-PCR analysis
of RNA extracted from adult mouse pituitary was performed using primers
that amplified exons 7-18, exons 14-18, and exons 30-32 of mouse
Fanca. Ethidium bromide staining identified PCR products for ail regions
amplified. A control GAPDH PCR product was also amplified, confirming
the integrity of the mouse pituitary cDNA. B) RNA was extracted from
L0T2, aT3-1, HeLa, and L cells; reverse transcribed; and first-strand
cDNA was analyzed by PCR for expression of Fanca. The PCR primers
corresponded to exons 7-18 of mouse Fanca cDNA and ethidium bro¬
mide staining identified a 450-bp product in L|3T2, HeLa, and L cells. No
Fanca expression was detectable when amplifying aT3-1 cDNA. In this
experiment, expression of Zfp276 was used as an internal control to check
PCR conditions and RNA integrity. A specific 1238-bp PCR product, cor¬
responding to Zfp276, was amplified from LPT2, aT3-1, and L cell first-
strand cDNA.
Differential GnRH regulation of Fanca mRNA was con¬
firmed by a combination of semiquantitative and quantita¬
tive RT-PCR. However, the DD-RT-PCR technique does
generate high numbers of false positives, and a number of
strategies have been suggested to eliminate this [23, 30,
31]. These were taken into account during the design of
our experiments and briefly include use of a time course,
so differences were easily recognized, RNA extraction and
cDNA synthesis was done simultaneously, and samples
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from different experiments were electrophoresed in dupli¬
cate to ensure repeatability. Thus, we established that, al¬
though Fanca mRNA was expressed at very low levels in
the LPT2 cell line, GnRH regulation was still rapid and
transient, with mRNA returning to unstimulated levels after
2 h. In contrast, when using microarray analysis, the design
of the cDNA microarray determines which transcripts are
identified. Although Fanca was omitted from the microar¬
ray, rapid transient increases in transcripts were measured
in response to GnRH treatment, most corresponded to im¬
mediate early gene products that had returned to baseline
levels by 3 h post-GnRH treatment, and early growth fac-
tor-1 (Egr-1) and c-Jun were induced over a wide range of
GnRH concentrations (1 nM up to 1 p,M) [32, 33]. Because
we and others all measure significant increases in gene ex¬
pression in LpT2 cells after one treatment with a pharma¬
cological dose of GnRH, this indicates that, although the
concentration of GnRH is important, the timing between
GnRH pulses is also a critical factor. It is not clear if the
same changes in gene expression would be induced with a
pulsatile GnRH treatment regime as in the normal physio¬
logical state, although our original experiment did address
this by using 15-min pulses separated by an interpulse in¬
terval of 75 min (Fig. 1A), we found it was not ideally
suited to isolation of differentially expressed transcripts and
that a shorter time course of induction of gene expression
was preferable.
The rapid, transient increase in Fanca mRNA levels
measured in response to GnRH was followed by a similar,
but longer, increase in Fanca protein levels. This suggests
that levels of Fanca mRNA are tightly controlled, and we
hypothesize that hormone treatment either increases Fanca
gene transcription and/or stabilizes Fanca mRNA. Measur¬
ing steady-state mRNA levels by quantitative RT-PCR does
not distinguish between these two possibilities. Our obser¬
vation that Fanca mRNA is highly regulated in a mature
GnRH-responsive gonadotroph cell line, an endocrine tis¬
sue, may explain why researchers had difficulties in de¬
tecting Fanca gene expression by in situ hybridization in
embryonic mouse testes, but did detect expression in adult
testes [27, 28, 34]. In keeping with the rapid, short-lived
peak in Fanca mRNA, we consistently found that hormonal
stimulation also increased levels of Fanca protein. Fanca
protein increased 2 h after treatment with GnRH, but per¬
sisted for longer, only starting to decline 6 h after treatment.
Because we used whole-cell extracts in this study, we have
yet to analyze if this increase in protein also results in a
recompartmentalization of Fanca within the cell in response
to hormone, but prior treatment of cells with cyclohexi-
mide, an inhibitor of translation, blocks the GnRH-induced
increase in Fanca protein levels (unpublished results), sug¬
gesting that the increase in Fanca protein is indeed due to
de novo translation. The hormonally induced increase in
Fanca protein suggests it may be a component of a rapid
response mechanism in these cells. Indeed, the action of
Fanca in immune cells is upstream of the immediate early
response genes [35], suggesting that Fanca may act as part
of a signal-transduction cascade. We and others have noted
that expression of Fanca protein is low because detection
requires either reasonable amounts of starting material [27]
or an enriched population of cells, indicating that relatively
small changes in protein expression could have a large im¬
pact. Interestingly, expression levels and posttranslational
modification are critically important for many proteins in¬
volved in signal transduction [36].
The hormonal regulation of expression and temporal pat¬
tern of Fanca gene activation indicates that this molecule
may be important for mature gonadotroph cell function.
While the existence of a complementary Zfp276 transcript
complicated our analysis, especially because it was coex-
pressed in L(3T2 cells, there was no clear evidence to in¬
dicate that Zfp276 mRNA was the original DD-RT-PCR
fragment or that it was hormonally regulated. Furthermore,
although Zfp276 mRNA was expressed, neither Fanca
mRNA or protein (data not shown) was detected in aT3-l
cells, which are a GnRH-responsive gonadotroph cell line
derived from embryonic Day 13.5 pituitaries, that exclu¬
sively express aGSU, but not LH or FSH [1 subunit [10,
37]. This indicates that Fanca gene expression is activated
late in pituitary development because LPT2 cells are de¬
rived from embryonic Day 16.5 pituitaries, and indeed, we
confirmed that Fanca was expressed in adult pituitary.
The pleiotropic nature of the FA syndrome, which in
humans is an autosomal recessive disorder characterized by
bone marrow failure, aplastic anemia, and variable predis¬
position to cancers of the gynecologic system among other
clinical features, including infertility [18, 38, 39], has made
it difficult to ascribe particular phenotypic features to mu¬
tations in any particular region of Fanca or any of the other
Fanconi complementation groups [40, 41]. Targeted disrup¬
tion of Fanca in mice has reproduced some of the associ¬
ated FA phenotypes described above, but the most consis¬
tent of these appears to be a severe reduction in fertility
[34, 42, 43]. Furthermore, although the pituitary was not
examined, the testes were identified as a major site of Fan¬
ca gene expression, and these mice developed ovarian gran¬
ulosa cell tumors [34], a phenotype also known to be con¬
sistent with elevated plasma levels of pituitary LH [44].
Elevated gonadotropin levels have also been reported in FA
patients [45], and there is evidence that FA impacts on re¬
production [46, 47]. Taken together, these observations sug¬
gest a role for Fanca in reproduction, especially gonadal
function, but how this impacts on the pituitary is under
further investigation.
There may be a link between FA and development of
pituitary neoplasms because pituitary tumors develop
through various mechanisms [48]. FA is a relatively rare
disease, while the incidence of pituitary adenoma within
the general population is high (—20%), and gonadotroph
cell neoplasms account for —35% of these [49]. However,
a specific subset of pituitary tumors (<2%) are caused by
mutations in the MEN1 gene, which encodes the transcrip¬
tional repressor MENIN [50] and interestingly, MENIN has
recently been shown to interact with FANCD2, the down¬
stream target of the FA complex [51].
In addition, a number of FA genes have been implicated
in ovarian tumorigenesis in man and mouse [52, 53] and
Fanca is required for gonadal function [34], GnRH, acting
through its receptor, is a key autocrine/paracrine regulator
of ovarian and testicular function [54] and has a role in
development of GnRH-responsive ovarian, breast, and
prostate cancer [55], This evidence and the prevalence of
endocrinopathies in patients support a role for the FA genes
in endocrine signaling [20]. Thus, we hypothesize that
GnRH regulation of Fanca gene expression may be im¬
portant for the normal endocrine function of the pituitary
and possibly reproductive organs.
In conclusion, Fanca was identified in and isolated from
mouse anterior pituitary gonadotrophs in a DD-RT-PCR
screen for transcripts regulated by GnRH. This broadens
the expression profile of Fanca into highly specialized en¬
docrine tissues and establishes hormonal regulation of the
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Fanca locus. The acute hormonal regulation of the mole¬
cule indicates that Fanca may have a role in mediating
GnRH responsiveness in mature gonadotrophs.
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